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SPONTANEOUS DERMATITIS IN y6 T CELL-DEFICIENT MICE: THE ROLE OF IgE,
GENETICS, AND DENDRITIC EPIDERMAL T CELLS
Jennifer H. Nam, Julie M. Lewis, and Robert E. Tigelaar.
School of Medicine, New Haven, CT.

Department of Dermatology, Yale University,

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense pruritus
and chronically relapsing eczematous skin lesions, often associated with elevated serum IgE levels. It has
previously been reported that non-obese diabetic (NOD) y6 T cell-deficient (6-/-) mice, but not C57BL/6
(B6) or (NOD X B6)F,.6-/- mice, develop an a|3 T cell-dependent, environmentally-influenced, localized
spontaneous dermatitis (SpD) resembling human AD. Reconstitution studies further demonstrated that the
SpD is down-regulated by Vy5+ dendritic epidermal T cells (DETC).

We analyzed whether IgE levels

correlated with genotype and/or the SpD phenotype. Total serum IgE levels (ELISA) were determined in
B6 wild-type (w.t.) and B6.6-/- mice, NOD w.t. and NOD.6-/- mice, and (F, X NOD).6-/- (BC) mice,
raised in ventilated and non-ventilated housing conditions. Higher IgE levels were found in NOD w.t. and
NOD.6-/- mice compared to B6 w.t. and B6.6-/- mice.

Total serum IgE levels did not correlate with

presence of SpD, nor with the environment in which they were housed.

These data suggest that IgE

antibodies do not play a primary role in the pathogenesis of SpD. Genome-wide microsatellite mapping
studies in other AD mouse models have identified major susceptibility intervals to chromosome 9 in
NC/Nga mice and to chromosome 14 in NOA mice.

Using primers distinguishing NOD and B6

polymorphisms in the centers of these intervals, DNA from BC.6-/- mice with SpD was analyzed by PCR.
For both intervals, the NOD/NOD vs. NOD/B6 ratios were 1.0, indicating that the interval(s) controlling
susceptibility to SpD in NOD.6-/- mice are distinct from those found in other mouse models of AD.
Finally, in search of ultimately defining the ligand(s) for the DETC-specific Vy5/V61 T-cell receptor
(TCR), a third goal was to develop a bioassay in a heterologous cell type, a rat basophil leukemia cell line,
RBL-2H3.

A RBL-2H3 cell line expressing the Vy5/V61 TCR was developed, and preliminary studies

performed in which pre-loaded 3H serotonin was measured for release from Vy5/V6l transfectants upon
stimulation.

The RBL bioassay is a first step towards defining the ligand(s) for the DETC-specific

Vy5/V6l TCR, which will help to elucidate the physiological role of this intriguing subset of y6 T cells.
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I. INTRODUCTION

A. BACKGROUND OF yb T CELLS
T cells are critical effectors of the vertebrate adaptive immune system. In most
mammals the vast majority of recirculating T cells in the blood and peripheral lymphoid
tissues (>90%) express an antigen-specific T-cell receptor (TCR), which includes a
disulfide-linked heterodimeric glycoprotein composed of a 42-45 kilodalton (kD) a chain
and a 35-42 kD (3 chain; each chain contains a variable and constant domain, a
transmembrane region, and a relatively short cytoplasmic tail [1],

The a and (3 chain

together serve to recognize specific antigens. Conventionally viewed as thymus-derived
cells that recirculate through lymph nodes and spleen via blood and lymph, these socalled a(3 T cells enter tissues following antigen-specific activation and mediate reactions
designed to control infection by pathogens foreign to the host [2], The a(3 T cells are
associated with either the CD4 or CDS co-receptor cell-surface protein.

CD4 T cells

recognize only peptides presented by self-Major Histocompatibility Complex (MHC)
class II molecules on the surface of target cells and differentiate according to thencytokine pattern into CD4 ThI and Th2 effector cells that activate macrophages and 13cell responses to antigen, respectively.

CD8 T cells, on the other hand, recognize

peptides bound only to MHC class I molecules, and differentiate into cytotoxic CDS T
cells [2], The TCR as a whole is composed of the ligand-binding heterodimer closely
associated with four additional, nonpolymorphic polypeptide chains [3],

These

nonpolymorphic transmembrane polypeptides, namely CD3e, CD3y, CD36, and TCRt
chains [4], are collectively known as the CD3 complex, which plays a critical role in

receptor assembly and cell-surface expression [5]. In addition, the CD3 complex is the
key through which signals are transduced from the TCR to the cell upon TCR activation
and cross-linking by antigen [5]. Antigen recognition and functional activities of cx[3 T
cells are understood in great depth, and therefore, have often been generalized to all T
cells. It is only in the recent past that we have begun to understand a distinct set of T
cells, comprising a minority of recirculating T cells (<10%), known as y6 T cells [6, 7],
The study of y6 T cells is relatively recent and stems from the discovery of their
rearranged genes, rather than from any knowledge of their biological function [8], The
existence of y8 T cells was not suspected when the TCR y gene was first cloned
independently from the genes for TCR a and (3 in early 1984.

Several years passed

before cells expressing the y gene product were discovered, which were found to express
this y chain as part of a CD3-associated heterodimer in conjunction with a second
unidentified chain [9-15],

Within the next three years, the other TCR subunit of this

unique heterodimer was discovered and designated TCR 6. The gene encoding it was
identified based upon gene rearrangement and subtractive hybridization [9, 16, 17], with
its location found to be within the TCR a locus [8, 18]. Further studies showed that cells
expressing y8 heterodimers did indeed exist and represented a new T cell class. Thus the
immunology of y8 T cells has been progressing in a “reversed direction,” i.e. from genes
to the TCR and from the TCR to a new class of lymphocytes [19]. The four TCR chain
gene families (a, (3, y, 6) appear strongly conserved across more than 450 million years of
evolution of the jawed vertebrates [9, 20]. Since their discovery, y6 T cells have been
recognized as regular constituents of higher immune systems, with major progress having
been made in elucidating both their physiological roles and the nature of their antigenic
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recognition [9]. Yet, a compelling explanation for the evolutionary conservation of y6
cells and the strong selective pressure for their retention is still lacking. While much is
known about TCR y and 6 gene organization, sequence repertoire, and ontogeny, our
understanding of the role of these cells in the immune system and the mechanisms by
which they function remains at best, only modest [8],

yS TCR Gene Structure
Like the a (3 TCR, the y6 TCR is expressed as a heterodimeric cell surface
molecule [10, 19]. Cell surface expression of the heterodimer and signaling through the
y6 TCR also require association with the CD3 complex of transmembrane proteins.
Thus, several similarities exist between the overall structure of the y6 TCR complex and
the a[3 TCR complex [21], However, a more detailed analysis of y6 TCR structure has
revealed substantial differences with oc(3 TCRs as well.
TCR proteins are derived from sets of germline genes containing arrays of coding
segments, named variable (V), joining (J), and in the case of (3 and 6, diversity (D)
regions [2],

The genomic organization of the TCR genes is shown schematically in

Figure 1 [22], Recirculating a|3 and y8 TCRs exhibit an enormous collective diversity
which is generated through a variety of mechanisms during the process of recombination.
One mechanism is combinatorial diversity through somatic rearrangement of the genes
through the complex of enzymes termed V(D)J recombinase, which brings different
coding segments into juxtaposition to produce a functional gene; such gene
rearrangement occurs during thymic development and is dependent on Recombinase

Figure 1. Schematic representation of murine T cell receptor loci. TCR-V gene segments are shown as
solid boxes; -D as bold vertical lines; -J as vertical lines; and -C as hatched boxes. Arrows depict
transcriptional orientation. The nomenclature used in this transcript is from Heilig & Tonegawa 1986 [60].
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Activating Gene (RAG) products, which are the lymphoid specific components of the
V(D)J recombinase [2],
For a|3 TCRs, —100 Va and -50 V(3 loci allow for -5,0000 different
combinations. However, the vast majority of TCR diversity among such recirculating
cells is concentrated within the V-J or V-D-J junctional region.

The huge diversity

potential of the junctional regions of the a and (3 genes is calculated to allow -lO1'^
different coding segments [23], Junctional (CDR3 region) diversity is achieved through
the activities of two enzymes: 1) DNA exonuclease, through which the recombining gene
segment ends are variably trimmed; and 2) terminal deoxynucleotidyl transferase (TdT),
which mediates insertion of variable numbers of non-germline-encoded (N) nucleotides
into these junctions. Of note, TdT is known to be expressed particularly abundantly in
thymocytes during late fetal thymic ontogeny [24],

This marked TCR heterogeneity

allows for the collective capacity of recirculating T cells to recognize a vast array of
foreign antigens. The y chain genes always involve V-J rearrangement, while the 6 chain
genes are assembled via V-D-J rearrangement, frequently involving D-D joining.
Additional, sometimes quite striking diversity is generated by the inclusion of
gennline-derived nucleotides (P elements), perhaps by transfer of nucleotides to the blunt
end of the opposite strand by a novel enzyme prior to trimming, insertion of non¬
germline encoded nucleotides, and ligation [25].

Collectively, this marked TCR

heterogeneity allows for the a(3 TCR recognition of a vast array of foreign antigens [2].
In marked contrast to the large number of V and J segments in the a and [J loci,
the y locus consists of only four Jy genes, each associated with a Cy gene, and seven Vy
genes [22, 26-29],

The 6locus, located within the alocus between the Va and
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Ja segments [18], contains approximately 10 VS genes, along with two D and two J
elements upstream of a single C gene [22]. With such a small number of Vy and VS
genes, there are less than 100 different possible combinations of coding segments through
somatic rearrangement.

However, in contrast to the limited V-gene combinatorial

diversity of yS TCR, the diversity potential of the junctional regions of such receptors is
actually several orders of magnitude greater than that of a(3 TCR (estimated to be ~101N
different combinations), with almost all the diversity concentrated at the V-J junctions of
both y and S chains [30, 31].

As mentioned previously, the 6 locus contains two D

segments, which can both be used in the same gene. The use of two D segments greatly
increases the variability of the 6 chain, mainly because extra N-region nucleotides can be
added at the junction between the two D gene segments as well as at the V-D and D-J
junctions [2], The existence of this extensive junctional diversity in the y and 6 chains
suggests that the potential repertoire is as large, or perhaps larger, than that of a|3 cells
[23].

However, evidence has shown that y and 6 chain diversity may be much more

restricted in certain anatomical sites, as will be discussed below.

Lineage, Development, and Distribution
In the fetal mouse thymus, productive rearrangement and surface expression of y6
TCR precedes that of a(3 TCR [31]. CD3+ y6+ cells appear as early as fetal day 14, and
outnumber CD3+ af3+ thymocytes until about fetal day 17 [10, 32], Studies have shown
that productive rearrangement and expression of y and 6 genes during ontogeny is not
random but rather is highly ordered, with subsets expressing a strikingly homogeneous
TCR arising in “waves” at different times in ontogeny [31, 32]. The first wave expresses
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an invariant TCR composed of Vy5 and V51 [33], Appearing around fetal day 14, these
Vy5/V51 T cells later become established selectively in the epidermis. After a few days
Vy5-bearing cells decline and are replaced by cells expressing the Vy6 gene, also paired
with the V61 chain. In normal healthy mice, these cells colonize the mucosal epithelia of
the tongue, vagina, uterus, and lung [21], In both the Vy5 and Vy6, as well as the V61,
chains of these very early y6 thymocytes, there is a virtual complete lack of non-germline
encoded (N) nucleotides between the various coding segments, reflecting the absence of
the enzyme TdT from these early fetal T cells [24], After these initial waves, T cells are
produced no longer in bursts but in a continuous fashion. By fetal day 17-18, CD3+ a(3 T
cells predominate, comprising more than 95% of the thymoctye population [2], The y6 T
cells produced at this stage differ in several ways from those of the early waves. They
exhibit a more diverse receptor repertoire, for which several different V gene segments
have been used, including Vyl, 2, 4, and 7. These particular Vy chains are often paired
with various V6 genes, and are later found mainly in peripheral lymphoid tissues rather
than in epithelial sites (though they do populate the epithelia of the lung and intestines)
[2], Additionally, in contrast to the early y6+ cells, the receptor sequences have abundant
N-nucleotide additions, resulting in markedly heterogeneous junctional regions [31].
Despite similarities in the development of peripheral y6 T-cell populations,
enormous differences exist between species regarding the tissue distributions and overall
sizes of y6 T-cell subsets [34]. For example, most peripheral y8 cells are double negative
for CD4 and CD8 [20].

In the periphery, 0.5-10% of peripheral blood T cells in the

human and ~3% of T cells in the murine spleen and lymph nodes are CD4-CD8- y6 cells
[10], In the chicken, on the other hand, the proportion of y8 cells in peripheral blood and
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spleen is higher, approaching 30% of CD3+ T cells, with most (-70%) chicken y6 cells in
the spleen being CD4-CD8+ cells. The remainder are CD4+CD8- cells, as are y6 cells
in chicken blood [10]. y8 T cells overall are comparable in numbers to cx|3 T cells in
sheep, cattle, pigs, and chickens, while they are rather infrequent in primates and rodents
[21]. The biological significance of these differences has yet to be made clear. If y8 Tcell subsets are functionally specialized, the differences may reflect varying requirements
for these functions among the species. In order to elucidate the physiologic purposes for
these cells, it is logical to approach the study of y8 T-cell subsets within an organism as
separate entities and to attempt to identify and assess their individual functions, as a
crucial adjunct to comparing y5 and a(3 T cells in a more global way.

Intraepithelial Lymphocytes (lELs)
By nature, body surfaces have been designed to inherently limit infection.

In

addition to having rapid-acting innate responses, such as epithelial cells that synthesize
and secrete chemokines, cytokines, and anti-microbial peptides (e.g. defensins), epithelia
harbor cells of the adaptive immune system that provide local protection [35],

For

example, B cells produce secretory immunoglobulin A, which can neutralize pathogens
as well as bind endocytosed pathogens during transcytosis across epithelial cells [36].
Additionally, substantial numbers of T cells are constitutively resident within epithelia.
Such intraepithelial lymphocytes (IELs) may be among the most abundant T cell subsets
given the large surface area of epithelia [35].
IELs are distinct from systemic T cells in several ways.

One of the most

distinguishing characteristics of IELs is their subset composition.

As previously
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described, conventional a|3 T cells are associated with either CD4 or CD8, which
consequently guides recognition of antigen in the context of MHC class I or II molecules
respectively. IELs, on the other hand, appear to function in the absence of CD4/CD8cx|3
coreceptors [35],

Studies have shown that IELs are usually positive for only CD8a

without CD8(3 (CD8a+|3-) or negative for both CD4 and CD8 (CD4-CD8a(3-) [33, 3739], T cells expressing CD8aa homodimer are essentially absent from the circulation,
whereas they comprise a large fraction of the CD8+ cells which make up >70% of small
intestinal IELs [37].

CD4-CD8- “double-negative” (DN) cells are also rare in the

systemic circulation, yet they make up >10% of murine small intestinal IELs and the
majority of IELs in other compartments [40], The observation that IELs are not typically
associated with CD4 or CD8 coreceptors suggests that IELs may recognize their ligands
directly or that they may preferentially recognize nonclassical MHC-like molecules [35],
Additionally, not only are IELs commonly enriched in TCRy6+ cells, they frequently
exhibit markedly limited tissue-associated antigen receptor diversity [20, 21, 41].
Between 35-65% of murine CD8+ small intestinal IELs and virtually all murine
epidermal and vaginal IELs express TCR y5 repertoires that are specific to their particular
site and distinct from those found in the blood [20], The prevalence in epithelial surfaces
of y6 cells with extremely limited diversity, together with the relative absence of y6 cells
from lymph nodes and T cell areas of the spleen, initiated the hypothesis that y6 cells do
not routinely rely on professional antigen-presenting cells for antigen recognition [20],
Instead, they may perform in a type of “first line of defense” role [42], This hypothesis
proposes that y6 cells recognize generic immunological “stress antigens” that are markers
of cell infection or transformation rather than unique pathogen-specific epitopes. The
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unconventional antigen speciticities of lELs are a rapidly-growing area of investigation,
which will be discussed later in further detail.
Though CD4+ a(3 T cells are under-represented in many 1EL compartments, not
all epithelial surfaces demonstrate such distinction [40, 43]. For example, among murine
large intestinal IELs, the majority of cells are still CD4 or CD8a|3, similar to those found
in the systemic circulation [44, 45].
The heterogeneity within IELs and the variability among IEL compartments have
led Elayday et al. (2001) to recently propose a simplified categorization of these cells.
Type “a” includes the conventional TCRcx(3+ cells that are activated within the systemic
circulation, recognizing their antigens through MHC restriction. Type “b” cells include
TCRa(3+CD8cxa+ and TCRy6+ IELs that respond to antigens outside of conventional
MHC restriction [40]. Several features distinguish type b from type a IELs, including not
only their lack of conventional MHC restriction, but also their inability to be
reconstituted from peripheral lymph nodes [46-48] and their lack of immunological
memory of infection [49-53]. Additionally, serial analysis of gene expression (SAGE)
applied directly ex vivo to murine TCRy6+ and TCRa|3+ intestinal IELs has revealed
differential gene expression between type a and type b IELs [40, 54]. The similarity of
gene

expression

between

TCRy6+

DN

IELs,

TCRy6+CD8aa + IELs and

TCRa[3+CD8aa+ IELs indeed forms the basis for their collective type b classification
[40], Of particular note among the genes expressed highly in type a IELs and not in type
b is Ly6C, a T cell memory marker. Conversely, only type b IELs distinctively express
high levels of Ly49E, a receptor that recognizes MHC class I molecules and inhibits
killing by NK cells by overruling the actions of the killer receptors [2, 54],

Such

distinctions provide insight into the different physiological roles played by these IEL
subtypes.

Dendritic Epidermal T Cells (DETC)
One of the most intriguing populations of type b IELs are murine epidermisrestricted dendritic T cells. In the early 1980s, cells in the murine epidermis were found
to characteristically express the Thy-1 alloantigen, in addition to forming a conspicuous
dendritic network among basal layer keratinocytes [55, 56], Thus, they were initially
named Thy-1+ dendritic epidermal cells (DEC). It was soon discovered that the adult
epidermis of all normal strains of mice was populated by la-, CD4-, CD8- cells that
displayed functional properties of T cells. The properties included responsiveness to
mitogen and interleukin (IL)-2, secretion of IL-2, and various forms of cytotoxicity [5759], The overwhelming majority of Thy-1+ DEC in normal adult epidermis was soon
found to be CD3+ in association with a yb-type of TCR; thus they were renamed DETC.
As the DETC antigen repertoire was further explored, it was discovered in 1988
that four independent DETC lines isolated from trunk skin of AKR/J mice expressed
TCRs of striking homogeneity [33]. The DETC clones used identical y coding segments
(Vy5JylCyl)*, as well as identical bcoding segments (V61D62J62C6). (*Using the
nomenclature for murine Vy gene segments set by Heilig and Tonegawa 1986 [60]). In
addition, the junctional regions of both the y and 6 chains were remarkably homogeneous,
with very little exonucleolytic nibbling or N nucleotide insertions. Quite startling was the
realization that these TCRs were identical to those expressed by the first wave of fetal
thymocytes. Further studies using both flow cytometric staining and polymerase chain

12

reaction analysis on freshly isolated DETC from a variety of different mouse strains
confirmed this homogeneity of DETC TCRs [32, 61].

Concomitantly, monoclonal

antibodies (MoAb) specific for the y8 TCR were being used to analyze uncultured
epidermal cells from various mouse strains. Stained epidermal cell suspensions using the
MoAb by the name of F536, which is specific for Vy5+ TCRs irrespective of the
paired 6 chain, showed that over 90% of the CD3+ cells were Vy5+ [62], By a different
approach, the 17D1 MoAb, which reacts only with cells expressing the Vy5 chain
associated with V81/D82/J82+ 8 chains, was used along with anti-CD3 to double stain
epidermal sheets. These results demonstrated that over 95% of CD3+ cells also stained
with 17D1 [63],

Certainly, these results imply that gene expression and somatic

diversification in DETC progenitors are strictly regulated, and that DETC recognition of
antigen may be extremely limited [33, 64],
Another striking characteristic of DETC is their apparent restriction in tissue
distribution, so far having been isolated only in the skin. Vy5/V81+ cells have not been
detected in any peripheral lymphoid tissues, including blood, lymph nodes, or spleen
[64], Additionally, cells with the DETC-type TCR have not been demonstrated in other
epithelial sites known to harbor other distinct subsets of y6 cells. For example, lELs in
gut epithelium have been found to selectively express Vy7+ cells, which, unlike DETC,
are not particularly paired with a specific 8 chain.

In addition, both the Vy7 and the

paired 8 chain show considerable diversity in their junctional sequences [65]. The y8 T
cells of the epithelium of the vagina, uterus, and tongue, on the other hand, are similar to
DETC in expressing a monomorphic TCR devoid of junctional diversity, with one of the
TCR chains consistently being V81. Flowever, they distinctly express the Vy6 instead of
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the Vy5 chain [66]. Likewise, the profile of y6 T cells in normal mouse lung is distinct
from that expressed in the skin, with cells in this location preferentially using Vy2, V61,
and V66 genes [67],
Although the role of the thymus in the generation of most T cells is well
established [2], the involvement of the thymus in the generation of DETC was less clear.
Evidence has accumulated over the past ten years that support the derivation of DETC
from early fetal thymocytes.

First, identical Vy5/V61 TCRs are seen on the earliest

CD3+ fetal thymocytes, which appear around day 12-13 of gestation, and remain the
predominant subtype until day 17 [32], In thymocytes examined after birth, the Vy5 or
V61 coding segments are rarely seen [68],

Second, reconstitution experiments, using

either thymus grafts and cell suspensions or purified CD3+ or 17D1+ day 16-17 fetal
thymocytes into neonate nu/nu (“nude” or athymic) mice (which otherwise lack CD3+
Vy5/V61+ DETC in the epidermis) showed evidence of gradual accumulation of such
cells in the epidermis in a manner consistent with in situ proliferation [69]. Interestingly,
engraftment with thymic lobes from newborn mice did not result in the appearance of
donor-type DETC in the skin of recipients, supporting the fact that Vy5+ cells may not be
detectable in the thymus after gestational day 18 [32], In addition, transfer of CD3- or
Vy5/V61- fetal thymocytes failed to result in epidermal CD3+ Vy5/VSl + cells. These
results indicate that DETC express their Vy5/V61 genes even before migrating to the skin
and are most likely thymic-dependent [64].

Yet these studies have not precluded the

possibility that some DETC are also derived independently of the thymus. Epidermis of
old nude mice in fact show dendritic CD3+, albeit 17D1-, cells [63], In addition, grafts
of 16-day fetal skin found to initially contain only scattered Thy-1+ CD3- TCR- cells
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gradually become populated by skin graft donor-type CD3+ Vy5+ DETC, which suggests
an intracutaneous, possibly thymic-independent differentiation [70],
The mechanism by which TCR diversity among DETC remains so limited has yet
to be defined. It has been postulated that DETC precursors actually have a limited gene
rearrangement potential [71, 72],

However, recent studies have shown that TCR

conformation rather than TCR specificity of particular gene segments may in fact be
more important for the function or development of lymphocyte repertoires associated
with a specific anatomic site, including the murine epidermis [73-75],

Utilizing

disruption of the Vy5 gene, Mallick-Wood et al. (1998) analyzed murine epidermal sheets
from Vy5-/- and Vy5+/+ littermates with MoAbs to Vy5, TCR5, and CD3e.

As

expected, Vy5+ cells were readily detectable in epidermis from Vy5+/+ mice, but not in
that from Vy5-/- mice.

However, dendritic CD3+ TCR8+ DETC were present in

Vy5-/- mice in numbers indistinguishable from Vy5+/+ controls, implying that other y8
TCRs could substitute for Vy5/V51. Surprisingly, it was discovered that staining with the
MoAb 17D1, which ordinarily reacts only with cells expressing both V61 and Vy5,
defining a characteristic DETC TCR conformation [63, 64], demonstrated epidermal
sheets from Vy5-/- mice to exhibit cells with the same conformation. This different y8
pairing associated with an outwardly normal DETC population was found to be Vyl/V51.
Thus, it appears that, similar to most B cells and a(3 T cells, epidermal y5 cells are
associated more with an antigen receptor conformation than with simple linear epitopes
specifically encoded by the Vy and V8 gene segments normally used by DETC [73]. In
another study [74], V61-/- mice were shown to have preserved DETC development in
relatively normal numbers, with the most frequently used TCR6 chain being V86.
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A recent study by Ferrero et al. (2001) presents data further supporting this notion
that DETC TCR conformation is critical to their development. Through analysis of early
fetal thymocytes, the authors found that Vy5 paired with both V55 and V56.3 as early as
gestational day 16, showing that Vy5 can pair with V5s other than V51. Thus, TCR
diversity of intrathymic DETC precursors appears much greater than that observed
among DETC in the skin. This observation raises the possibility that only fetal thymic y5
T cells expressing an appropriate TCR will localize later in the epidermis [75].

The

authors of this study further investigated the importance of yb TCR specificity for DETC
migration/localization in the skin by generating a new TCR-5 transgenic (Tg) mouse,
using the V56.3 segment, which was chosen for its ability to pair with Vy5 in putative
DETC precursors of wild-type mice. As expected, fetal thymocytes expressed the V56.3
transgene in association with Vy5 as early as gestational day 15-16 on both wild-type and
TCR-5-/- backgrounds, with a normal percentage of DETC being found in the epidennis
of wild-type V66.3Tg mice.

Interestingly, virtually all DETC from these wild-type

V66.3Tg mice expressed Vy5 and V56.3 segments, in contrast to non-Tg littermates.
Surprisingly, no CD3+ cells were found in epidermal cell suspensions from TCR-5-/V66.3Tg mice. With the observation that V66.3Tg yb T cells indeed reconstitute other y5
T cell compartments, including those in the intestine, liver, and spleen, the authors
concluded that a second TCR-5 expressed by wild-type mice, most probably V51 as
shown by their PCR and sequence analysis, is a prerequisite for DETC maturation and/or
localization in the skin.
Such evidence for the selective establishment in the skin ofy5 cells with TCRs of
particular conformations raises several possibilities. One hypothesis is that certain DETC
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cells mature as a result of selection by specific “DETC selecting ligands” in the fetal
thymus and thus that y6 T cells may pass through a similar intrathymic selection process
as that by a[3 T cells [75]. Another possibility is that TCR specificity itself directs the
migration of y6 T cells to the skin. Yet another prospect is that y6 T cells express diverse
TCR specificities which can all migrate to the skin, but only those having a permissive
TCR would be retained and/or locally expand [75], Such a selection could be attributed
to the recognition of cellular antigen(s) within the target tissue, such as any expressed
specifically by keratinocytes in the skin in a sort of peripheral positive selection process.
If a particular DETC TCR conformation is critical for DETC development (i.e.
migration and/or localization), as suggested by these studies, as opposed to simple linear
epitope recognition as encoded by specific TCR gene segments, the question is
emphasized as to the specificity of the DETC TCR in terms of ligand recognition and
TCR activation.

If it is assumed that the different DETC populations found in these

experiments serve the same function within the epithelia, it can be concluded that ligand
recognition by DETC TCR is not specific to y6 pairing. Rather the conformation of the
complementarity-determining region (CDR) 3, which, by extrapolation from
immunoglobulin (Ig) and TCRa(3, is likely to be an important contact site for antigen
[73], may not be specific to any one epitope.

Another possibility it that the DETC

ligand(s) may map partly or wholly outside CDR3, still markedly and selectively
activating the y6 T cells, just as anti-clonotypic antibody and superantigens act on cx[3 T
cells in vivo [76, 77],
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TCR Specificity/Antigen Recognition by DETC
One of the keys to unfolding the elusive biological functions of DETC lies in
discovering the specific ligands of their TCRs and elucidating the manner in which they
respond to their ligands. While conventional a[3 T cells recognize their antigens in the
context of highly polymorphic classical MHC molecules guided by their expression of
CD4 or CD8 coreceptors [6, 8], the observation that y8 T cells, particularly IELs and
especially DETC, are usually double-negative lends favor to the idea that IELs may
preferentially recognize nonclassical MHC-like molecules. The interactions between y8
TCRs and their ligands are believed to be distinct from those directing the interaction
between oc|3 TCRs and their ligands [8, 78]. There may be two types of TCRy8-mediated
T-cell stimulation [6]. The first may be stimulation of y6 T cells by antigen-specific
ligands that bind to a highly diverse TCR y5 site. In this case, ligands would include the
antigenic peptide plus a presenting molecule, such as MHC, MHC-like molecule, or CD1,
or the protein itself. Primary stimulation would cause monoclonal expansion of y6 cells
with a unique TCR.

The second form of y5 T cell stimulation may be through the

binding of ligands to an invariant site on distinct TCR y6 isotypes [6]. Here, ligands
would be more ubiquitous and perhaps highly conserved, such as a heat shock protein
(Hsp) peptide [79], that act as generic immunological distress signals rather than unique
pathogen-specific epitopes [35, 42].
Of murine and human y6 T cells that have been stimulated by peptides in the
context of MHC class I or II molecules, some conventional antigen recognition by y6 T
cells has been shown [80-83]. Yet the majority of y5 T cells have been found to be MHC
independent.

Murine y6 T cells have been identified that are under the control of the

MHC class I-like gene Qa-1 within the H-2T locus, with later experiments showing the
ability of the Qa-1 molecule to bind Hsp peptides [84-86], These y8 T cells were found
to recognize synthetic peptides in a processing-independent fashion [84], Evidence is
indeed increasing that murine y6 T cells can recognize surface-expressed proteins directly
and independently from antigen-processing and MHC presentation [6], For example, a
herpes vims protein was discovered to stimulate y6 T cells directly without need for
processing or presentation [87],
Genetic analysis of the y6 TCR reveals that the CDR1 and CDR2 regions are
highly diverse, unlike that of the a|3 TCR [8], With such diversity, it appears that the y8
TCR would not accommodate recognition in the context of MHC molecules. Yet, in the
past decade, the closely related nonclassical MHC class I molecules T10 and T22 have
been identified as ligands for y8 T cells, two independently isolated clones called KN6
and G8 [88, 89],

Analysis of the T10/T22 recognition by G8 shows it to be clearly

different from MHC class I recognition by a[3 T cells, with T10/T22 not requiring
peptide or any other ligand for cell surface expression or recognition by y5 T cells [90,
91]. The T22 or T10 heavy chain need only be associated with (C-microglobulin ([CM)
in a properly folded and stable heterodimer in order to be recognized by y5 T cells and in
turn stimulate them [91]. There is no evidence that T10 or T22 present antigen to y6
TCR. In fact, the primary sequences of these two nonclassical MHC molecules suggest
that the necessary structural features to bind peptide are absent [88, 92],

Structural

differences found between T22 and classical MHC class I (class la) molecules, with the
peptide binding groove being narrower and shorter than that of the conventional MHC
molecule, further support the idea that y8 and a(3 TCRs recognize antigens differently
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and that yb TCRs may in fact be more like immunoglobulins in their recognition
properties [91]. Interestingly, it has been found that the affinity of the G8 interaction
with T10 and T22 is of higher affinity than most oc[3 TCR-ligand interactions, suggesting
that these yb T cells may require TCRs with unusually high on-rates in order to
antigenically capture these ligands, which are only expressed transiently at the cell
surface [90], Additionally, the dissociation rate of G8 from T10 or T22 has been found to
be significantly lower than that for most a[3 TCR-peptide-MHC interactions [90, 93],
Thus, the threshold at which yb T cells respond to T10 or T22 may be much higher than
that required to trigger a[3 T cells. Such a mechanism may play a key role in preventing
the easy activation of yb T cells by self antigens inappropriately.
Additional ligands have recently been identified for human yb T cells: distant
MHC class I homologues called MICA and MICB [94, 95],

Unlike MHC class la

proteins, the expression of MIC proteins in normal tissues is restricted mainly to
intestinal epithelium [96]. Functionally distinct from classical MHC class I molecules,
MICA and MICB seem to play no role in presenting intracellular antigen [95],

The

recently determined crystal structure of MICA supports this notion, as it revealed an
inverted peptide binding groove facing the cell essentially incompatible with peptide
presentation [97], Rather than antigen-presenting molecules, they may be functioning as
self-antigens that can be stress-induced [95].

MICA and MICB have also been

implicated as tumor-associated antigens, with expression being shown in carcinomas of
the lung, breast, kidney, ovary, prostate, and colon, with significantly increased
frequencies of V61 yb T cells [94]. Both MICA and MICB are recognized by cytotoxic
V61+ yb T cells [95]. V61 yb T cell lines and clones derived from the tumors were
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shown to recognize these molecules on tumor cell lines and on heterologous and
autologous tumor cells. Thus, MICA/B may serve as antigens for V51 yb T cells in a
process of tumor immune surveillance [94], Though it appears that the recognition of
these MHC homologues is mediated via TCR recognition [95], the nature of the
interactions is curious since T cells expressing diverse CDR3 regions are capable of
engaging these molecules [95],

It is possible that such a common antigen specificity

might enable a subset of V61 yb T cells to respond uniformly to MICA/B, which may act
as generic tissue “stress” signals triggered by infection or transformation [94],

No

evidence thus far has demonstrated definitive interaction of MICA/B with yb TCR. More
recently, a receptor for MICA has been detected on most yb T cells, as well as on CD8+
a|3 T cells and natural killer (NK) cells, identified as NKG2D [98], It has been shown
that engagement of NKG2D can activate cytolytic responses by yb T cells and NK cells
against epithelial tumor cells and transfectants expressing MICA.

Thus, NKG2D

recognition of MICA and MICB may serve to provide enhancement of innate antitumor
activities of NK cells and antigen-specific T-cell responses [98]. Though the MICA/B
locus is not conserved in the mouse, and thus no murine MICA/B homologues exist, mice
express NKG2D, as well as counterpart NKG2D ligands. These NKG2D ligands have
been cloned and found to be MHC class I-like molecules of the Rae-1 family and H60
[99].

Intriguingly, it has been recently demonstrated that skin cells exposed to

carcinogens express Rae-1 and H60 [100].
prospects to be DETC-specific ligands.

These molecules are indeed favorable
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Functional Activities of DETC
DETC comprise one of two populations of leukocytes in the epidermis of adult
mice, the other being Langerhans cells. As they reside normally in epithelial tissues,
DETC live a rather sessile life in close contact with keratinocytes [101]. The biologic
roles of y8 T cells and DETC in particular, with such curious and marked genetic and
anatomic restriction, remain one of the most persistent and obvious questions.
Nonetheless, several different functions have so far been described.

A. Tissue Maintenance
Given that DETC exclusively colonize the epidermis, it seems probable that their
functions are associated specifically with this tissue. In fact, it was found that epidermal
y8 T cells do indeed support the growth of keratinocytes through secreting a factor
indistinguishable from keratinocyte growth factor (KGF), also referred to as fibroblast
growth factor VII (FGFVII) [102, 103], Interestingly, freshly isolated resting DETC do
not produce KGF, while DETC activated with anti-TCR MoAb do express KGF. Other
types of epithelial/mucosal y8 T cells, such as activated y8 IELs from the gastrointestinal
tract, but not lymphoid a(3 or y8 T cells, have been found to produce KGF, demonstrating
a likely interdependence between y8 T cells and their surrounding epithelial cells [102,
104], Because KGF is also produced by dermal fibroblasts [103], it is possible that KGF
production by y8 T cells is merely redundant. Flowever, it is more likely that production
of this factor by y8 T cells becomes important under conditions when fibroblasts are not
stimulated, such as in response to signals that are only perceived by y8 T cells, and
possibly through the y8 TCR [21]. Again, the ligand(s) for DETC are not yet known.

22

Studies have shown that keratinocytes themselves express a ligand for the antigen
receptor of DETC. Specifically, Havran et al. (1991) showed that DETC were stimulated
to produce lymphokmes and to proliferate on contact with freshly isolated skin
keratinocytes or a cultured keratinocyte cell line, PAM [105],

Stimulation of DETC

could not be detected, on the other hand, after coculture with freshly isolated fibroblasts,
splenocytes, or peritoneal exudates cells, showing that DETC can respond to
keratinocytes but not to other cells tested. The authors of this study also demonstrated,
through antibody inhibition with MoAbs specific for Vy3 TCR and CD3s chain, as well
as TCR gene transfer experiments, that the responses of DETC to keratinocytes are
indeed TCR dependent.

With these results showing that DETC TCR can recognize

antigens expressed by skin-derived keratinocytes, but with no evidence that DETC are
activated in situ in normal skin, Havran et al. (1991) proposed that the antigen is induced
by “stress” that is associated with dissociation of the tissue or by in vitro tissue culture.
A potential target may be antigens derived from endogenous Hsps, as most mammalian
cells in tissue culture can express increased levels of Hsps [106, 107], Other studies have
consistently provided evidence supporting the ability of injured keratinocytes or
transformed keratinocyte cell lines to stimulate DETC.

It has been shown that

keratinocyte damage in situ, caused by contact sensitizing agents, induces localized
proliferation of epidermal y8 T cells, whereas the same agents do not stimulate the DETC
directly [108-110],

These results strongly suggest that DETC recognize keratinocyte

damage and function in a form of self-surveillance, allowing such resident invariant y6 T
cells to respond to a variety of deleterious agents without the need for diverse TCRs that
have specificity for foreign antigens [105], Indeed, this form of immune recognition may

23

have arisen as one of the earliest forms of protection against damage and disease. Such
stimulation of resident DETC by damaged keratinocytes may in turn be capable of
promoting keratinocyte growth and wound healing [111]. The interaction between y6
IELs and their epidermal neighbors is in fact bidirectional.

DETC depend on the

presence of IL-7 for their growth and differentiation, which keratinocytes have been
shown to produce [35, 112]. Moreover, IL-7 prevents apoptotic cell death that would
ordinarily be induced in DETC when exposed to exogenous corticosteroids [112],
Extension studies of different cytokines expressed by keratinocytes at mRNA and/or
protein levels have additionally shown epidermal cytokines to regulate the growth of
DETC in three different ways: 1) a paracrine mechanism by which keratinocyte-derived
cytokines (including IL-7 and tumor necrosis factor [TNF]-a) promote the growth of
DETC; 2) an autocrine mechanism by which DETC-derived cytokines, including IL-2
and IL-4, support their own growth; and 3) a reciprocal pathway in which DETC-derived
interferon (IFN)-y modulates the growth of keratinocytes [112],

Thus, the symbiotic

relationship between DETC and their neighboring keratinocytes is clearly demonstrated.
Further evidence for the role of y6 T cells in epithelial homeostasis comes from
studies of intestinal epithelia of mice. IELs are known to regulate enterocyte turnover in
monkeys and in guinea pigs [44] and to express enzymes that regulate lipid and
cholesterol metabolism [113],

Furthermore, in mice and humans, specific adhesion

molecules, namely aE[37 integrin on IELs and E-cadherin on enterocytes promote close
contact between IELs and intestinal epithelial cells [114, 115], This adhesion mechanism
may not only promote selective immigration into and retention of intestinal IELs in the
gut, but also support functional interactions between both cell types [6]. Mice that are
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congenitally deficient in y6 T cells have been found to have a reduction in epithelial cell
turnover, as well as overall reduced crypt cell numbers and diminished epithelial
differentiation [116]. The influence of y6 T cells on intestinal epithelial differentiation
likely not only affects normal homeostasis but also tissue integrity during infections. For
example, TCR6-/- mice infected with the parasite Eimeria vermiforrnis (a natural
coccidian pathogen of the mouse gut) suffer increased intestinal damage with a
pathologically exaggerated pro-inflammatory a(3 T cell response compared to controls, as
well as exacerbated intestinal bleeding, which could be suppressed by adoptive transfer
of bulk IELs. This finding indeed supports the notion that the contribution of y6 T cells
lies in tissue preservation and/or the ability to regulate the consequences of the a|3 T-cell
response [117]. The fact that there is a selective increase in intestinal y6 IELs in patients
with celiac disease lends further support to the idea that y6 T cells maintain epithelial
integrity [118]. In this disease, a wheat protein allergy causes CD4+ a(3 T cell-mediated
erosion of the small intestinal villi.

The dramatic expansion of y6 T cells into the

intestinal epithelium may reflect the IELs response to a pathognomonic change in the
enterocytes, with the purpose to suppress tissue infiltration by systemic T cells. In fact,
peak y6 IEL representation seems to correlate inversely with disease symptoms [118].

B. Immunoprotection
Another role that has been implicated for y6 T cells is that of recognizing and
destroying pathogens directly. Specifically, activated Vy5/V61+ DETC were found to
kill a variety of target cells, including transformed keratinocytes and melanoma tumor
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cells [109], as well as to secrete a number of lymphokines [64], Short-term DETC lines,
containing about 95% Vy5+ cells, have been shown to produce small amounts of IL-4
and IFN-y when stimulated with anti-TCR MoAbs, with large amounts of IL-2, while
long-term (>1 year) DETC lines produce similar amounts of IL-2 and IFN-y, but no
detectable IL-4 [64], The lymphokine profile of long-term DETC appears to resemble
that of CD4+ TCR a|3+ ThI cells, which typically promote cell-mediated immunity [2],
Studies that have produced profiles of cytokine mRNA of DETC have confirmed these
findings, showing that the short-term DETC lines express mRNA for not only IL-2 and
IFN-y, but also IL-la, IL-3, IL-6, IL-7, TNF-a and (3, and granulocyte macrophagecolony stimulating factor (GM-CSF) [119], further supporting their bias away from Th2
and toward ThI [20, 120].

On the other hand, other very recent studies (Tigelaar,

unpublished observations) of short-term DETC lines have shown that such lines can also
express abundant messenger RNA (mRNA) transcripts for the immunoregulatory (downregulatory) cytokines transforming growth factor (TGF)-[3 and IL-10.
The role of y6 T cells in eradicating transformed epithelial cells in vivo leads to
the hypothesis that y6 cells thereby function to not only promote epithelial integrity, but
also to prevent dissemination of infected or malignant cells [42], In fact, the protective
role of y6 T cells has been implicated in several studies of both infection and malignancy.
From early on in the study of y6 T cells, it has been noted that y5 cells are potently
stimulated by mycobacteria, in addition to accumulating at certain sites of microbial
replication and selectively expanding in peripheral blood or lymphoid organs in patients
suffering from various bacterial or protozoal infections as well as in numerous murine
infection models [67, 81, 121-129]. Furthermore, experiments using anti-TCRyb MoAbs
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have been shown to exacerbate experimental infections of mice with various bacterial and
protozoal pathogens [130-133],

The availability of TCR[3 and TCR6 gene disruption

mutants lacking a|3 (TCR|3-/-) ory6 (TCR6-/-) T cells, respectively, allowed for further
insights. For example, in a mouse model of experimental listeriosis, both TCR6-/- and
TCR(j-/~ mice proved rather resistant to infection [134], However, when the TCR[3-/mice were treated with TCRyb MoAbs, the mice became susceptible to listeriosis. These
findings suggest that y8 T cells indeed play a role in antimicrobial immunity; yet, they
may be performing primarily compensatory functions that only become salient in the
absence of a|3 T cells [6]. Other studies have suggested an overtly protective function of
y6 T cells. In a study on infection by Mycobacterium tuberculosis (an aerobic, acid-fast
bacillus forming exudative and granulomatous lesions), TCR5-/- mutants succumbed to
the infection while immunocompetent controls did not [135]. Likewise, airway infection
of mice by Nocardia asteroides (an aerobic filamentous gram-positive bacteria that
causes pulmonary infection progressing to abscess and sinus tract formation) leads to
100% fatality in TCR5-/- mice, while 100% of wild-type mice clear the infection [136],
As DETC have been found to produce IFN-y, the phenotype exhibited in the TCR8-/mice was likely enhanced by the failed recruitment of neutrophils and macrophages by
the y5 T cells. y5 T cells do appear to play a unique immunoprotective role since the
presence of a(3 T cells in the TCR5-/- infected mice was not sufficient to prevent
infection and eventual mortality.
Studies on the immunoprotective functions of y5 cells using the Eimeria
vermiformis infection system on murine intestinal mucosal surfaces have revealed

additional interesting observations regarding the biological role of yb cells. a(3 T cell-

27

deficient mice revealed a marked susceptibility to primary infection by Eimeria, as wel!
as a failure to develop immunity to rechallenge [117].

In contrast, y6 T cell-deficient

mice did not show any defects in infection or immunity development.

Comparison

between TCR|3-/- mice and TCR([3 X 6)-/- mice which lack all T cells showed the latter
to be even more susceptible to infection, implying that though they do not seem to be
required by a|3 T-cell competent mice, y6 cells do respond to the infection, as well as
play a role in pathogen clearance [117]. A further comparison between IFN-y-/- mice
and TCR(|3X 6)-/- mice showed both models were equally susceptible to infection,
lending support to the idea that y6 cells may be contributing to infection control through
the production of IFN-y. Interestingly, when Eimeria infection was studied on mice of
different ages, a marked difference in infection susceptibility was found [120], In young
mice, in complete contrast to adult mice, TCRfW- mice show little or no increased
susceptibility to primary infection.

On the other hand, infection susceptibility is

markedly increased in young TCR6-/- mice. These results fit together well with the
observation that in all vertebrates in which yb cells have been studied, y6 cells are
disproportionately abundant in young animals, at the body surfaces [120].

Thus,

evidence points to an hypothesis of an age-dependent role for yb T cells in which they are
more important for controlling primary infections in young animals before a[3 T cells
assume this role [120].
Evidence has shown that yb T cells may also play a role in down-regulating
epithelial malignancies. Human intestinal y6 IELs have been shown to kill human bowel
carcinomas and other intestinal epithelial cell lines [94, 95], Additionally, TCR6-/- mice
have been found to be more susceptible to development of colon carcinomas [137], Most

recently, Girardi et al. (2001) have shown that yb T cell-deficient mice are significantly
more susceptible to cutaneous carcinogenesis. Cutaneous malignancy was induced either
by inoculation of cell of the squamous cell carcinoma line PDV or by chemical
carcinogenesis using intradermal injection of methylcholanthrene (MCA) or applications
of dimethylbenz(n)anthracene (DMBA) and phorbol ester (12-0-tetradecanoylphorbol;
TPA).

In all three regimens, yb T cell-deficiency promoted cutaneous tumor

development. The susceptibility of TCR6-/- mice indeed indicates that the antitumor
effect of yb cells are not simply substituted by that of a[3 T cells and NK cells [100],
Interestingly, comparison of tumor development via PDV cell injection in wild-type
mice, TCR6-/- mice, TCR(3-/- mice, and TCR|3-/-6-/- mice showed that 60% of
TCR6-/- mice developed at least one tumor, compared to <20% of control mice.
Meanwhile, -100% of injected sites developed as tumors in TCRfW- and TCR|3-/-6-/mice, suggesting that a(3 cells and yb cells each regulate the growth of PDV-caused
tumors, but in different manners [100],
In sum, yb

T cells appear to exert important effector functions for

immunoprotection distinct from that of cx[3 T cells. Possible mechanisms include being
directly antipathogenic via cytolytic and/or ThI activities, initiating antipathogenic
activities in other cells, such as macrophages or neutrophils, via the action of cytokines,
and contributing to immunoprotection through their protection and maintenance of
epithelial cells via the production of epithelial growth factors [120],
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C. Immunoregulation
Increasing evidence suggests that another biological role y6 T cells may play is in
the regulation of other members of the immune system. For example, macrophages are
normally activated to produce cytokines, such as TNF-a, which has multiple biological
roles including stimulation of dendritic cell migration to lymph nodes and maturation,
hepatocyte activation to synthesize acute-phase proteins, and bone marrow endothelium
release of neutrophils [2].

Macrophages appear to have markedly suppressed TNF-a

production in mice lacking y5 T cells, suggesting that y8 T cells may play a role in
macrophage activation [138].

Additionally, in studies of Gram-negative bacterium-

induced septic shock, it has been shown that TCR5-/- mice prove more resistant to
developing shock [125], This finding can be explained in light of the fact that Gram¬
negative bacterial infections provoke abundant TNF-a production, suggesting that the
lack of y6 T cells may impair TNF-a production and thus allow avoidance of this harmful
sequelae [6].
Several studies have specifically demonstrated that y6 T cells may play a critical
role in the regulation of inflammation, both by controlling the response of activated a(3 T
cells and in the resolution of inflammation. For example, immunocompetent mice treated
with anti-TCRy8 MoAbs show markedly increased activation of a(3 T cells reflected by
IL-2 production and target cell lysis in vitro [139],

A murine model of infection by

Listeria monocytogenes (a facultative intracellular bacterium) shows additional evidence.

Flere, intravenous or intraperitoneal inoculation of healthy immunocompetent mice
resulted in a vigorous inflammatory response with the subsequent development of
Listeria-specific cytolytic a(3 T cells, leading to a clearance of infection within 7-10 days
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[132, 134], In mice lacking y6 T cells, however, resolution of the inflammatory response
was much impaired; instead of small granulomatous lesions around infected hepatocytes
which are eventually cleared by Listeria-specific a|3 T cells and activated macrophages,
severe liver parencymal damage ensued, characterized by large necrotic lesions and
Listeria not confined to individual hepatocytes [132, 134]. In a separate experiment also

involving Listeria infection, it was further shown that y6 T cells tend to increase
simultaneously with or after activated a|3 T-cell responses, in addition to producing IL10, an inhibitor of activation and growth of ThI cells [140], Thus, it was proposed that
y6 T cells regulate inflammatory responses of a[3 T cells [141].
Additional studies have implicated that y5+ IELs in particular, resident in the skin
or the gut, may locally down-regulate a|3 T cell-initiated inflammatory responses to
allergens or pathogens [117, 142-146].

In several studies, the model of contact

hypersensitivity to allergens such as 2,4-dinitrofluorobenzene (DNFB) has been used,
from which data have been consistent with a down-regulating effect of DETC on
conventional T cells (reviewed in [147]).
antigen-specific

Studies have also reported an ability of

y6 T cells to down-regulate same allergen-induced contact

hypersensitivity, possibly by the killing of allergen-specific a(3 T cells [148, 149],
A model of graft versus host disease (GVHD) has previously demonstrated the
integral role of y6 T cells in suppressing autoreactive T cells [145]. In this mouse model,
a C57BL/6-derived autoreactive T-cell clone was injected intradermally into the footpad
of syngeneic mice.

The grafted cells were shown to take residence in the epidermis

where they cause histological changes resembling those seen in human cutaneous GVHD
[150].

Whereas GVHD in this model is usually self-limiting with spontaneously
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recovered epidermis becoming resistant to subsequent induction of GVHD, TCR6-/mice developed cutaneous GVHD that lasted longer than in normal controls [145],
Additionally, these mice did not show any resistance to subsequent cutaneous induction
of GVHD, even though the presence of a large population of a(l T cells was detected in
the place of epidermal y6 T cells. When epidermal y8 T cells were reconstituted through
injections with day 16 fetal thymocytes from normal mice, resistance against GVHD was
restored [145]. Such data clearly point to the role of DETC in local epithelial protection
and maintenance, such as in the context of autoimmunity.
In these previous studies, none have critically tested the hypothesis that the
specific subset of Vy5+ DETC down-regulate cutaneous inflammatory reactions, while
other y6+ cells do not.

Recently, Girardi et al. (2002) examined the physiological

consequences of DETC deficiency in several different genetic strains of y6 T celldeficient mice, in addition to conducting adoptive transfer experiments in which
FVB.6-/- (Taconic) mice received either Vy5+ cells or other subpopulations of y6 cells.
The study led to several conclusions. The first observation was that a specific phenotype
consisting of a spontaneous cutaneous inflammation of the ears in nonobese diabetic
(NOD) mice developed by 5-6 weeks of age without any external manipulation.
However, only NOD.6-/- mice showed this cutaneous phenotype, while NOD wild-type
mice did not.

Histopathologic examination of NOD.6-/- ear skin resembled that of

chronic dermatitis: a thickened epidermis, mild intercellular edema, scattered
mononuclear inflammatory cells within the epidermis, and a thickened dermis with
dilated blood vessels, eosinophils, mononuclear inflammatory cells, and highly increased
numbers of mast cells.

Baseline ear thickness was shown to be markedly increased.
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Intriguingly, this spontaneous dermatitis was strain-dependent. FVB.6-/- showed less
dramatic but highly significant increases in ear thickness compared to FVB wild-type
animals, while C57BL/6.8-/- and wild-type mice showed no clinical or histologic
evidence of the phenotype [147],

The second conclusion was that the spontaneous

dermatitis phenotype appeared to have an inheritance pattern consistent with a single
autosomal recessive gene controlling the susceptibility of the NOD.6-/- mice.

In an

analysis of NOD.8-/- and C57BL/6.8-/- mice, bred to produce Fi, F2, and (Fi X NOD)
backcross (BC) offspring, 24.5% of the F2 mice and 42% of the BC mice were identified
to have the NOD-like phenotype. These incidence rates were consistent with a possible
single autosomal recessive gene inheritance, in which case the expected frequency of the
phenotype in the F2 population is 25% and in the BC population 50% [147], A third
conclusion from the study was that allergic and irritant contact dermatitis reactions are
enhanced in 8-/- mice, but also in a strain-dependent way.

FVB.8-/- mice showed

strikingly augmented ear swelling to both allergic contact dermatitis induced by
sensitization and challenge by DNFB and irritant contact dermatitis, induced by
application of TPA, while C57BL/6.8-/- did not.

Finally, the authors found that

spontaneous and augmented irritant dermatitis responses in 8-/- mice require a(3 T cells,
since (3—/—6—/— did not show evidence of either, and that Vy5+ DETC are necessary and
sufficient for down-regulation of dermatitis. Indeed, FVB.8-/- mice reconstituted at 1-3
days old with >98% pure Vy5+ gestational day 17 fetal thymocytes did not show
evidence of spontaneous dermatitis, whereas those injected with Vy5- fetal thymocytes
had an increased baseline ear thickness comparable to those of FVB.8-/- mice [147],
However, because the ears of the Vy5- recipients was found to be only minimally
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reconstituted with Vy5- y6+ T cells, it could not be concluded that Vy5- y6+ cells could
in fact play an anti-inflammatory role if they were present in substantial numbers. Yet, in
one experiment where it was possible to populate the skin with substantial numbers of y6
cells bearing non-DETC TCRs (derived from peripheral lymph nodes of TCR.|3-/donors), no down-regulation of a[3 T cell-induced local inflammation was seen.
The data from this study provide evidence that Vy5+ DETC play a nonredundant,
local regulatory role of cutaneous inflammation induced by aj3 T cells. Yet, there remain
many unanswered questions. First, the spontaneous, localized, cutaneous inflammation
that develops in particular strains of 6-/- mice resembles a chronic dermatitis that may
be similar to human atopic dermatitis (AD) [151]. Thus, the phenotype observed in this
study may serve as a new animal model for human AD. In fact, a few mouse models
have already been proposed for this chronic inflammatory disease, in which many genetic
analyses have been undertaken [152-154], Additional studies evaluating IgE levels and
the effects of the environment on development of the dermatitis are needed in order to
elucidate the similarities and differences between the spontaneous dermatitis seen in
these 6-/- mice and human AD.

In addition, the need for further detailed genetic

analyses is salient in order to clarify any relation between the current model and existing
models of chronic cutaneous inflammation mimicking human AD.

Relevance of DETC Model to Humans
The situation in human skin is quite different from that in murine skin. In normal
human skin the majority of CD3+ cells (>95%) are localized in the dermis, whereas only
2-5% of CD3+ cells are within the epidermis [155, 156]. Furthermore, in the dermis, up
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to 80% of the CD3+ cells possess the a(3 TCR, whereas only 2-9% bear the y6 TCR [155,
157], Of the 2-5% of CD3+ cells within the epidermis, 60% express the a(3 TCR and 1829% the y6 TCR [155, 156, 158], Some even report a proportion less than 0.1% of CD3+
intraepidermal T cells expressing the y6 TCR [157, 159],

In addition to the stark

difference in prevalence of mtraepidermal yS+ cells, human skin and murine skin also
differ in that the y8 T cells in human skin lack the dendritic shape of DETC [160], The
functions of y8 T cells in human skin is unknown, and currently, it is generally accepted
that a morphologic equivalent of murine DETC does not exist in humans [156, 161].
However, most recently, an analysis of normal human skin has revealed that cutaneous y8
T cells express a highly restricted TCR8 repertoire distinct from that of peripheral blood
y8 T cells [160]. From separate skin areas, identical dominant TCR8 rearrangements
could be identified. Based on these recent findings, it is indeed conceivable that human
cutaneous y5 T cells, albeit of a smaller population, represent a functional equivalent of
murine DETC.

B. GENETICS OF ATOPIC DERMATITIS
Allergic diseases, both systemic and site-specific, affect approximately 20-30% of
the general population and constitute a major source of suffering, disability and loss of
productivity throughout the world.

Atopy refers to the predisposition to develop the

group of inflammatory diseases which occur following exposure to antigens that are
otherwise innocuous, for example, dust mite, pollen, mould and animal dander [162],
Atopic diseases as many other immunological diseases are multifactorial complex traits
with a significant impact of both genetic and environmental factors on the outcome of the
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disease.

The identification of the multiple genetic and environmental factors is

confounded by heterogeneity both within a specific atopic disorder, such as asthma,
allergic rhinitis, allergic conjunctivitis, and atopic dermatitis, and between the groups of
diseases.

Thus, symptoms produced may be phenotypically indistinguishable to the

clinician even though the genetic predisposition for a specific disorder may in fact result
from distinct sets of susceptibility genes in different individuals. Despite these inherent
difficulties, there has been remarkable progress towards the identification of the various
factors which contribute to the pathophysiology of atopic diseases. During the past 30
years, much of the focus has been on defining the cells and molecules which mediate the
allergic reaction [163],

Further elucidation has been achieved through studies of the

nature of allergens and from fundamental investigations of the immune response [164],
Several studies involving both extended-family and twin-study approaches have provided
clear evidence that both the atopic condition in general and specific allergic disorders
have a strong genetic component. Like other complex genetic diseases, however, there is
a clear environmental role, making the estimate of the number of genes contributing to
the heritability of the condition not at all clear. While there are certainly major genes that
control atopy in general, disease-specific genes that determine which disease an atopic
individual develops are also likely to exist [165, 166]. Defining such genetic factors will
shed light on pathophysiologic mechanisms, which in turn should lead to better treatment
strategies. In the analysis of complex traits, however, the genetic analysis is complicated
by genetic heterogeneity, phenocopies, gene interactions, and incomplete penetrance.
The marked increase in the prevalence of AD over the past three decades has led
investigators to aggressively pursue elucidation of its pathogenesis [167],

AD is
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characterized by complex symptoms including a chronically relapsing course, extreme
pruritus, and eczematous skin lesions with typical morphology and distribution, which
are associated with IgE hyperresponsiveness to environmental allergens [168], AD is one
of the most common skin diseases in children with a family history of atopy, with the
prevalence of atopic eczema peaking in the first 5 years of life [169, 170], Twin studies
have helped to elucidate the genetic component to atopic eczema, showing concordance
of disease in monozygotic twins (0.72) compared with dizygotic twins (0.21) [171].
Most atopic diseases have a heritability of between 0.60 and 0.72 [172], In looking for
genetic factors that might predispose an individual to atopy, it is logical to examine the
pathophysiologic pathways involved in allergic responses to focus the initial search on a
few key genes.

Very few studies to date have been done on the genetics of atopic

dermatitis, with reported findings often being discordant [166], The genomic regions of
interest in the initial studies include chromosome 5q31 (in the region of the genes coding
for IL-4, IL-5, IL-9, IL-13, interferon regulatory factor 1, GM-CSF-2, CSF-1 receptor,
and platelet-derived growth factor receptor) [173, 174] and chromosome 11 q 13 (at the
locus for the high-affinity Fee receptor 1, FcsRI) [175-182], One linkage study using
markers on 11 q 13 flanking the FcsRI locus showed negative findings [182], while a later
study showed some evidence for support in a subgroup of families with atopic dermatitis
[183].

An association between atopic eczema and the presence of a polymorphic

restriction site within the mast cell chymase (MCC) gene on chromosome 14q 11.2 has
been shown in the Japanese population [184], with a proposed second association with a
polymorphism in the promoter of IL-4 on chromosome 5q [185],

Most recently, an

association between atopic dermatitis and IL-13, which plays an important role in the

37

induction of IgE synthesis and in the pathogenesis of allergic diseases [186-188] was
investigated.

A novel IL-13 coding region variant at 4257 bp was found to have a

significant association with both high total serum IgE level and AD [189].
An alternative approach involves performing a genome-wide search to identify
novel candidate regions [178],

With this approach, linkage analysis studies are

performed using microsatellite markers dispersed at roughly equal intervals throughout
the genome. LOD scores (log base 10 of the likelihood ratio under the hypotheses of
linkage and non-linkage) are determined, which serve as the major criterion of the
likelihood that an atopy gene resides at that location in the genome.

To date, two

genome-wide screens for atopic dermatitis in humans have been reported. The first of
these found linkage of AD to chromosome 3q21 [190], The second screen found linkage
of AD or AD and asthma combined to chromosomes lq21, 17q25, and 20p [191]. All
four linkages correspond to known psoriasis susceptibility loci [191], suggesting that the
regions contain clusters of genes with general effects on skin immunity and
inflammation.

It is clear that both approaches, analyzing candidate genes and using

genome-wide mapping studies, have yielded potentially important genes which may
contribute to genetic predisposition for atopic disease [165].
Inbred mouse strains have proven very valid for the dissection of such
complicated phenotypes as atopic dermatitis in the following ways: (1) phenotypic
variance between genetically identical individuals has been shown to be caused solely by
environmental and stochastic events; (2) segregation of genomic regions or candidate
genes can be investigated in large offspring populations; (3) linked chromosomal
segments can be further refined with congenic mouse strains, where parts of the candidate
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region are introgressed into an identical genetic background; (4) single and combined
functions of candidate genes can be investigated by mutation through gene disruption,
transgenesis and cross-breeding of such strains; and (5) random mutations within the
genome through chemicals can detect novel candidate genes, which are involved in the
critical pathways and networks of these complex traits [192], While several studies have
investigated the genetics of atopy-related phenotypes of the respiratory tract in inbred
mouse strains [192], mouse models for atopy-related phenotypes of the skin have been
rare to date.
Thus far, two genome-wide linkage screens for susceptibility loci for atopic
dermatitis have been performed in two different mouse models. The Naruto Research
Institute Otsuka Atrichia (NOA) mouse is a mutant mouse strain recently discovered in
1997, having originated from a spontaneously sparsely coated mutant male mouse
obtained in 1982 by cross breeding between a female C3H/He mouse and a male ddY
(hairy strain) mouse [193]. The NOA mouse is characterized by becoming completely
hairless and smooth-skinned in adulthood until the spontaneous development of severe
ulcerative skin lesions from the tenth week of age. The animals are housed under barriersystem conditions, periodically subjected to microbiological monitoring, and confirmed
to be free of categories A, B, C, and E of microbes and parasites specified for monitoring
in mice and rats by the ICLAS Monitoring Center (Asia) [194], Prevalence rates of these
ulcerative skin lesions are 30% by the tenth week of age, increasing to 90% by the 20,h
week of age. In severe cases, the lesions extend to cover almost 20% of the body surface
area. Histologically, the ulcerative skin lesions show epidermal desquamation, thickened
dermis with a proliferation of inflammatory cells and collagen bundles, and a striking
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accumulation of mast cells in and around the lesions [193], Additionally, NOA mice
with ulcerative skin lesions show a significantly increased level of serum IgE compared
to NOA mice without ulcerative skin lesions, HRS/J mice (a standard hairless mutant
mouse), and two strains of hairy mice, all housed in the same conditions [193]. Analysis
of NOA backcross progeny of five different mouse strains revealed a significant
association between ulcerative skin lesions and markers in the middle of chromosome 4
[153].

Interestingly, the genetic background of the five parental strains used in the

backcross breeding to susceptible NOA mice appeared to have a significant impact on the
incidence of skin lesions in the progeny: atopic dermatitis developed three times more
often in progeny derived from Tr2 responder mice (BALB/cByJ and DBA/2J) than from
Th1 responder mice (C3H and C57BL6/J). A search for the modifier genes revealed two
chromosomal regions with candidate genes suppressing the development of the NOA
atopic dermatitis-like skin disease: in the middle of chromosome 7 and in the telomeric
region of chromosome 13 [154], Both loci correspond to regions of synteny to human
chromosomes where linkage to different atopic phenotypes has previously been described
(chromosome 5q 13 and 11 q 13). In addition, both regions contain candidate genes for
atopic dermatitis. The region on chromosome 7 encodes the gene for IL-16, the mRNA
of which has been shown to be upregulated in acute atopic dennatitis and is associated
with increased numbers of CD4+ T cells at the site of inflammation [195],

The

chromosome 13 region contains the possible candidate gene of phosphoinositide-3-kinase
regulatory subunit, polypeptide 1 (Pik3rl), which belongs to a family of enzymes
involved in the generation of lipid mediators, which in turn activate a series ol
intracellular kinases [196].
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A second mouse model for human atopic dermatitis is an inbred strain called
NC/Nga [152],

NC/Nga mice were originated from Japanese fancy mice (Nishiki-

Nezumi) and established as an inbred strain in 1955 [197], Some Japanese researchers
noticed development of spontaneous dermatitis just before or after weaning, but the cause
and pathogenesis remained unclear [198], Upon further investigation, it was observed
that these mice spontaneously suffer severe dermatitis in the presence of nonspecified
environmental factors. The spontaneous dermatitis developed in NC/Nga mice housed
only in air-uncontrolled conventional rooms. In contrast, no skin lesions were detected
clinically in mice maintained in specific pathogen-free (SPF) conditions consisting of a
laminar filter-air flow enclosure in a bioclean room [198], Prevalent symptoms of the
spontaneous dermatitis included itching, erythema, hemorrhage, edema, crust, drying,
and excoriation/erosion hyperplasia of the epidermis region in the face, neck, and/or
back, which are all exacerbated by aging. Furthermore, NC mice showed characteristic
features of human AD by histopathological examination, such as macrophages and
eosinophils invading the dermis, increases and activation of mast cells and lymphocytes,
reduction of ceramide, appearance of activated mast cells, and lesional CD4+ T cells
[152], Intriguingly, similarly aged BALB/c mice maintained with conventional NC/Nga
mice in the same cage from 7 to 17 weeks of age showed no significant clinical signs or
symptoms, suggesting that the dermatitis seen in conventional NC/Nga mice was due not
simply to the presence of an environmental factor but also to specific factors intrinsic to
the NC/Nga background. Detailed genome-wide mapping studies of NC/Nga backcross
mice were subsequently performed in order to identify the genetic loci responsible for
human AD using the NC/Nga mouse model.

The most significant linkage result was
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found on chromosome 9, termed Derml.

Several candidate genes are located near

Derml, including thymus cell antigen 1, theta (Thyl), ILlOr, IL18, and cytoplasmic
tyrosine kinase (Csk). IL-18 and IL-10 receptor might present the best candidate genes in
this region as both have been shown to be important for the propagation of atopic
dermatitis, being strongly downregulated in acute lesions of atopic dermatitis in humans
[199, 200],
Though the chromosomal regions found in the genome-wide screens for atopic
dermatitis in humans do not correspond to the regions identified in the above-mentioned
mouse models, further studies may indeed reveal regions corresponding to those found in
the human system and will undoubtedly contribute largely to the elucidation of the genes
involved in human AD.

C. ATOPIC DERMATITIS AND IgE
As previously mentioned, patients with atopic eczema often have personal or
family histories of atopic respiratory disease (asthma and allergic rhinitis) [201-203] and
are often characterized by heightened IgE responsiveness [204], Overwhelming evidence
does assert that atopy is indeed a TH2-mediated disease [165].

The well-known

mechanism involves individuals being sensitized to a certain allergen, followed by
synthesis of allergen-specific IgE molecules which bind to the high-affinity IgE receptor
on mast cells and basophils [2, 37, 165], Upon re-exposure to allergen, membrane-bound
IgE molecules are cross-linked and signals are transduced through antigen-recognition
activation motifs, which are found in multiple receptors such as the TCR-CD3 complex,
and the Fc receptors [205]. These signals then mediate degranulation of the cells and
preformed mediators of allergic inflammation found in the granules are released.
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Receptor cross-linking additionally results in the activation of cytokine gene transcription
as well as the synthesis of a large panel of newly formed mediators [206], Atopy could
theoretically result from an abnormal regulation of this process at several control points.
The total serum IgE level is highest in patients with atopic eczema compared with
patients with asthma, perennial rhinitis, and hay fever [172], Patients with atopic eczema
and atopic respiratory disease often show high serum IgE levels [207], blood eosinophilia
[208] , increased deposition of eosinophil granule major basic protein in skin lesions
[209] , and increased number of mast cells in skin lesions [210],

However, patients

without personal and family histories of atopic respiratory disease tend to show normal
IgE concentration [211-213], normal eosinophil count [208], scant deposition of major
basic protein in skin lesions [209], and a normal number of mast cells in skin lesions
[210] . Additionally, it has previously been shown that a significant difference exists in
the genotype distribution of mast cell chymase, a serine protease secreted by mast cells,
between patients with normal IgE concentration and patients with very high IgE
concentration [214], Yet these two groups of patients did not show any difference in the
morphological appearance of the skin lesions and the clinical course. Thus, the genetic
background of atopic eczema might be heterogeneous and IgE responsiveness may be
controlled separately from actual development of the atopic dermatitis phenotype.
Further study is indeed needed to clarify the dominant factor determining IgE
responsiveness in patients with atopic eczema, as well as the actual role of IgE in the
development of atopic dermatitis.
In the proposed mouse models for human AD, the skin lesions that appear in
mouse skin are associated with increased IgE levels.

Plasma levels of total IgE in
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NC/Nga mice are markedly elevated from 8 weeks of age, when mild dermatitis is
clinically evident, and increase significantly by 10 weeks, plateauing at 17 weeks, thus
con-elating with clinical severity of dermatitis [198], In NOA also, severe ulcerative skin
lesions are associated with a significantly increased level of serum IgE [193],

D. GOALS OF PRESENT STUDY
Although great attention has been focused on the pathogenesis of human AD, the
exact etiology remains unclear.

Establishment of a suitable animal model is of great

importance in elucidating the pathogenesis of this chronic inflammatory skin disease.
Girardi et al. (2002) demonstrated a spontaneous, localized, cutaneous inflammation that
developed in particular strains of 6-/- mice resembled a chronic dermatitis resembling
human AD. Thus, the phenotype observed may serve as a new animal model for human
AD. As higher IgE levels have been found in human AD patients, the present study
sought to determine similarities and differences between the spontaneous dermatitis
observed in susceptible NOD.8-/- mice and human AD by measuring serum IgE levels
in these mice.

When compared to IgE levels of mice lacking clinical signs of

spontaneous dermatitis, including NOD.8-/- housed in SPF conditions, NOD wild-type
(w.t.), C57BL/6 (B6) (non-susceptible), and (NOD X B6)Fi mice, NOD.8-/- mice
exhibiting spontaneous dermatitis is expected to show significantly higher total serum
IgE levels if IgE indeed plays a primary role in the pathogenesis of the spontaneous
dermatitis. Likewise, if genotypically identical mice, such as (Fi X NOD)BC.8-/- mice,
which show high levels of inflammation are compared to those showing low or absent
levels of inflammation, it is expected that higher serum IgE levels will be found among
mice with higher levels of inflammation.
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As Girardi et al. (2002) showed that the spontaneous dermatitis phenotype is
strikingly strain-dependent, existing in NOD but not C57BL/6 mice, a second goal of the
present study was to elucidate the genetic role governing the susceptibility to spontaneous
dermatitis.

Analysis of NOD and B6 simple sequence length polymorphisms at specific

loci was performed to clarify the relation between the current model and existing mouse
models of human AD, namely NOA and NC/Nga mice.

It is hypothesized that the

current NOD model will show linkage of spontaneous dermatitis to either of the two
major determinant quantitative-trait loci already identified through genome-wide searches
to be responsible for atopic dermatitis-like skin lesions in the NOA and NC/Nga mice.
Finally, in the search of ultimately defining the ligand(s) for the DETC-specific
Vy5/V61 TCR, a third goal of the present study was to develop a bioassay in which
activation of the Vy5/V51 TCR could be assessed.

A very useful strategy entails

isolating the y6 TCR in a heterologous cell type. Such y6 TCR transfectants have been
developed using the rat basophil luekemia (RBL) cell line, using a specific clone called
RBL-2H3. This cell line presumably does not express NKG2D, CD8, or other receptors
expressed by y6 cells, and theoretically avoids the problem of cell activation through an
accessory molecule. The background on the development of a RBL bioassay to test TCR
activation is briefly discussed below.

Research Design
Development of a bioassay to assess activation through the y5 TCR
FceRI vs. TCRt, signal transduction pathways

The RBL-2H3 clone [215] is a subclone from the original Rat Basophil Leukemia
cell line [216], and has been widely used to study the signal transduction pathway of the
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high affinity receptor it bears for IgE, FceRI. The FceRI structure and signaling cascade
resemble those ot the a[3 TCR complex. The FceRI complex is composed of an IgEbinding a chain, a four-transmembrane (3 chain, and two disulphide-linked y chains [217],
Each (3 and y subunit contains a single immunoreceptor tyrosine-based activation motif
(ITAM), resulting in a total of three ITAMs per FcsRI receptor complex.
IgE/antigen binding, the (3

Upon

chain-associated Src family tyrosine kinase Lyn

phosphorylates the tyrosine residues on the y chain.

Another protein tyrosine kinase

called Syk then binds to the phosphorylated ITAMs in FcsRIy, resulting in Syk
phosphorylation by Lyn.

Activated Syk subsequently phosphorylates the membrane-

associated cytoplasmic adaptor protein LAT, initiating downstream pathways including
phospholipase C-y (PLC-y) and sphingosine kinase, leading to degranulation.
The signaling cascade utilized by the a|3 TCR parallels that of the FceRI receptor.
As previously described, the c*|3 TCR is a ligand-binding heterodimer closely associated
with a CD3 signaling complex [3], The CD3 signaling complex consists of 6/e and y/e
heterodimers, in addition to a disulphide-linked TCRt, homodimer [4, 218],

TCRf is

highly homologous to the FcsRIy chain [219], with the significant difference that each
TCR^ contains three ITAMs compared to a single ITAM on FcsRIy. Upon TCR ligation
by MHC-presented antigen, the three ITAMs are phosphorylated by the Src family
kinases Lck or Fyn [4],

A kinase homologous to Syk, ZAP-70, then binds to the

phosphorylated ITAMs and itself is phosphorylated by Lck/Fyn.

Activated ZAP-70

subsequently phosphorylates LAT, leading to activation of downstream pathways
including PLC-y, ultimately resulting in transcription of specific genes.
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The signaling capacity of TCRg and FceRIy has been studied in detail in RBL
cells as well as in T cell lines. Early studies showed that t, and y were each sufficient for
full activation of cells [205, 220]. Furthermore, through studies involving the fusion of
the transmembrane domain and cytoplasmic tail of t, and

y

to the extracellular domains of

cell surface antigens such as CD4 and CDS [205, 220], in addition to studies involving
fusion to the extracellular domain of the receptor IL-2Ra [221], with expression in T cell
lines, the cytoplasmic tail of CQ was shown to deliver a more potent signal than

y

when

expressed in the BW5147 T cell line. When tested in the RBL-2FI3 line, 2, fusions were
found to elicit a stronger response in this system as well. As each
IT AMs compared to one on each

y

t,

chain contains three

chain, the stronger response of the t, fusions may be

explained by increased strength of signaling due to the greater number of phosphorylated
IT AMs in the

t,

signaling complex. Indeed, it has been shown that the intensity of the

response to signaling by recombinant ITAM-containing polypeptide chains is dependent
on the number of ITAMs present [222],

Serotonin Release Assay

RBL cells have the ability to release endogenous mediators such as histamine
from intracellular granules, in addition to incorporating exogenous molecules and storing
them in intracellular granules. Upon binding of antigen/IgE complexes to FceRI, they are
activated to release the content of their secretory granules.

The original RBL lines

secreted very low levels of histamine upon antigen/IgE complex binding to FceRI [216],
While some subclones, including RBL-2H3, did release histamine upon stimulation as
detected by ELISA, the histamine content was significantly lower than that of normal
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mast cells. A more sensitive degranulation assay was subsequently developed [223], In
this assay system, RBL-2H3 cells incorporate 3H 5-hydroxytryptamine (serotonin) into
their secretory granules via incubation with the radioactive substance overnight. The
activated cells release the content of their secretory granules, including their endogenous
histamine and the exogenously loaded 3H serotonin.

The percentage of released

radioactivity is easily measured by scintillation counting.

TCR Expression in the RBL System

The RBL-2H3 line was used in early attempts to produce a soluble a(3 TCR for
crystallographic analysis and measurements of the affinity between TCR ct(3, MHC, and
antigen [224], The extracellular domains of the a and (3 chains of the T cell hybridoma
2B4 TCR were fused with the transmembrane and cytoplasmic tail of the TCR t, chain,
and were stably expressed as cx-g and |3-£, chains on the cell surface. The cytoplasmic
domain of g induces cell activation when attached to heterologous proteins that are crosslinked by antibody [205, 220, 221], Thus, the ability of an a-t/(3-t heterodimer to bind
antigen-MHC could be tested by exposure of the cells that expressed this heterodimer to
antigen-pulsed presenting cells.

In addition, the t, transmembrane domain induces

disulfide dimerization when attached to heterologous proteins [205, 220],

The t,

constructs, even in the absence of the CD3 complex, demonstrated the ability to signal
upon exposure of the transfectants to cells that presented the appropriate antigen-MHC
complex, with activation measured by release of 3H serotonin [224], Engel et al. (1992)
also demonstrated efficient transport to the cell surface of a and (3 chains that was
dependent on disulfide-linked heterodimer formation induced by the g chain [224],
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With the evidence of strong signaling capacity through the cytoplasmic tail of
along with previous studies demonstrating the ability to stably and efficiently express
functional t, fusion constructs on the RBL cell surface, the RBL system provides an
attractive method for studying y6 TCR specificity.

In this system, the TCR can

presumably be isolated in order to search for its ligand(s) since rat basophil cells should
not express molecules that could bind ligands on mouse target cells. Additionally, the
serotonin release assay is a simple yet highly sensitive method in which to measure
activation through the y6 TCR.

While traditional T cell activation assays measure

proliferation or IL-2 release after 24 hours of activation or more [205, 220], serotonin
release has the additional advantage of allowing measurement after only 45 minutes of
activation. Once stably expressed on the RBL cell surface, Vy5 TCRg and V61 TCRL
chimeric constructs co-transfected into RBL-2H3 cells should have the ability to
stimulate signal tranduction upon TCR engagement with ligand, leading to degranulation
and serotonin release, thus providing a system through which the DETC TCR ligand(s)
can be identified.
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II. MATERIALS AND METHODS
A. TOTAL SERUM IgE MEASUREMENTS
1. Animals
C57BL/6 (B6) wild-type (&+/+, containing normal yb T cells) and non-obese
diabetic (NOD/LtJ) wild-type mice purchased from The Jackson Laboratory (Bar Harbor,
Maine, USA) have been maintained at the animal facilities of Yale University. B6 mice
deficient in yb T cells (TCR.8-/-) (The Jackson Laboratory; Bar Harbor) were
backcrossed to NOD mice 14 generations to produce NOD.6-/- mice used in this study.
For genetic analyses, (NOD X B6)Fi.6-/- and (B6 X NOD)Fi.8-/- offspring were used,
produced by mating NOD.8-/- mice with B6.6-/- mice using both sexes in each strain.
In addition, F2.6-/- offspring generated by intercrossing F1.6—/— mice, as well as (Fi X
NOD)BC.6-/- and (NOD X F1 )BC,6-/- mice produced by backcrossing F1.6—/— mice to
NOD.8-/- mice (again using both sexes), were used. Mice were kept in two different
housing conditions from birth. Conventional, non-ventilated cages (CNVC) were filtertopped cages with sterilized food and water, along with autoclaved corncob bedding,
changed at least once a week. Individually-ventilated cages (IVC) were also filter-topped
cages with sterilized food, water, and corncob bedding, but in such cages room air is
changed ~17 times per hour. In such a setting, bedding remains substantially drier and
requires changing only every 10-14 days.

Repeat testing of mice in both housing

conditions failed to identify known bacteria! pathogens, mites, or pinworms on the skin.
Serum IgE samples were collected from the following (number of) mice in the
specified housing environments: (10) B6 wild-type housed in CNVC,

(31) B6.8-/-

housed in CNVC, (6) NOD wild-type housed in CNVC, (7) NOD wild-type housed in
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IVC, (40) NOD.6-/- housed in CNVC, (26) NOD.6-/- housed in IVC, and (24) (B6 X
NOD)F].6-/- and (NOD X B6)Fj.6-/- housed in CNVC. The number of samples for
each type of mouse and housing environment was determined by the number of mice
available within the same age range at the time of testing and from which at least 50 pi of
serum was able to obtained.

Additionally, serum was collected from

(Fi X

NOD)BC.S-/- and (NOD X Fi)BC.§-/- mice housed in CNVC, in order to compare
total IgE levels in

(32) mice with a high level of inflammation with (33) mice showing a

low level of inflammation. High inflammation mice were defined by selecting the first
15 males and first 17 females from a list in which all mice (121 males and 114 females)
were ordered from highest to lowest according to their mean baseline ear thicknesses
(inches x 1 O'3) measured by an engineer’s micrometer.

Low inflammation mice were

defined by selecting the last 16 males and last 17 females from the same list.

2. Serum collection
Sera were collected from mice at age 11-16 weeks. Mice were anesthetized by
placement in an anesthetic jar containing Metofane on gauze squares under screening.
Blood was collected from the retro-orbital sinus by gently inserting and twisting the tip of
a glass capillary Pasteur pipette below the eye between the globe and lower eyelid.
Blood was transferred into a labeled 1.5 ml plastic microcentrifuge Eppendorf tube using
a pipette bulb to carefully blow out the sample. A volume of approximately 0.25 ml was
obtained from each animal. Gentle manual pressure with a gauze pad was applied to the
site of collection on each mouse for a few seconds until bleeding was completely
stopped.

For some mice, blood was collected via cardiac puncture as a terminal

collection method using a 1 ml syringe and 22 gauge, 1-inch needle, inserted through the
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left thoracic wall at the point where heartbeat was felt. Blood collection was followed by
immediate euthanization ot the animal by cervical dislocation while under anesthesia as
outlined by the Yale University Animal Resources Center [225],

Blood samples were

allowed to clot for 4-6 hours at 4°C, were then centrifuged for 5 minutes at 1200 rotations
per minute (rpm), and sera were collected into separate clean 1.5 ml plastic Eppendorf
tubes using a 1000 pi pipetman (Gilson), transferring minimal amounts of cellular
product. Samples were centrifuged for another 5 minutes at 1200 rpm. Sera were then
transferred into clean 1.5 ml plastic Eppendorf tubes and stored at -4°C until use, at
which time samples were thawed at room temperature and kept on ice.
Ear phenotypes and baseline thicknesses of the specific animals used for the
measurement of serum IgE levels were assessed on the day of serum collection by Robert
Tigelaar, M.D., in which presence/absence of dennatitis was recorded, as well as baseline
ear thicknesses using an engineer’s micrometer.

3. Antibody measurement by Enzyme-Linked Immunosorbant Assay (ELISA)
For determination of total serum IgE levels, 96-well microtiter plates (Nalge Nunc
International, Rochester, New York, USA) were coated with sheep anti-mouse IgE (15.9
mg/ml, 1:000 dilution; The Binding Site, Birmingham, United Kingdom) in boratebuffered saline (pH=8) at 4°C overnight.

The following steps were performed, with

plates being washed 2 times with phosphate buffered saline (PBS)/0.05% Tween-20
(20mM Tris, 150 rnM NaCl, 0.1% tween) and 1 time with PBS between each step.
Blocking was performed with 1% bovine serum albumin (BSA) in borate saline (BSABS) for 1 hour at 37°C, after which sera were diluted serially (starting at a 1:10 dilution)
in 1% BSA-BS in replicate (two for each dilution) wells and incubated for 2 hours at
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37°C. This was followed by incubation for 1 hour at 37°C with an optimal dilution of
biotin-labeled secondary rat anti-mouse IgE antibody (1 mg/ml, 1:2000 dilution; Clone
LO-ME-3, BioSource International).

Streptavidin-conjugated horseradish peroxidase

(1.25 mg/ml, 1:5000 dilution; Zymed Laboratories, San Francisco, California, USA) was
added for a 30-minute incubation at 37°C, followed by addition of 3,3’,5,5’tetramethylbenzidine (TMB) substrate solution (DAKO Corp., Carpinteria, California,
USA) and termination of the reaction with 6N HC1. Color change was read at 450 nm on
a microplate ELISA reader (Bio-Tek Instruments Inc., Winooski, Vermont, USA).
Antibody concentrations were calculated using DeltaSoft™ software by comparison to a
mouse IgE standard (starting concentration 100 ng/ml; Monoclonal Anti-dinitrophenyl
(DNP) Clone SPE-7 Purified Mouse Antibody, Sigma, St. Louis, Missouri, USA).

4. Statistical analysis
Statistical significance was determined using a standard Student’s unpaired twotailed r-test [226], Ap-value of < 0.05 was considered significant.

B. GENETIC ANALYSIS
1. Animals
To understand better the genetics governing the susceptibility to spontaneous
dermatitis (SpD), the (Fi X NOD)BC.6-/- and (NOD X F,)BC.6-/- mice produced by
backcrossing Fi .5—/— mice to NOD.6-/- mice (using both sexes as described above) were
used in the analysis of NOD and B6 simple sequence length polymorphisms (SSLPs) at
certain loci. As described in the study by Girardi et al. (2002), susceptible (“NOD-like”)
mice were identified by an increased baseline ear thickness ot > 5 SDs above the average
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means for “resistant” B6.6-/- and Fi .6—/— mice; i.e., BC females with an ear thickness of
> 14.0 (in. X 10"3), and BC males with an ear thickness > 15.5 were classified as
susceptible. A total of 99 of 235 (42%) BC mice had the NOD-like phenotype using
these criteria.

2. DNA Extraction
Livers were removed from euthanized donors (using either cervical dislocation or
Metofane anesthesia overdose) from each of the 99 (Fi X NOD)BC.b-/- and (NOD X
Fi)BC.6-/- mice identified to have obvious SpD by the above criteria.

Using the

DNeasy protocol for animal tissues (DNeasy® Tissue Kit, QIAGEN Inc.; Valencia,
California, USA), approximately 25 mg of tissue was cut up into small pieces, placed into
a 1.5 ml microcentrifuge tube, and incubated with proteinase K and tissue lysis buffer at
55°C until tissue was completely lysed, with occasional vortexing to disperse the sample.
Complete digestion was achieved with overnight incubation, i.e. typically 15-18 hours.
Samples were subsequently treated with 1 pi of RNAse A (100 mg/ml) and incubated at
37°C for 1 hour. Direct cell lysis was performed using the optimized buffer system as
outlined by the QIAGEN protocol, and lysates were loaded onto the DNeasy mini
column. During a brief centrifugation, DNA was selectively bound to the DNeasy silicagel membrane as contaminants passed through. Remaining contaminants and enzyme
inhibitors were removed in two efficient wash steps and DNA was then eluted in Buffer
AE, provided in the QIAGEN DNeasy® Tissue Kit, and was ready for use.
DNA yield was determined for each sample by measuring the concentration of
DNA in the eluate by its absorbance at 260 nm using a spectrophotometer. An A26o of 1
(with a 1 cm detection path) corresponds to 50 jig DNA per milliliter water. Water was
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used as a diluent when measuring DNA concentration since the relationship between
absorbance and concentration is based on extinction coefficients calculated for nucleic
acids in water [227], The spectrophotometer was always calibrated with distilled water.
An example of the calculations involved in DNA quantification is shown below:

Volume of DNA sample

= 100 pi

Dilution

= 20 pi of DNA sample + 180 pi distilled water
(1:10 dilution)

Measure absorbance of diluted sample in a 0.2 ml cuvette:
0.2

A260

-

Concentration of DNA sample

= 50 pg/ml X A260 X dilution factor
= 50 pg/ml X 0.2 X 10
= 100 pg/ml

Total amount

= concentration X volume of sample in ml
= 100 pg/ml X 0.1 ml
= 10 pg of DNA

The ratio of the readings at 260 nm and 280 nm (A260/A280) was calculated for 46 random
samples to provide an estimate of the purity of DNA with respect to contaminants that
absorb UV, such as protein. When absorbance is measured in lOmM TrisCl, pH 8.5,
pure DNA has an A260/A280 ratio of 1.8-2.0.

The A260/A280 ratio is influenced

considerably by pH, and since water is not buffered, the pH and resulting ratio can vary
greatly (DNeasy® Tissue Kit Handbook, QIAGEN Inc.).

Of the samples whose

absorbances were all measured in water, the A260/A280 ratios ranged from 1.35 to 3.41.
With the exception of 4 samples, all samples had ratios within the 1.5-2.0 range.
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3. Primers
As previously discussed, genome-wide microsatellite mapping studies in two
other distinct mouse models of “atopic dermatitis-like” disease have recently mapped
major susceptibility intervals controlling dermatitis to a region on chromosome 9 in
NC/Nga mice [152] and on chromosome 14 in NOA mice [153]. In the NC/Nga (NC)
model, linkage disequilibrium between dermatitis and various chromosome-specific
microsatellite markers was examined in backcross progeny between (NC X MSM/MS)Fi
and NC, MSM/MS being an inbred strain from Japanese wild mice, Mus musculus

molossinus. To map major quantitative trait loci (QTLs) for dermatitis, genotyping data
on each marker were analyzed by the X test. X results were evaluated by the values for
suggestive linkage (X > 8.7) and for significant linkage (%2 > 15.2) [228, 229], The
analysis revealed that the locus of the major determinant was tightly linked to D9Mitl63,

D9Mit72, D9Mitl43, D9Mitl03, D9Mit207, and D9MH209, as indicated by these
markers showing the highest and most significant X values (% = 16.4). The position of
the six reported loci was at 33.0 centiMorgans (cM) and 34.0 cM. Therefore, in order to
determine if susceptibility to SpD in NOD.6-/- mice is controlled by a locus in the same
interval, the D9Mitl05 locus at position 33.9 cM was chosen to be analyzed in the (Fi X
NOD)BC.6-/- and (NOD X Fi)BC.S-/- mice.

A PCR primer set which distinguishes

NOD from B6 SSLPs specific for this locus (Map Pairs) was synthesized at Yale
University Howard Hughes Medical Institute/Keck Oligonucleotide Synthesis Facility
(Oligoz-R-Us). The primer sequences were as follows: 5’-ACA GAG AAA GGA CAG
AGA TCC TG-3’ and 5’-TAT CAA ATT GGG AGT CAT TTA TGG-3’. The expected
size of the PCR product was 145 base pairs (bp) in the B6 genome and 116 bp in the
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NOD genome, i.e. a size difference of 29 bp between the two PCR products (see Table 1)
capable of readily being visualized after electrophoresis through a 3% agarose gel.

Locus

D9Mitl05
D14Mit262

Genetic
Position (cM)
33.9
37.2

C57BL/6

NOD

Difference (bp)

145
124

116
154

29
30

Table 1. Expected size (in bp) of PCR product using primer sets (Map Pairs)
distinguishing B6 from NOD SSLPs. D9Mit105 was selected based on the results by

Kohara et al. (2001) demonstrating significant linkage between dermatitis in NC/Nga
mice and markers on chromosome 9 at loci in positions 33.0-34.0 cM. D14MH262 was
selected based on the results by Natori et al. (1999) showing linkage between ulcerative
skin lesions in NOA mice and markers on chromosome 14 in the vicinity of 32.5-40.0 cM.

In the NOA model, linkage analysis was performed in NOA backcross progeny,
generated by first crossing NOA mice with five other murine strains (B6, IQI, C3H/HeJ,
DBA/2J, and BALB/cByJ) and then breeding backcross animals. Using microsatellite
markers selected at 10- to 20-cM intervals, Natori et al. (1999) scanned the entire
genomes of 559 backcross offspring from the five parental strains.

Linkage analysis

revealed a significant association between ulcerative skin lesions and markers on murine
chromosome 14. Statistical analysis revealed that the critical region was assigned to the
vicinity of D14Mit236, at position 32.5 cM {y~ = 86.89; P < 0.001), and D14Mit 160, at
position 40.0 cM (y2 = 86.62; P < 0.001).

To determine if susceptibility to SpD in

NOD.6-/- mice is controlled by a locus in the vicinity of these identified loci, the

D14Mit262 locus at position 37.2 cM was chosen to be analyzed as this locus is
approximately in the center of the interval between D14Mit236 and Dl4Mitl60. A PC'R
primer set distinguishing NOD from B6 simple sequence length polymorphisms (SSLPs)
at D14Mit262 was identified (Map Pairs) and synthesized as follows: 5'-CAG AAG
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GGA AAT CTT AAA ATG AGG-3’ and 5’-CAA CTT AGA TGC ATA CAC AGT
TTG C-3\ The expected size of the PCR product was 124 bp in the B6 genome and 154
bp in the NOD genome, i.e. a size difference of 30 bp between the two PCR products (see
Table 1).

4. Polymerase Chain Reaction (PCR) Amplifications
Genomic PCR amplifications were performed on all 99 (Fi X NOD)BC.6-/- and
(NOD X Fi)BC.5-/- samples, each sample in two separate reactions, one with primers
for D9Mitl05 and one with primers for D14MU262. PCR amplifications were performed
in 50-pl reaction mixtures, consisting of 80 ng of genomic DNA, 25 pmol of each primer,
5 pi of 10X PCR Reaction Buffer (Roche Diagnostics Corporation, Indianapolis, Indiana,
USA), 5 pi of ImM dNTPs, 0.5pl of Taq Polymerase (5 units/pl, Roche), and 31.5 pi of
double-distilled water (ddFEO).

PCR conditions included amplification at 94°C for 5

minutes, followed by 30 cycles of melting at 94°C for 60 seconds, annealing at 54°C for
60 seconds, and an extension of 72°C for 60 seconds. A final extension for 7 minutes at
72°C ended the process. All PCR reactions were performed in a DNA Thermal Cycler
480 (Perkin Elmer Cetus, Norwalk, Connecticut, USA).

PCR products were

electrophoresed on 3% agarose gels in IX TAE (0.04 M Tris-acetate, 0.001 M
ethylenediamine tetraacetic acid {EDTA}) buffer run at 60-80 volts, stained with
ethidium bromide, and visualized under ultraviolet irradiation.

5. Statistical analysis
The number of recombinant genotypes (heterozygous, NOD/B6, versus
homozygous, NOD/NOD) for each marker locus was calculated. Genotyping data on
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each marker were analyzed by the x2 test. Suggestive linkage was defined by a X value
of > 8.7 and significant linkage by a X value of > 15.2 [228, 229],

C. CONSTRUCTION OF V5-J1-Cy1/V1-D2-J2-C5 T-CELL RECEPTOR
1. Generation of Expression Construct
a. DETC cDNA production from mRNA
Messenger RNA (mRNA) was extracted from dendritic epidermal T cell (DETC)
clones previously established by Julie Lewis, Ph.D. and Robert Tigelaar, M.D.
(Departments of Dermatology and Immunobiology at Yale University).

Clones #7

(named 30E12), #9 (30B9), #12 (3G8), #15 (30F4), #16 (10F1), and #18 (210C11) were
used, all of which were established by limiting dilution of interface epidermal cells from
C57BL/6-TdT transgenic mice, stimulated initially with 10 U/ml IL-2 + 2 pg/ml
concanavalin A (ConA) + 1 pg/ml indomethacin, followed by expansion and twiceweekly feeding with 5 U/ml IL-2 (Lewis, personal communication). All DETC clones
had previously been sequenced by Tigelaar, with clones #7, #9, and #12 shown to have
the canonical Vy5 chain, and clones #15, #16, and #18 shown to have the canonical V61
chain (Tigelaar, personal communication). Using reverse-transcriptase PCR (RT-PCR),
DETC copy DNA (cDNA) was generated from the mRNA by Tigelaar, as outlined by the
QIAGEN OmniScript RT kit protocol (QIAGEN Inc.; Valencia, California, USA).
Briefly, 2 pi of Oligo-dT primer (10 mM) was added to 3 pi of each RNA sample and
incubated for 7 minutes at 68°C in the DNA Thermal Cycler 480. To each sample, 15 pi
of the following mix was added: 2 pi of 10X Buffer RT, 2 pi of 5mM dNTPs, 1 pi of
RNase inhibitor (10 units/pl), 1 pi of OmniScript RT, and 9 pi of RNase-free water.
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Each 20 pi reaction was carried out at 37°C for 60 minutes, followed by placement on ice
when reactions were done.

b. Amplifying Vy5 and V81 chains from DETC cDNA
Three pi of cDNA from clone #7, #9, and #12 were pooled together. Similarly, 3
pi of cDNA from clone #15, #16, and #18 were pooled together. Using 2 pi of pooled
cDNA for each reaction, the extracellular domains of Vy5 and V81 from the DETC TCR
were amplified using the primers below (see Figure 2A). The 5' primers added an Xho I
restriction site immediately before the leader sequence of Vy5 and V61. The 3’ primers
added a Bgl II restriction site directly after the cysteines involved in the interchain
disulphide bond, allowing for fusion to the thrombin linker region and CD3^ (see Figure
2B).

Briefly, the PCR amplifications were performed in 50-pl reaction mixtures,

consisting of the following: 2 pi of pooled DETC cDNA (5 ng/pl), 25 pmol of each
primer, 5 pi of 10X Pfu Reaction Buffer (Roche Diagnostics Corporation, Indianapolis,
Indiana, USA), 5 pi of ImM dNTPs, 0.5pi of Pfu Polymerase (2.5 units/pl, Roche), and
33.5 pi of ddFFO.

PCR conditions included amplification at 94°C for 3 minutes,

followed by 34 cycles of melting at 94°C for 45 seconds, annealing at 55°C for 60
seconds, and an extension of 72°C for 5 minutes. A final extension for 5 minutes at 72°C
ended the process. All PCR reactions were performed in a DNA Thermal Cycler 480.
Vy5 and V61 cDNAs were purified from 1% agarose IX TAE gels using the protocol
from the QIAEx®II Gel Extraction Kit (QIAGEN Inc.; Valencia, California, USA). Vy5
and V61 cDNAs (80 ng in a 24 pi volume reaction) were then sequenced to confirm the
correct sequence for each chain.
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Figure 2A.

Primers used to generate TCR-t, fusion constructs.

added and start codons are shown as labeled.
CCACC was added before the ATG.

Restriction sites
The consensus Kozak sequence

5’ Vy5 primer
Xho I site

Start Codon

5’- CCG CTC GAG CCA CCA TGT CAA CCT CTT GGC TTT TTC -3’
3’ Vy5 primer
Bgl II site

5’- CCA GAT CTC CGC AAG TTG TAG GCT TGG TAC TC -3’
5’ V61 primer
Xho I site

Start Codon

5’- CCG CTC GAG CCA CCA TGC TTT GGA GAT GTC CAG TC -3’
3’ V61 primer
Bgl II site

5’- CCA GAT CTC CGC AAG GCT CTG AAA TTT GTG TG -3’

Figure 2B. Thrombin linker region and fusion to

Thrombin cleavage site is shown
in bold and italics. Bgl II restriction site is shown as indicated. The cysteines involved in
the interchain disulfide bonds in y, 6 or £ in bold. The terminal end of the 3’ primers are
shown to demonstrate their action in creating fusion of the y or 6 gene to the thrombin
linker region.

Bgl II site

;

I

Thrombin linker region

___

I

ACT TGC GGA GAT CTG GTT CCC CGG GGA TCA TCA CGG CTG GAT CTC TGC
TGA ACG CCT CTA GAC C

-►
TCRq

Terminal end of 3’ primer

Bgl II site

V61

l

Thrombin linker region

CCT TGC GGA GAT CTG GTT CCC CGG GGA TCA TCA CGG CTG GAT CTC TGC
GGA ACG CCT CTA GAC C
Terminal end of 3’ primer

-►
TCRt;
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c. pCDL-SRa296 Vector
The pCDL-SRa296 vector was kindly provided by Carrie Steele, Ph.D. and
Adrian Hayday, Ph.D. (Peter Gorer Department of Immunobiology of the Guy’s King’s
St. Thomas’ School of Medicine at Guy’s Hospital, London, England). The construct
encoded a TCRV55 gene linked to a mouse TCRg gene and contained the SRa promoter
from Simian virus 40 (SV40), which expresses in all cell types.

The pCDL-SRcx296

vector contains a Pst I restriction enzyme site, which can be utilized to linearize
constructs for transfection.

d. Digestion Reactions
In order to remove TCRV65, pCDL-SRa296 was digested with Bgl II and Xho I
enzymes.

Reactions were performed in 20 pi volumes, with 1 unit Bgl II (10,000

units/ml, New England BioLabs), 1 unit Xho I (20,000 units/ml, New England BioLabs),
IX BSA (100 pg/ml; New England BioLabs), IX Buffer 3 (50 mM Tris-HCl, 10 mM
MgCL, 100 mM NaCl, 1 mM 2,3-dihydroxy-1,4-dithiobutane {DTT}, pH 7.9 at 25°C;
New England BioLabs), and 5-10 pi pCDL-SRa296, with the rest of volume made up
with ddH20.

The digested pCDL-SRa296 vector excluding the TCRV65 gene was

purified from 1% agarose IX TAE gels using the protocol from the QIAEx®II Gel
Extraction Kit (QIAGEN Inc.; Valencia, California, USA).

e. Ligation Reactions
The Vy5 and V61 cDNAs were cloned into the pCDL-SRa296 vector already
containing a thrombin linker and CD3g, through the Xho I and Bgl II restriction sites for
linkage. As a consequence, the extracellular domains of TCRy and 6 chains are fused
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directly to the transmembrane and cytoplasmic domains of CD3<^ (see Figure 3).
Twenty-pl ligation reactions were set up in 0.5 ml microcentrifuge Eppendorf tubes,
consisting of 15.5-16.25 pi of Vy5 or V81 purified DNA, 0.75-1.5 pi pCDL-SRcx296
vector, 1 pi T4 DNA Ligase (400,000 units/ml. New England BioLabs), and 2 pi 10X T4
Ligase buffer (New England BioLabs), such that the inserEvector concentration ratio was
in the range of 10-20:1. Reactions were performed at 16°C for 2 hours, followed by heatinactivation of T4 Ligase at 65°C for 10 minutes.

Samples were placed on ice after

reactions were completed.

Figure 3. Completed constructs. TCR Vy5 and V51 chains were ligated into pCDLSRo.296 using Xho I and Bgl II sites. pCDL-SRa296 contains a Pst I site, which was
used to linearize constructs for transfection AmpR indicates the ampicillin resistance
gene contained in the pCDL-SRa296 vector

Vy5

TCR;

VcSi

tcr;

SV40
Promot

R
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f. Plasmid Transformations
Plasmids were transformed into MAX Efficiency® DH5a™ Competent Cells
(competent E-coli, Invitrogen; Carlsbad, California, USA). One, 4, or 15 pi of ligation
product were gently mixed into 50 ml of DH5a™ competent cells and incubated on ice
for 30 minutes. The cells were then heat-shocked in a 42°C water bath for 45 seconds,
followed by a 2-minute incubation on ice.

Nine-hundred pi of SOC medium (2%

Bacto®tryptone {Difco Laboratories, Detroit, Michigan, USA}, 0.5% Bacto®yeast
extract {Difco}, lOmM NaCl, 2.5 mM KC1, lOmM MgCE, 10 mM MgS04, 20 mM
Glucose) were added at room temperature. Vials were then shaken horizontally at 37°C
for 1 hour at -225 rpm.

g. Plasmid Isolation
Newly-transformed DH5a™ competent cells were plated onto freshly prepared
Luna-Bertani (LB) agar plates with 100 pg/ml ampicillin using a flame-sterilized glass
rod to spread cells in a circular motion until dried onto plate. Plates were placed liddown in a plate incubator at 37°C overnight.
Five ml LB + 100 pg/ml ampicillin cultures of transformed DH5a™ cells
selected by individual colonies were grown in a horizontal shaker -245 rpm at 37°C
overnight. Bacteria were pelleted by centrifugation for 10 minutes at 2250 rpm (Sorval
RT7plus). The supernatant was discarded, and the bacterial pellet was resuspended in
250 pi of Buffer PI, provided in the QIAprep® Spin Miniprep Kit (QIAGEN Inc.;
Valencia, California, USA), by repeated pipetting.

Resuspended bacteria were

transferred to a 1.5 ml microcentrifuge Eppendorf tube. DNA was isolated from bacteria
as directed by the QIAprep® Spin Miniprep Kit manufacturers with the following

64

modifications. After the wash step with Buffer PE, samples in mini-columns were spun
for 1 minute at 13,000 rpm.

Samples were centrifuged for an additional 3 minutes to

remove residual Buffer PE before proceeding to the elution step. At the elution step, 30
pi of Buffer EB was added to the mini-column, followed by a 5-minute incubation at
room temperature.

Samples were then centrifuged at 13,000 rpm for 2 minutes.

A

second elution with 20 pi of Buffer EB was then performed, with an additional 5-minute
incubation at room temperature, followed by centrifugation at 13,000 rpm for 2 minutes.
The eluates were combined in the same tube.

These modifications were found to

optimize DNA yield and concentration.
Digestion reactions with Xho I and Bgl II enzymes were set up for DNA obtained
from each transformed colony to ensure that the proper Vy5 and V61 chains were present
in addition to the pCDL-SRa296 vector.

Single-enzyme digestions were set up as a

control alongside double-enzyme digests. For double-enzyme digests, the reactions were
performed in 20 pi volumes, consisting of the following: 5 pi of DNA, 2 pi of Buffer 3
(New England BioLabs), 0.2 pi 100X BSA (10 mg/ml; New England Biolabs), 0.5 pi of
Xho I (20,000 units/ml; New England BioLabs), 0.5 pi of Bgl II (10,000 units/ml; New
England BioLabs), and 11.8 pi of ddFEO.

Single-enzyme digests consisted of the

following, also in 20 pi total volumes: 5 pi of DNA, 2 pi of Buffer 2(10 mM Tris-HCl,
10 mM MgCE, 50 mM NaCl, 1 mM DTT, pEI 7.9 at 25°C, New England BioLabs), 0.2
pi of 100X BSA, 0.5 pi of Xho I, and 12.3 pi of ddfEO. Reactions were performed at
37°C for 2 hours. Digestion products were electrophoresed on 2% agarose IX TAE gels,
stained with ethidium bromide, and visualized under ultraviolet radiation.
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To verify that correct sequences of the Vy5 and VS1 chains had been ligated into
the pCDL-SRot296 vector, samples of Vy5- and V61-containing plasmid DNA (700 ng in
24 pi volume reactions) were sent to the Keck DNA Sequencing Facility at Yale
University for sequencing prior to their being used for transfection into heterologous
cells.

2. Transfection into Rat Basophil Leukemia (RBL) Cells
a. RBL-2H3 Cell Line
The rat basophil leukemia cell line (RBL-2H3) was kindly provided by Carrie
Steele, Ph.D., and Adrian Hayday, Ph.D. The RBLs were cultured at 37°C and 5% CCE
in Minimum Essential Medium (MEM) with Earl’s Salts (Gibco Life Technologies), 10%
Fetal Calf Serum (FCS, Gibco Life Technologies), 1% Non-Essential Amino Acids
(Gibco Life Technologies), 2 mM L-Glutamine, 100 units/ml Penicillin, and 100 ug/ml
Streptomycin. MEM with the stated added ingredients is referred to as complete MEM
(CMEM).

b. Transfection Protocol
For stable transfection, Vy5 pCDL-SRa296 and V61 pCDL-SRa296 were
linearized with Pst I (100,000 units/ml, New England BioLabs). Reaction concentrations
were 40 units of Pst I, 38 pg of plasmid constructs, IX Buffer 3 (New England BioLabs),
and rest of volume made up with ddFEO.

To provide the neomycin resistance gene

required for selection of transfectants, a plasmid called pCiNeo was linearized with Xho I
(20,000 units/ml, New England BioLabs). Reaction concentrations were 25 units of Xho
I, 21 pg of pCiNeo, IX BSA, IX Buffer 2 (New England BioLabs), and rest of volume
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made up with ddH:0. Linearized DNA was extracted with phenol:chloroform:isoamylalcohol (25:24:1, Merck), ethanol precipitated, and resuspended in 10-20 pi of ddHLO,
giving a final concentration of ~1 pg/pl for each linearized construct.
The following steps were performed by Carrie Steele, Ph.D. at Guy’s King’s St.
Thomas’ School of Medicine Guy’s Hospital in London, England. RBL-2H3 cells were
trypsinized and resuspended in 0.25 ml of Dulbecco’s Modified Essential Media
(DMEM), with 16% FCS, 20 mM Hepes (Gibco Life Technologies), 2 mM L-Glutamine,
100 units/ml Penicillin, 100 pg/ml Streptomycin, and 150 pg/ml Gentamicin (Gibco Life
Technologies) at a concentration of 4 X 107 cells/ml. The cell suspension was transferred
to a 0.4 cm gap cuvette with 9 pg linearized Vy5 pCDL-SRa296, 9 pg V81 pCDLSRa.296, and 2 pg pCiNeo. A charge of 260 V and 500 mF was applied with a gene
pulser (Bio-Rad) at room temperature.

Following a 10-minute recovery at room

temperature, the cells were transferred back into CMEM for culture. Forty-eight hours
after transfection, cells were selected in 0.5 mg/ml G418 sulfate (Gibco Life
Technologies), with selection increasing to 1 mg/ml after another 48 hours. G418 is an
aminoglycoside active against aerobic and facultative aerobic gram-negative bacilli as
well as some gram-positive bacteria [230]. In general, this antibiotic is used for selection
of transfectants expressing an aminoglycoside-modifying enzyme, one of which is
conferred to the RBL transfectants used in this experiment by the co-transfection with
pCiNeo containing the neomycin resistance gene. Control transfectants were generated
by transfection of RBL cells with pCiNeo alone to generate the RBLneo line.
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3. Selection of Individual RBLyS Clones
Individual RBLy6 clones were isolated in cloning wells through two methods.
The first method entailed limiting dilutions, in which transfected RBL cells that had been
selected by 1 mg/ml G418 were trypsinized and diluted to a concentration of ~1 cell/300
pi. In a 96-well flat-bottomed plate, 100 pi of cells at this concentration were transferred
to each well and allowed to grow in CMEM at 37°C and 5% CCE. With such a strategy,
individual clones would each have to be tested for the presence of the y5 TCR.

The

second method was utilized after a population of RBLy6+ transfectants was identified by
monoclonal antibody staining and flow cytometry (described below), from which
RBLy5+ cells were single-sorted into individual wells of a flat-bottomed 96-well plate.
With this method, any clone that proliferated would be expected to express the y6 TCR.

a. Antibodies
The monoclonal antibodies (MoAb) to murine proteins used in this project were
acquired from PharMingen unless otherwise stated. The following antibodies were used
to stain RBL transfectants: phycoerythrin (PE)-conjugated hamster anti-CS TCR (PEGL3), fluorescein isothiocynate (FITC)-conjugated hamster anti-C6 TCR (FITC-GL3),
PE-conjugated anti-hamster IgG (isotype-matched control antibody), FITC-conjugated
anti-hamster IgG (isotype-matched control antibody), rat IgM (control antibody), and
FITC-conjugated anti-rat IgG + IgM (as secondary antibody to detect 17D1).

17D1

MoAb specific for DETC Vy5/V61 TCR [64] was kindly provided by Lewis and Tigelaar
(Yale University, Department of Dermatology).
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b. Flow Cytometry
Approximately 1 X I0h cells were incubated with the appropriate MoAb on ice
for 30-60 minutes, then washed twice in staining buffer (IX PBS/1 % FCS) by
centrifuging sample at 1200 rpm for 5 minutes, with staining buffer being discarded
between washes. Cells were resuspended in 1 ml staining buffer and placed into Falcon®
2058 polystyrene tubes (Becton Dickinson; Sunnyvale, California, USA).

Isotype-

matched control antibodies were used at the same concentrations as test antibodies.
Analysis was performed with a FACScan™ (Becton Dickinson) with electronic gates set
on live cells by a combination of forward and side light scatter. A minimum of 104 live
events was collected per sample and data were analyzed with CellQUEST™ software.

c. Fluorescence Activated Cell Sorting (FACS)
RBL transfectants were incubated with PE-GL3 on ice for 30-60 minutes, then
washed in staining buffer, all under sterile conditions. Cells were resuspended in 1 ml
staining buffer and placed into sterile Falcon® 2058 polystyrene tubes. Transfectants
were then analyzed by flow cytometry, and GL3 positive cells were subsequently sorted
using Fluorescence Activated Cell Sorting (FACS) technology. FACS was performed
with the generous help of staff at the Guy’s King’s St. Thomas’ School of Medicine
Guy’s Hospital in London, England, using a Mo Flo high speed cell sorter (Cytomation).
The Vy5/V51 + RBL cells were cultured in 10% FCS/CMEM at 37°C and 5% CO2. This
“enriched” population was allowed to proliferate until re-analysis with PE-GL3, FITCGL3, and 17D1 with FITC-anti-rat IgG + IgM at a later time point determined by rate of
proliferation. The percentage of Vy5/V61 TCR+ RBL transfectants was expected to be
significantly higher in any population in which such “enrichment was performed.

69

4. RBL-3H Serotonin Release Assay Protocol
The RBL transfectants were removed from culture flasks using Versene (EDTA),
counted, and pelleted by centrifugation.

The cells were then resuspended in 10%

FCS/MEM + l mg/ml G418 media to a concentration of 3 X IQ4 cell/100 pi, and 100 pi
added to multiple wells of a flat-bottomed 96-well plate.

Transfectants were loaded

overnight at 37°C with 5-[l,2-3H(N)] hydroxytryptamine binoxalate (3H serotonin), at a
concentration of 4 pCi/ml, or 0.4 pCi/well. The next day, cells were washed twice with
ice-cold DMEM containing 2% FCS to remove excess serotonin that had not been
incorporated into cells.
assay.

Four testing conditions were set up in triplicate wells for an

First, GL3 hybridoma cells were used as effector cells in order to determine

whether the transfectants would release serotonin in response to cell-bound ligand. In
addition to secreting antibody specific for the constant (C) region of the 5 gene, the GL3
hybridoma expresses surface anti-TCR6 antibody which has been found to successfully
cross-link theTCR on RBLybtransfectants, signaling for serotonin release in a dosedependent fashion (Steele and Hayday, unpublished data). Second, transfectants were
incubated with supernatant collected from cultures of 17D1 hybridoma cells, which
contains soluble 17D1 antibody specific for the Vy5/V61 TCR [64],

To determine if

transfectants would release serotonin in response to as-yet unidentified ligands on
keratinocytes, skin keratinocytes from the PDV line were used as target cells. Finally,
phorbol myristate acetate (PMA)/ionomycin was used at a concentration of 0.5 pg PM A
+ 5 X 10'5 pmoles of ionomycin per 50 pL in each well. PMA/ionomycin causes a rise in
intracellular Ca

resulting in degranulation, thus allowing it to be an appropriate positive
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control to demonstrate ability of RBLyb transfectants to release serotonin upon
stimulation, albeit not through the yb TCR.
Effector cells were prepared at a concentration of 3 X 105 cells/well, i.e. a 1:10
RBL transfectant:effector cell ratio. Effector cells were reconstituted in a volume of 50
pl/well, using 2% FCS/complete DMEM (DMEM with added 2 mM L-Glutamine, 100
units/ml Penicillin, and 100 pg/ml Streptomycin). For the 17D1 supernatant, 50 pi were
added directly to the RBL cells.

The plate was incubated for 45 minutes at 37°C.

Supernatants were harvested and transferred to a UniFilter™ 96-well microplate with a
built-in filter (PerkinElmer Life Sciences). Cells were then lysed in 1% Nonidet P-40
detergent in PBS (20mM Tris pH 8.0, 150 mM NaCl, 0.2% sodium azide, 1% NP-40
detergent), and lysates were transferred to the same UniFilter™ microplate in separate
wells. The UniFilter™ microplate was incubated at 37°C until all wells were dried. To
each well, 25 ml of scintillation fluid was then added, and UniFilter™ plate was placed in
a Microplate Scintillation & Luminescence Counter (Packard) to quantitate 3H content.
Percentage 41 serotonin release was calculated using the following formula:

% 3H serotonin release =

counts per minute (cpm) in supernatant
cpm in supernatant + cpm in lysate

Triplicate wells were averaged to obtain a mean % 3H serotonin release for each testing
condition.

71

III. RESULTS

A. TOTAL SERUM IgE MEASUREMENTS
1. Lack of correlation between total IgE levels and SpD in C57BL/6 and
NOD mice
Total serum IgE levels in wild-type (w.t.) and 6-/- mice on C57BL/6 and NOD
backgrounds were measured by ELISA. All B6 mice regardless of genotype were housed
in CNVC. In contrast, groups of NOD w.t. and NOD.6-/- mice were housed in different
environmental settings, some in CNVC and others in IVC. As described in the Girardi et
al. study (2002), the development of a spontaneous, chronic, localized dermatitis in 6-/mice, manifested by erythema, edema, and pruritus, along with a thickened epidermis
showing histopathologic features typical of chronic dermatitis, was previously found to
be strikingly genotype- and strain-dependent. Unmanipulated NOD.6-/- mice developed
a spontaneous cutaneous inflammation of the ears, while normal NOD controls did not.
Additionally, both C57BL/6 w.t. and C57BL/6.5-/- mice showed no clinical or
histological evidence of spontaneous dermatitis. This SpD phenotype was further found
to be environmentally-dependent, as

NOD.8-/- mice raised from birth in CNVC

developed obvious dermatitis by 6 weeks of age, while age-matched NOD.6-/- mice
raised from birth in IVC failed to develop clinical or histologic evidence of dermatitis
[231].
Based on these findings, with the hypothesis that IgE plays a critical role in the
pathogenesis of this inflammatory dermatitis, it was expected that total serum IgE levels
would correlate positively with the presence of SpD. In other words, NOD.6-/- mice
housed in CNVC, which presumably contains the appropriate environmental triggers
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necessary to provoke an inflammatory process within the epidermis, would have
significantly higher IgE levels than NOD.6-/- mice housed in IVC and NOD w.t. mice in
either environment. In addition, it was expected that NOD.5-/- would show higher IgE
levels than both B6 w.t. and B6.8-/- mice, which did not exhibit skin inflammation
despite being housed with the same environmental triggers as the NOD.6-/- mice which
showed inflammation.
As previously mentioned, ear phenotypes and baseline thicknesses of the specific
animals (age 11-16 weeks) from which serum IgE levels were sampled were assessed on
the day of serum collection. As expected, B6 w.t. mice housed in CNVC did not show
any signs of cutaneous inflammation. In addition, B6.6-/- mice housed in CNVC did
not develop signs of spontaneous dermatitis (SpD), having a mean baseline ear thickness
of 11.9 + 0.2 in. X 10'3 (Figure 4A). No signs of SpD were found in NOD w.t. mice
housed in CNVC, which had a mean baseline ear thickness measurement of 11.9 + 0.5
in. X 10'3. Also as expected, NOD.6-/- mice housed in IVC had a comparable level of
baseline ear thickness of 11.8 + 0.4 in. X 10"3. Meanwhile, NOD.6-/- mice housed in
CNVC showed a baseline ear thickness of 19.9 + 0.7 in. X

10"3, significantly higher than

NOD w.t. mice and NOD.8-/- mice housed in IVC (p < 10"7).

These results were

consistent with previous findings showing that such spontaneous, chronic cutaneous
inflammation is dependent on several factors: 1) type of strain, developing in the NOD
background and not the C57BL/6; 2) the presence of y8 T cells, developing only in 6-/mice; and 3) the presence of appropriate environmental antigenic stimulation, developing
only in mice housed in the CNVC environment [147, 231].
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Strain
TCR Genotype
Housing

B6

NOD

NOD

(B6 X NOD)F

8+/+

8-/-

8+/+

8-/-

8+/+

8-/-

8-/-

CNVC

CNVC

CNVC

CNVC

IVC

IVC

CNVC

Figure 4A. Spontaneous dermatitis (SpD) developed only in NOD.5-/- mice housed in conventional
non-ventilated cages (CNVC). None of the mice housed in individually-ventilated cages (IVC) showed
signs of SpD Of the mice housed in CNVC, only NOD.5-/- mice exhibited erythema and pruritus, as well
as ear swelling manifested by an increase in baseline ear thickness. Ears were measured using an
engineer'micrometer and are expressed as in. X 10 3 + standard error of the mean (SEM) *p < 10

Strain
TCR Genotype
Housing

NOD

NOD

B6

(B6 X NOD)F,

8+/+

8-/-

8+/+

8-/-

8+/+

8-/—

8-/-

CNVC

CNVC

CNVC

CNVC

IVC

IVC

CNVC

Figure 4B. Serum total IgE levels and presence of SpD do not correlate. Total IgE levels (determined
by ELISA) within a given strain did not differ based on the presence/absence of SpD or y§ cells, nor on the
environment in which they were housed IgE levels were significantly higher in both NOD w.t. and NOD 8mice than in similarly housed B6 w.t. and B6.8-/- mice *p < 0 05 vs. C57BL/6 w.t. and C57BL/6.6- **p <
0.001 vs. C57BL/6 w.t. and C57BL/6.5-/-
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Surprisingly, however, total serum IgE levels did not correlate with presence of
SpD, nor with the environment in which they were housed. Total serum IgE levels of
NOD.5-/- mice housed in CNVC and those housed in IVC did not differ (Figure 4B).
Furthermore, total serum IgE levels did not differ based on the presence or absence of
y8 T cells. NOD w.t. mice, housed either in CNVC or in IVC, had levels of total serum
IgE comparable to NOD.6-/- mice (CNVC: 204 + 59 (SEM) ng/ml; IVC: 349 ±112). In
contrast, total serum IgE levels were significantly strain-dependent. B6 w.t. mice housed
in CNVC had an average total serum IgE level of 70 + 42 ng/ml (p < 0.05 versus NOD
w.t. housed in CNVC and in IVC), while B6.8-/- mice had an average level of 51 +22
ng/ml (p < 0.001 versus NOD.8-/- mice housed in CNVC and in IVC).
Among (B6 X NOD)Fi.8-/- mice housed in CNVC, no clinical signs of
spontaneous dermatitis developed, and baseline ear thickness was indistinguishable from
that seen in age- and sex-matched B6.8-/- mice, consistent with results found by Girardi
et al. (2002). Interestingly, the mean total serum IgE level found in (B6 X NOD)F].6-/mice was also indistinguishable from that seen in B6.8-/- mice, having a mean
concentration of 82 + 24 ng/ml, suggesting that recessive gene(s) are responsible for the
high total serum IgE levels in NOD (w.t. and 8-/-) mice.

2. Lack of correlation between total IgE levels and SpD among (Fi X
NOD)BC.8-/- and (NOD X Fi)BC.5-/- mice
Of 235 (Fi X NOD)BC.8-/- and (NOD X Fi)BC.8-/- mice, all housed in CNVC,
32 animals with the highest level of inflammation and 33 animals with the lowest level of
inflammation were selected from which to obtain total serum IgE measurements.
Individual ear measurements ranged from 11.00 to 28.50 in. X 10 \

The mean baseline
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ear thickness of BC.5-/- mice with high level of inflammation (“presence of SpD”) was
22.5 + 2.7 in. X 10"3, while that of BC.6-/- mice with lack of inflammation (“absence of
SpD”) was 11.9 + 0.7 in. X 10"' (p < 10"‘(1) (Figure 5A). Again, contrary to the expected
finding that animals with signs of SpD would show higher IgE levels than those which
did not, no correlation was found between serum IgE concentration and the presence of
SpD in BC.6-/- mice. The mean total serum IgE level of BC.8-/- mice with obvious
inflammation was 249 + 48 ng/ml, while that of BC.6-/- mice without inflammation was
229 + 48 ng/ml (Figure 5B).
These findings, therefore, do not lend support to the hypothesis that IgE
antibodies play a primary role in the pathogenesis of SpD in genetically susceptible and
appropriately housed mice. However, they do not formally exclude a role for IgE or
other antibodies in the mechanism(s) accounting for the development of this phenotype.

3. Total IgE levels higher in females versus males
In an analysis of BC.5-/- mice segregated by sex, Girardi et al. (2002) had found
that 48% (55/114) of females and 36% (44/121) of males were NOD-like.

These

differences between the male and female incidences of the susceptible phenotype were
not statistically significant. Likewise, the frequency of phenotypically susceptible mice
was similar in groups of BC animals segregated according to the sex of the NOD parent
[147],

In sum, there was no statistically significant evidence for sex-linked genes

affecting the development of spontaneous dermatitis. In this same study, it was found
that baseline ear thickness in males tended to be higher than age-matched female
counterparts. Such results are not surprising given the larger overall size of male animals
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(F1 X N0D)BC.5-/Presence of SpD
Absence of SpD
Figure 5A. (B6 X NOD)Fi X NOD backcross (BC).8-/- mice categorized as “presence of SpD” showed
significant inflammation, as shown by significantly higher increased ear thickness measurements,
compared to those with “absence of SpD.” Thirty-two (of 235) BC mice were identified to have the
highest measurements of ear thickness (“presence of SpD”), while 33 BC mice were selected for their lowest
ear thickness measurements (“absence of SpD”). The difference in mean baseline ear thicknesses was
statistically significant. *p < 1026
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(Ft X NOD)BC.5-/Presence of SpD
Absence of SpD
Figure 5B. The presence of SpD in (Ft X NOD) BC.5-/- mice was not associated with higher SgE
levels. Thirty-two (of 235) BC mice were identified to have the highest measurements of ear thickness
(“presence of SpD”), while 33 BC mice were selected for their lowest ear thickness measurements
(“absence of SpD"). There was no difference in IgE levels despite the difference in SpD development.
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compared to females.

In the present analysis, among the BC.6-/- mice showing the

lowest level of inflammation, measurements ranged from 11.00 to 11.75 in. X 10"3
(mean=11.3 + 0.1) for females, and 12.25 to 13.00 (mean=12.5 + 0.1) for males ( p <
10"13). Interestingly, however, among the BC.6-/- mice with obvious SpD, female mice
had a mean baseline ear thickness of 23.7 + 0.7 in. X 10‘3 (ranging from 20.25 to 28.50),
while male mice had a mean ear thickness of 21.2 + 0.5 in. X 10"3 (ranging from 16.75 to
24.00; p < 0.005) (Figure 6A). More intriguing was the finding that the total serum IgE
level in female BC.6-/- mice with inflammation was significantly higher than that of
males with inflammation (348 + 78 ng/ml vs. 137 + 34 ng/ml: p < 0.03) (Figure 6B).
Among BC.5-/- mice which lacked signs of SpD, there was no difference in mean total
serum IgE levels between males and females.
Female mice were also found to have higher IgE levels than their male
counterparts in three other groups, all of which were mice deficient in y6 T cells and
housed in CNVC (Figure 6C). In NOD.5-/- mice housed in CNVC, which were the only
animals showing evidence of spontaneous dermatitis, there was no difference in mean
baseline ear thickness of females versus males. However, mean total IgE concentration
was significantly higher in females compared to males (p < 0.05). In B6.S-/- and
Fj .6—/— mice housed in CNVC, no animals developed spontaneous inflammation.
Nonetheless, curiously, females compared to males were found to have significantly
higher total IgE levels (p < 0.05), whereas no significant difference in total serum IgE
concentration was found between males and females among 5+/+ mice or among &-/mice housed in IVC.
)
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(Ft X NOD)BC.5-/~
Presence of SpD
Absence of SpD

Mean Total IgE Concentration (ng/ml) + SEM

Figure 6A. Among BC.6-/- mice showing SpD, female mice had a greater mean baseline ear
thickness compared to male mice. Among BC.5-/- without SpD, male mice had a greater mean
baseline ear thickness compared to females, consistent with their larger overall size In BC.8-/- mice
with SpD, on the other hand, female mice had a significantly higher mean baseline ear thickness than
male mice. *p < 0.005

(Ft X NOD)BC.5-/Presence of SpD
Absence of SpD
Figure 6B. Among BC.5-/- mice showing SpD, female mice had higher total serum IgE levels
compared to male mice. This finding was in contrast from that seen among BC.8-/- mice lacking
signs of SpD, in which there was no difference in mean total serum IgE levels between males and
females *p < 0.03

Mean Total IgE Concentration (ng/ml) + SEM
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Figure 6C. Female mice had higher total serum IgE levels than male mice. In all groups of mice but
one, female mice showed a tendency to have higher total IgE levels than their male counterparts. These
differences were statistically significant only among 6-1- mice housed in CNVC *p < 0.05
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B. GENETIC ANALYSIS
1. Genetic interval(s) controlling susceptibility to SpD in NOD.5-/- mice are
distinct from those found for other mouse models of AD
Genome-wide microsatellite mapping studies in two other distinct mouse models of
“atopic dermatitis-like” disease have recently mapped major susceptibility intervals
controlling dermatitis to a region on chromosome 9 in NC/Nga mice and on chromosome
14 in NOA mice [152, 153].

With primers which distinguish NOD from B6 simple

sequence length polymorphisms approximately in the centers of the previously described
susceptibility intervals on chromosomes 9 (.D9Mitl05) and 14 (D14MH262), analysis was
performed of the DNA obtained from the 99 BC mice with obvious SpD using the criteria
described in the previous chapter. If there were no linkage between the loci and the SpD
phenotype, the expected number of samples exhibiting the NOD-specific SSLP on both
chromosomes (NOD/NOD) would be exactly half the total number of samples tested, i.e.
of 60 total samples, 30 would show NOD/NOD and 30 NOD/B6. Such a finding would
lead to a yj value of 0. A suggestive linkage, on the other hand, is defined by a x value
of > 8.7, while significant linkage is defined by a X value of > 15.2 [228], The similar
frequencies of homozygous (NOD/NOD) versus heterozygous (NOD/B6) genotypes for
the

D9Mitl05 and D14MU262 clearly indicate that the interval(s) controlling

susceptibility to SpD in NOD.5-/- mice are not the same as those found for the NC/Nga
or NOA mice (Table 2).

The genetic interval(s) controlling susceptibility to SpD in

NOD.8-/- mice are indeed distinct from intervals previously described for susceptibility
to AD-like disease in other mouse models established to date.
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Chromosome 9
(D9Mit105)

Chromosome 14
(D14Mit262)

Genotype

Observed

Expected

Observed

Expected

NOD/NOD

50

49.5

28

30

NOD/C57BL.6

49

49.5

32

30

Table 2. The genetic interval(s) controlling susceptibility to SpD in NOD.5-/- mice
are distinct from those found for other mouse models of AD. y2 analyses of the
frequencies of homozygous (NOD/NOD) versus heterozygous (NOD/B6) genotypes for
two specific genetic loci. Genome-wide microsatellite mapping studies in two other
distinct mouse models of “atopic dermatitis-like” disease have recently mapped major
susceptibility intervals controlling dermatitis to a region on chromosome 9 in NC/Nga
mice and on chromosome 14 in NOA mice. With primers which distinguish NOD from
B6 simple sequence length polymorphisms in the approximate centers of the previously
described susceptibility intervals on chromosomes 9 and 14, analysis of the DNA (by
PCR amplification and gel electrophoresis) obtained from the 99 BC.8-/- mice with
obvious SpD was done. The similar frequencies of homozygous versus heterozygous
genotypes for these loci clearly indicate that the interval(s) controlling susceptibility to
SpD in NOD.8-/- mice are not the same as those found for the NC/Nga or NOA mice.
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C. CONSTRUCTION OF V5-J1-Cy1/V1-D2-J2-C6 T-CELL RECEPTOR
1. Generation of Expression Constructs
a. Vy5 and V61 genes and chimeric constructs
Vy5 and V51 cDNA were amplified from DETC eDNA produced by RT-PCR from
freshly-isolated DETC mRNA. Primers were designed such that the PCR product would
be flanked at its 5’ end by an Xho I restriction site just before the leader sequence, and at
its 3’ end by a Bgl 11 restriction site. The Bgl II restriction site was added strategically to
truncate the Vy5 and V61 genes directly after the cysteine residues involved in the
interchain disulfide bond. Such placement of the Bgl II site allowed for the direct fusion
of the extracellular domains of Vy5 and V61 to the thrombin linker region and CD3E.
TCR^ provides the transmembrane domain for both chains. The Vy5 cDNA amplification
showed the expected size of 779 bp, while the V81 cDNA amplification showed the
expected size of 767 bp. TCRy and TCR8 cDNAs were then purified from 1% agarose
IX TAE gels using QIAExII® gel extraction and gene sequences were confirmed by
fluorescence based DNA sequence analysis on an ABI 377 automatic sequencer
(performed on a fee-for-service basis in Yale University’s Keck Center facilities).
The Vy5 sequence was found to have a conservative single point mutation at
position 823, substituting a thymine base (T) for a cytosine base (C).

The triplet

sequences of CCT and CCC both code for proline, thus allowing for conservation of
amino acid sequence.

The V61 sequence also showed a conservative single point

mutation, this time at position 616, substituting a guanine base (G) for an adenine base
(A). In this case, the triplet sequences of AAG and AAA both code for lysine, thus again
allowing for conservation of amino acid sequence. Therefore, the sequences of both Vy5
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and V61 were confirmed to encode the proper sequence of amino acids to form the
DETC TCR.

b. pCDL-SRa296 vector
The pCDL-SRa296 vector was kindly provided by Carrie Steele, Ph.D. from the
laboratory of Adrian Hayday, Ph.D. (Guy’s Hospital, London, England) as a construct
containing a V65 gene linked directly to a mouse TCR^ gene through a region encoding a
thrombin cleavage site. The V65 gene was removed by digestion with the Xho I and Bgl
II restriction enzymes, followed by purification of the digested pCDL-SRa296 vector
using QIAExII® gel extraction.

c. Ligation Reactions
The Vy5 and V61 chains were ligated into the pCDL-SRa296 vector through the
Xho I and Bgl II restriction sites. The measured concentrations of the purified Vy5 and
V51 cDNAs were 4.69 ng/pl and 2.35 ng/pl, respectively.
purified pCDL-SRa296 vector was 14 ng/pl.

The concentration of the

In order to set up reactions with an

insert:vector concentration ratio of 10-20:1, 15.5 pi of Vy5 and 16.3 pi of VS1 purified
DNA were ligated into 1.5 pi and 1 pi of pCDL-SRa296 vector, respectively. After the
ligation reactions were completed at 16°C, samples were incubated at 65°C for 10
minutes to heat-inactivate the T4 ligase, followed by placement on ice and storage at 20°C until used for transformation.
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d. Plasmid Transformations and Isolation
The complete plasmids were transformed into MAX Efficiency DH5a™
Competent Cells and individual colonies were isolated and grown. Digestion reactions
with Xho I and Bgl II enzymes were set up for DNA obtained from each transformed
colony to ensure proper Vy5 and V61 chains were present in addition to the pCDLSRa296 vector.

Figure 7 shows single-enzyme and double-enzyme digests of two

transformed colonies for Vy5-pCDL-SRa296 and two transformed colonies for V61pCDL-SRa296 (other colonies not shown). Each of these transformed colonies showed
evidence of the appropriately-sized Vy5 and V51 chain, along with the pCDL-SRa296
vector, confirming successful transformation of the E.coli cells.
Approximately 700 ng of plasmid DNA from one colony transformed with the
Vy5-pCDL-SRa296 plasmid and 700 ng of plasmid DNA from one colony transformed
with the V81-pCDL-SRa296 plasmid were sent for sequencing before being used in
electroporation of the heterologous cell type RBL-2H3. Each of these colonies indeed
showed the same sequence for the Vy5 and V81 chains as those found for the chains
before ligation into the vector and transformation of the E.coli cells (data not shown).
Thus, conservation of correct sequences was confirmed.

2. Transfection of RBL-2H3
a. Electroporation
RBL-2H3 cells were transfected by electroporation with both Vy5-pCDL-SRa296
and V81 -pCDL-SRa296 constructs, linearized by digestion with Pst I, along with
linearized pCiNeo. Cells were transferred back to CMEM for culture, then selected in
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Figure 7. Xho I single-enzyme and Xho l/Bgl II double-enzyme digests of Vy5pCDL-SRo296 and V51-pCDL-SRa296 transformed colonies.
Each of the
transformed E.coli colonies showed evidence of the appropriately-sized Vy5 or V81 chain
and the digested pCDL-SRa296 vector, confirming successful transformation of the
bacteria with the Vy5/V81 -pCDL-SRa296 plasmids.
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0.5 mg/ml G418 sulfate forty-eight hours after transfection, with selection increasing to 1
mg/ml after another 48 hours. The parent line of RBL-2H3 cells was also successfully
transfected with pCiNeo only (RBL-Neo), allowing these cells to be used later as a
negative control.

3. Transfectants Expressing Vy5/V51
a. Enrichment of Bulk Transfectants
Approximately 4 X 107 RBL-2H3 cells were transfected simultaneously with Vy5pCDL-SRa296, V61-pCDL-SRa296, and pCiNeo plasmids. Selection with 0.5 mg/ml
G418, followed by selection with 1.0 mg/ml G418, was carried out over 4 days. On post¬
transfection day 10 (PTD-10), the y6 transfectants that had been growing in a 10-ml petri
dish were analyzed by flow cytometry, after staining the cells with PE-conjugated anti06 antibody (PE-GL3). Of the cells analyzed, 0.3% stained positive for GL3 (data not
shown). As expected, C6 was not detected on RBL-Neo negative control transfectants
(Figure 8A). Using FACS technology, 192 of the GL3-positive cells were sorted into 2
separate 96-well flat-bottomed plates, one cell per well, in order to develop clonal
populations.

Approximately 900 GL3-positive cells remained, which were then

transferred in bulk to a 10-ml petri dish with normal culture media CMEM.

Such

“enrichment” was expected to show a significantly higher percentage of GL3-positive
cells upon future analysis.
These “bulk” transfectants were allowed to grow in CMEM + 1.0 mg/ml G418 for
an additional

10 days, at which point they were re-analyzed with PE-GL3.

Approximately 1.76 X 106 cells were counted, of which 10-12% were found to be GL3-
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positive (Figure 8B). After analysis, 1.2 X 10(’ cells were transferred into a mediumsized (T50 ml) flask to continue growing in culture.
Curiously, the RBL y6 transfectants at this point, after transfer to a 50-ml flask,
did not show steady growth. In fact, a large proportion of cells quickly died, indicated by
their floating in culture versus remaining attached to the bottom of the flask.

The

remaining cells that survived (exact percentage or number unknown) continued to appear
attached to the flask bottom but did not exhibit visible proliferation. Discrete groups of
cells began to grow in clumps, i.e. cells appearing to divide but accumulating on top of
each other; however, the cultured cells did not reach confluence.

Two weeks after

having transferred the cells to a 50-ml flask (PTD 34), the RBL y6 transfectants were
trypsinized and transferred to a flat-bottomed single well in a 6-well plate. Growth of the
cells was soon visible, and on PTD 38, confluence of the cells in the well allowed for
transfer of the cells to a 25-ml flask. On PTD 39, cells had reached confluence and were
thus transferred to a larger 50-ml flask.

Ten days later, on PTD 49, cells were re¬

analyzed with PE-conjugated GL3 antibody, at which point 18.5% of the cells were
found to be GL3-positive (Figure 8C).
Cells were transferred to a 75-mi flask in order to allow proliferation, with the
intention to freeze cells as stock for future sorting and culturing. Immediately prior to
freezing, on PTD 59, FACS analyses showed that 16-17% of the RBL transfectants were
GL3-positive, with a similar percentage (16%) of cells staining positively with 17D1
MoAb, detected by consequent staining with FITC-conjugated anti-rat IgG + IgM (Figure
9A and 9B).
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b. Clonal Populations
Of the 192 GL3-positive cells that were single-sorted into two 96-well plates, a
total of approximately 23 clones on one 96-well plate and 20 clones on the other 96-well
plate eventually grew into visible colonies.

Approximately 50 of these colonies total

were allowed to proliferate, being transferred only after they reached a minimum size
(approximately 1 mm in diameter) and cultured into increasingly larger volumes of
media.

When colonies had expanded to approximately 6 X 10' cells (reaching

confluence in a single well of a 6-well plate), they were each analyzed by FACS to
determine percentage of cells positive for GL3.

Several colonies showed 0.1% GL3-

positive cells, while others showed approximately 4% to 11%. Only one colony (#45)
showed a substantially higher percentage of GL3-positive cells compared to the other
colonies tested (Figure 10A). This colony was 28% GL3-positive when first analyzed 17
days after being picked from the 96-well plate (PTD 38). Staining with 17D1 MoAb on
the cells of this colony on the same day showed the cells to be 18% positive, a slightly
lower percentage than that found of GL3-positive cells (Figure 10B).

On day 24 after

being picked from the 96-well plate (PTD 45), clone #45 was analyzed again and the
GL3-positive cells sorted by FACS.

Of 7.63 X 106 cells total, approximately 400,000

cells were GL3-positive. The GL3-positive cells were cultured for three days and then
re-analyzed by double-staining, i.e. initial staining with PE-GL3, followed by incubation
with 17D1 MoAb, and finally by staining with FITC-conjugated anti-rat IgG + IgM in
order to detect 17D1.

FACS analysis revealed cells to be 81% GL3-positive and 65%

17D1-positive (Figure 11).
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4. Serotonin Release Assay
With the isolation and identification of a single RBL Vy5/V8l TCR-positive
clone, the salient question was to determine if the RBL transfectants would release
serotonin in response to ligand.

Clone #45 GL3-positive enriched cells (84% GL3-

positive and 21% 17D 1-positive) and RBL-Neo controls were cultured separately
overnight in the presence of ’H serotonin.

Activation was induced by incubating the

plated cells in four different testing conditions.

PMA/ionomycin was used to stimulate

the RBL cells in order to show that the transfectants could indeed be activated to release
pre-loaded 3H serotonin. PMA/ionomycin causes a rise in intracellular Ca2+, bypassing
signal transduction and resulting in degranulation. Stimulation by PMA/ionomycin did
indeed induce an 18-fold increase in serotonin release over control cells cultured only in
media (Figure 12). There was no statistical difference in activation between Clone #45
and RBL-Neo control cells. Soluble 17D1 antibody specific for the Vy5/V8l TCR was
used to determine if the RBL transfectants could be activated by this monoclonal
antibody targeting the specific TCR. Supernatant collected from 17D1 hybridoma cells
was added directly to the RBL transfectants in a volume of 50 pi.

This sterile but

unpurified supernatant containing 17D1 MoAb has been shown to successfully activate
DETC lines (Lewis, personal communication), in which over 95% of cells express the
identical Vy5/VSl TCR [64].

In this assay, incubation of the RBL transfectants with

17D1 supernatant did not induce increased serotonin release compared to controls. To
determine whether the transfectants would release serotonin in response to cell-bound
ligand, GL3 hybridoma cells were used as target cells. The GL3 hybridoma expresses
surface anti-TCR8 antibody, which cross-links TCR on the RBLs, leading to signaling for

95

serotonin release. GL3 hybridoma cells were incubated with RBL transfectants at a 1:10
RBL transfectant:effector cell ratio.

In this assay, induced serotonin release was

minimal, with no significant difference compared to controls.

Activation by GL3

hybridoma in a dose-dependent fashion was not tested.
Lastly, an epithelial cell line was tested for expression of a ligand for the Vy5/V5l
TCR. Mouse PDV keratinocytes, which had been harvested from culture in a flask by
scraping and were not heat-shocked or infected, were incubated with RBL transfectants.
Upon activation, transfectants released preloaded serotonin at levels approximately 3-fold
greater than that of RBL-Neo controls (see Figure 12), releasing up to 28% of preloaded
FI serotonin.

Of the three replicate wells, there was one low outlying point which

increased the standard deviation, making it fairly large (9%).

Nonetheless, the

percentage of serotonin release in response to activation by PDV keratinocytes was
significantly greater for Clone #45 cells compared to RBL-Neo controls {p < 0.05).

RBL-Neo
Clone #45
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IV. DISCUSSION

A. SPONTANEOUS DERMATITIS AND IgE
Atopic dermatitis (AD) is a common, chronic relapsing inflammatory skin
disease, characterized by typically distributed eczematous skin lesions and intense
pruritus, often associated with elevated levels of total and antigen-specific IgE and a
personal or family history of atopic diseases [232-234], Research into AD over the last
40 years has been dominated by exploration of the cellular and molecular mechanisms
[151].

This work has indeed produced breakthroughs in elucidating the etiology and

pathogenesis of this complex chronic disease.

For example, skin lesions in AD

consistently exhibit a mononuclear cell infiltrate, predominantly in the dennis, consisting
of activated memory CD4+ T cells and macrophages [232], implicating a major role for
both these types of cells in the pathogenesis of AD. Several findings indicate eosinophil
involvement in AD, including the occasional presence of eosinophils in the dermis and
the common finding of eosinophil-derived major basic protein and eosinophil cationic
protein, which are associated with eosinophil degeneration [208, 235, 236]. Skin lesions
in AD are also characterized by highly increased numbers of infiltrating, fully granulated
mast cells [237], as well as increased numbers of dermal dendritic cells (CDs) and
epidermal Langerhans cells [238, 239], A reduction of ceramides in atopic skin, leading
to a disrupted skin barrier has also been described as an etiologic factor [240],

Finally,

the acute skm lesions of AD show a significant increase in the number of cells expressing
the Th2 cytokines IL-4, IL-5, and IL-13 [241, 242], while in later stages of the disease,
IL-12 expression increases and TH2 switches to TH1 immune responses, characterized by
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the expression of such Tul-type cytokines as IFN-y in chronic lesions [243],

Yet,

despite these recent advances, the etiology and pathogenesis of AD are still not precisely
understood.

Various names have been assigned to this condition, including atopic

eczema, neurodermatitis constitutionalis, endogenous eczema, eczema flexurarum,
Besnier’s prurigo, asthma eczema, and hay fever eczema, reflecting the uncertainty in the
understanding of the exact pathophysiology of this disease [244, 245 ], To further explore
the pathogenesis and treatment of AD, suitable animal models are indeed required.

SpD Similar to Human AD
The spontaneous dermatitis (SpD) phenotype that developed in unmanipulated
NOD.6-/- mice of the present study has several similarities to features of human AD.
The SpD was characterized by the clinical signs of erythema, edema, and pruritus, as well
as the histopathologic features typical of chronic dermatitis, including a thickened
epidermis with intercellular edema, mononuclear inflammatory cells scattered throughout
the epidermis, and a thickened dermis with infiltrating mononuclear inflammatory cells,
eosinophils, and highly increased numbers of mast cells [147]. The SpD shares other
features with human AD as well, including: genetic predisposition [166, 183, 185, 246248], appearing in 8-/- mice on some (e.g. NOD and FVB), but not other (e.g. C57BL/6)
genetic backgrounds; dependence on a(3 T cells [249], appearing in 8-/- mice but not in
(3—/—8—/— mice; skin localization to areas commonly exposed to environmental irritants
and/or allergens [168], developing only on the ear skin of these mice; and increased
expression of contact dermatitis [250], showing strikingly augmented ear swelling to the
allergen DNFB and the irritant TP A when compared to reactions induced in 8+/+ mice.
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Thus, the SpD induced in NOD.6-/- mice housed in the appropriate environment
(conventional non-ventilated cages) may provide a novel animal model for studying the
pathogenesis of human AD.

The Role of IgE in Atopic Dermatitis
The specific question addressed in the present study was the role of IgE
antibodies in the pathogenesis of SpD.

It is now widely accepted that IgE mediates

immediate hypersensitivity, also called type I allergy [251], The first step in an allergic
reaction is the binding of a certain allergen to allergen-specific IgE molecules bound to
the high-affinity IgE receptor (FceRI) on mast cells, resulting in prompt release of a
series of chemical mediators, such as histamine and serotonin, in addition to a variety of
enzymes, including mast-cell chymase, tryptase, and serine esterases, which play
important roles in initiating allergic-type and anaphylactic-type responses [165], Upon
activation, mast cells also secrete large amounts of cytokines, such as TNF-a, IL-4, and
IL-13, chemokmes, including MIP-la, which attracts monocytes, macrophages, and
neutrophils, and lipid mediators such as leukotrienes and platelet-activating factor (PAF),
all of which act in concert to orchestrate an inflammatory cascade that is amplified by the
recruitment of eosinophils, basophils, and Th2 lymphocytes [252-254], In contrast to the
widely accepted role of IgE in immediate hypersensitivity, the pathologic role of IgE in
chronic allergic inflammation as seen in atopic diseases, such as asthma and atopic
dermatitis, is controversial [255]. It has been generally considered that chronic allergic
inflammation is mediated mainly by T cells as opposed to IgE and mast cells [256],
Several lines of evidence point to an importance of T cells and other endogenous
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cutaneous cells in AD.

T cells comprise an important component of the histologic

findings in chronic AD lesions, which feature the T cells in hyperplastic epidermis, often
associated with GM-CSF production [257], In the dermis, significant mononuclear cell
aggregates are frequently observed in the perivascular space, reflecting the high degrees
of trafficking of leukocytes, including macrophages, Langerhans’ cells, dendritic cells,
and lymphoid cells.

Edema is another feature in the perivascular area of atopic skin,

which is believed to be T-cell dependent [257], Edema and pruritus in both acute and
chronic lesions are associated with an abnormal pattern of epidermal infiltration by
activated T cells and macrophages. Immunohistochemistry shows these T cells to be
indeed activated, as demonstrated by HLA-DR expression [257].

Furthermore,

empirically, therapies that inhibit T cells, through the suppression of T-cell activation,
cytokine production, or migration, have been shown to ameliorate AD. Clinical studies
using topical FK506 or tacrolimus, oral cyclosporine A, ASM 981, and photopheresis
provide compelling evidence that T cells play a key role in the pathomechanism of AD
[257].
If cell-mediated immune reactions are considered the predominant player in the
pathomechanism of this disease, the atopic context manifested by increased IgE and IgEmediated allergic reactions in the blood and skin of AD patients creates confusion. To
further complicate the understanding of AD pathogenesis, high concentrations of total
and allergen-specific IgE in the blood and skin are in fact not a consistent finding among
AD patients. Two forms of AD have recently been proposed based on this discrepancy.
The “allergic” or “extrinsic” form of AD (EAD) is associated with elevated levels of IgE
and appears to comprise the majority of AD patients [258],

In the “nonallergic

or
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“intrinsic” form (IAD), also known as nonallergic atopiform eczema or nonallergic
atopiform dermatitis [259], which has been reported to represent 10-30% of all AD
patients, patients have normal total serum IgE levels and no allergen-specific IgE,
although they exhibit the same clinical phenotype [260],

This suggests that elevated

allergen-specific IgE levels are not a prerequisite in the pathogenesis of IAD and key
mechanisms contributing to this subtype of AD are still unknown. Conversely, however,
recent studies have shown the ability of anti-IgE MoAb (omalizumab) to attenuate both
immediate and delayed inflammatory responses, specifically in the treatment of allergic
respiratory disorders [261, 262],

Such results suggest that IgE might indeed mediate

allergic reactions beyond type I allergy.

Though it is generally accepted that an

immunological dysregulation of biphasic Th1/Th2 activity plays a central role in the
pathogenesis of AD [263, 264], the specific role of IgE in the development of AD
remains to be elucidated.

Proposed Mouse Models of Human Atopic Dermatitis

Total serum IgE levels found in mice of the present study did not correlate with
presence of SpD, nor with the environment in which they were housed. While NOD.6-/mice housed in CNVC were the only group to exhibit signs of SpD, their total serum IgE
levels did not differ from those of NOD.6-/- housed in I VC or of NOD w.t. mice housed
in either CNVC or IVC. Additionally, (Fi X NOD) BC.6-/- mice which showed obvious
SpD did not demonstrate elevated total IgE levels compared to BC.6-/- mice without
SpD. These results do not support a primary role of IgE in the pathogenesis of SpD. If
IgE antibodies played a predominant role in the development of SpD, one would expect
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not only to see significantly elevated IgE levels in NOD.6-/- mice housed in CNVC,
which showed SpD, but also to see a direct correlation between IgE level and severity of
clinical dermatitis, as measured, for example, by thickness of ear skin.
The findings from this study are also not consistent with those found in other
mouse models of AD.

For example, though similarities exist between the present

findings and that of Matsuda et al. (1997) for the NC/Nga mouse model, one of the key
differences is the finding of markedly increased total serum IgE levels in the latter. The
atopic dermatitis-like lesions exhibited in NC/Nga mice are similar to those of the
NOD.8-/- mice in several ways.

As in the present study, the development of

spontaneous dermatitis occurred only in mice raised in conventional housing as opposed
to a specific pathogen-free (SPF) environment consisting of a laminar filter-air flow
enclosure in a bioclean room [198], Clinical signs and symptoms seen in conventional
NC/Nga mice were similar to those of NOD.8-/-, albeit of a higher degree of severity
and affecting areas not confined to the ears. The dermatitis was characterized by itching,
erythema and hemorrhage, followed by edema, superficial erosion, deep excoriation,
scaling and dryness of the skin, and alopecia in the face, ears, neck and dorsal skin, as
well as growth retardation. Clinical severity of the dermatitis, examined in mice from 7
to 17 weeks of age, was minimal at 7 weeks old and steadily increased with age.
Histological features of dorsal skin from conventional NC/Nga mice showed significant
changes similar to those found in conventional-housed NOD.8-/— mice and human AD
lesions. These changes were apparent as early as at 7 weeks old and increased in degree
with age, characterized by a thickened epidermis with moderate hyperplasia and
prominent hyperkeratosis, intercellular edema, and increased numbers ot mast cells and
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eosinophils with degranulation [198], Interestingly, Matsuda et al. (1997) also found that
age-matched BALB/c mice maintained in the same conventional housing as NC/Nga
mice from 7 to 17 weeks of age did not show any significant clinical signs or symptoms,
similar to the findings that mice of the C57BL/6 background did not exhibit signs of SpD.
In contrast to the NOD.6-/- mice, conventional NC/Nga mice were found to have high
levels of IgE (-25 ug/ml) at 8 weeks of age, when mild dermatitis was clinically evident.
By 10 weeks, IgE levels were markedly increased (-70 pg/ml), and plateaued at 17
weeks, thus correlating with clinical severity of dermatitis. In contrast, plasma IgE levels
in SPF NC/Nga and BALB/c mice remained at levels <0.5 pg/ml. The direct correlation
between IgE levels and clinical severity of dermatitis in conventional NC/Nga mice was
similar to that reported in AD patients with IgE hyperproduction [265, 266],
The Naruto Research Institute Otsuka Atrichia (NOA) mouse is another strain that
has served as a mouse model of human AD, as these mice develop severe ulcerative skin
lesions that are associated with accumulation of mast cells and scratching behavior [193].
In NOA mice, high levels of serum IgE are found as well. NOA mice with ulcerative
skin lesions show significantly higher serum IgE levels compared to NOA mice without
skin lesions (-2,900 ng/ml vs. 400 ng/ml at 16 weeks of age; -11,000 ng/ml vs. 450
ng/ml at 32 weeks of age), while control hairy mouse strains maintain very low levels of
serum IgE (0-200 ng/ml) [193].
More recently, another mouse strain has been introduced as mice with naturally
occurring dermatitis similar to human AD. DS-Nh originated from a mutant male mouse
with deficient hair growth in an inbred DS strain colony at Aburahi Laboratories
(Shionogi & Co., Ltd., Shiga, Japan) in 1976 [267],

The hairless phenotype of this
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euthymic mouse shows an autosomal dominant inheritance, which is quite different from
other well-known hairless phenotypes [268-270], Heterozygous mutant DS Ng/+ mice
housed under conventional conditions, assessed from ages 5 through 24 weeks old, were
shown to develop skin symptoms similar to those of AD, including erythema, edema,
excoriation, erosion, dry skin and desquamation of the forehead, lateral face, perioral
area, neck, anterior chest and joint areas of their forelegs [267], Early clinical symptoms,
such as erythema, edema, excoriation, and dry skin, appeared in all mice at 9 weeks of
age. Clinical severity increased steadily until the mice were 25 weeks old, at which time
it remained stable. In contrast to conventionally housed DS-Nh mice, DS-Nh mice raised
under SPF conditions, as well as conventionally housed DS mice, did not show any
significant signs of spontaneous dermatitis.

Notably, the authors found that NC/Nga

mice housed in the conventional conditions used in their study failed to develop
dermatitis over 30 weeks of observation.

Significant histologic changes, including

hyperkeratosis, acanthosis, slight intercellular edema of the epidermis, and infiltration of
inflammatory cells, were observed in the skin lesions of all DS-Nh mice at 9 weeks or
older, concurrent with the appearance of the clinical symptoms. Such histologic changes
became more apparent with age. In facial skin tissue, conventional DS-Nh mice showed
significantly higher numbers of degranulated mast cells and eosinophils compared to SPF
DS-Nh and conventional DS mice [267], Among DS-Nh mice raised under SPF
conditions or in DS mice raised in SPF or conventional housing, no significant
histopathological changes were observed throughout the 29-week observation period.
Again in contrast to the findings in NOD.6-/- mice ot the present study, the level ot total
serum IgE was significantly increased only in conventionally housed DS-Nh mice and
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not in DS-Nh mice raised under SPF conditions. Interestingly, serum IgE levels were not
detected until 17 weeks ot age (—200 ng/ml), but from that point on, levels subsequently
increased with age (-2500 ng/ml + 2000 at 20 weeks, -4000 ng/ml ±1200 at 25 weeks,
and -4500 ng/ml + 1700 at 30 weeks).

Comparison of NOD. 8-/- Mice with Other Mouse Models

A few key observations can be made in comparing the findings from the present
study with those from the previously proposed mouse models of AD.

First, all the

proposed mouse models, in addition to NOD.8-/- mice, are similar in exhibiting a
naturally occurring, spontaneous dermatitis, presenting AD-like symptoms and
histopathological changes.

Second, the spontaneous dermatitis occurs only in

conventional conditions, as opposed to specific pathogen-free or ventilated housing
conditions, implying the necessity of environmental triggers in initiating the chronic
cutaneous inflammatory process.

As described in these first two comparisons, the

clinical and histopathologic features, as well as the dependence on environmental
triggers, of the dermatitis exhibited in these mice all lend support to their validity in
serving as mouse models for human AD. A third comparison between NC/Nga, NOA,
and DS-Nh mice and NOD.8-/- mice reveals an obvious difference between NOD.8-/mice and the first three mouse models. NOD.8-/- mice do not exhibit elevated total
serum IgE levels in association with the spontaneous dermatitis phenotype when
compared to mice that do not exhibit the SpD phenotype.

I hough there was a lack ot

correlation between IgE levels and presence of dermatitis, a role tor IgE in the
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pathogenesis of SpD cannot be formally excluded in this study.

The findings of this

study can be interpreted in at least two ways.

1. NOD.d-/- as a Model for Atopiform Dermatitis

One hypothesis explaining the lack of correlation between IgE levels and SpD is
that the dermatitis observed in the present study is in fact not of an atopic nature. It is
quite possible that the triggers for the SpD phenotype are as-yet unidentified factors
found in the conventional non-ventilated cages that act on the skin as an irritant, and not
an allergen. Because these mice do not demonstrate elevated levels of total serum IgE
levels compared to controls, it is conceivable that the NOD.6-/- mice may represent a
novel model for “intrinsic” AD, or more accurately “atopiform dermatitis” [259], It has
been proposed that atopy should be defined as the genetically determined and
environmentally influenced syndrome in which the primary immunological abnormality
is the production of allergen-specific IgE [259],

Accordingly, the term “atopiform

dermatitis” should be used to describe the condition, which affects 20% of patients with
presumed AD, that is clinically identical to atopic dermatitis, but lacks the AD hallmark
of allergen-specific and elevated levels of IgE. Recent evidence provides support for the
hypothesis that patients with intrinsic AD display characteristics that differ from the
phenomena typically seen in atopic disease.

A hallmark of IAD is a lower FceRI

expression of CDla+ epidermal dendritic cells [271]. Additionally, it has been shown
that skin derived T cells from EAD give effective B cell help for IgE production, while T
cells from IAD patients do not [212], In a recent study on the phenotype of monocytes
and serum levels of cytokines regulating the IgE production from nonatopic individuals
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and patients with extrinsic and intrinsic dermatitis, the authors found the surface
expression of the high- and low-affinity receptor for IgE (FceRI and FceRII/CD23) and
the IL-4Ra chain to be significantly elevated in monocytes from patients with EAD
compared to those with 1AD.

Serum levels of IL-13 were significantly increased in

patients with IAD, while levels of IL-5 were increased in patients with EAD.
Furthermore, the frequency of the IL-4Ra polymorphism C3223T and the IL-4
polymorphism C590T, which have been previously shown to play a relevant part in
atopic diseases [272, 273], tended to be higher in EAD than in IAD. Thus, IAD patients
appear to exhibit phenotypic and immunologic features distinct from those of patients
with EAD or other atopic disorders [274], supporting the idea that these two forms of AD
may have different pathogenic mechanisms.
If the SpD observed in the NOD.6-/- housed in CNVC of the present study is in
fact representative of an atopiform dermatitis, rather than a true atopic dermatitis, one
may expect to see the phenotypic and immunologic features characterizing IAD patients
in contrast to EAD patients. Indeed, further studies including serum measurements of
cytokines such as IL-13 and IL-5 are feasible and warranted to further elucidate the
pathogenesis of SpD.

The characterization of FceRI or FceRII receptors on the

monocytes and epidermal dendritic cells of the mice would also be useful in order to
assess similarities or differences between this model and findings which characterize
IAD.

Intriguingly, however, studies to date have shown that murine epidermal

Langerhans cells in fact do not express FceRII at all [275], while the presence of FceRI
also has not been demonstrated. This finding suggests that murine Langerhans cells in
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mice may hold a pathogenetic in spontaneous dermatitis distinct from that of their
counterparts in human AD.
It is worth noting an interesting finding from a recently-established mouse line
using the NC/Nga mouse model of AD. STAT6-deficient (STAT6-/-) NC mice were
created in order to address the functional relevance of IgE and TH2-mediated immune
responses in NC mice to the development of AD-like skin lesions [276].

STAT6 is a

critical transcriptional factor that regulates IL-4-mediated immune responses.
Phosphorylated and activated through an IL-4R-mediated signal, STAT6 translocates as a
phosphorylated homodimer and subsequently regulates lL-4-mediated transcriptional
events, including Th2 differentiation, expression of cell surface markers, and Ig class
switching to IgE [277, 278],

STAT6-/- NC/Nga mice are unable to mount the Tn2

cytokine production required for serum IgE response. Unexpectedly, these mice were
observed to still elicit AD-like skin lesions at equivalent frequency and time of onset
compared with normal NC/Nga littermates.

Histological features of the lesions were

consistent with the pathogenesis of AD, characterized by infiltration of eosinophils and
mast cells. However, these mice failed to produce IgE and Th2 cytokines. The lymph
nodes proximal to the skin regions with lesions showed massive enlargement elicited by
the accumulation of activated IFN-y-secreting T cells.

In addition, IL-18, IL-12, and

IFN-y were found to be highly expressed at the skin lesions, along with elevated
expression of eotaxin 2, a newly identified potent chemoattractant tor eosinophils, and its
receptor, CCR3. This study demonstrates that the TH2-mediated immune response is not
necessary for the development of AD-like skin disease in NC/Nga mice. It is possible
that the skin microenvironment, that of affected skin regions, which favors IFN-y and
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IL-18 production and associated infiltration of eosinophils, may be more important than
Th2 cytokines in the development of AD in NC/Nga mice [276], This study lends further
support to the idea that the SpD in NOD.6-/- mice may not be atopic in nature, but have
a mechanism that is independent of TH2 cells and IgE antibodies.

2. NOD. 8-/- Mice as a Model for True Atopic Disease

A second interpretation of the results from this study may be that the SpD in
NOD.6-/- is a form of true atopic disease, associated with elevated IgE levels, but the
elevation was simply not detected at the time of serum collection. For example, in the
DS-Nh mice discussed above, serum IgE levels did not become elevated until after 17
weeks of age, incongruent with the much earlier development of clinical symptoms, such
as erythema and excoriation, at 9 weeks of age. The reason for an 8-week lag in IgE
elevation is unclear. Yet based on this finding, it is indeed conceivable that if serum IgE
levels are measured in the NOD mice serially starting from at least 5-6 weeks of age,
when clinical symptoms first appear, for a longer time period, e.g. 30 weeks, a significant
increase in IgE levels may in fact be detected, in a manner not necessarily coordinated
with the appearance of clinical symptoms. This observation is in contrast to the finding
in NC/Nga mice of the direct temporal correlation between IgE elevation and clinical
development of dermatitis, and raises the question of the direct role of IgE in causing the
AD-like lesions in these mice. Perhaps an additional factor driving the IgE synthesis is
missing or blocked, even temporarily, and the pathogenesis of the disease is due
primarily to non-IgE-mediated mechanisms, such as cytokines like IL-13 directly or
indirectly driving the disease by the stimulation ot eosinophils, interactions with B cells,
or alterations of certain signal transduction pathways, like that ot IL-13R, whose role has

previously been implicated in atopic diseases [279]. After the production of serum IgE
begins to increase, IgE antibodies may begin to play a more direct role in the propagation
of the disease. Mast cells, basophils, and eosinophils are certainly not the only cells of
IgE-mediated action.

Monocytes and dendritic cells such as Langerhans cells or the

recently described inflammatory dendritic epidermal cells [280] have been shown to
perform IgE-mediated antigen focusing, i.e. IgE increases their presenting capacity up to
100-1000 fold in vitro [281, 282], Additionally, FceRI has been found to be significantly
upregulated on lesional epidermal dendritic cells of AD [280],

Three different IgE-

binding structures have in fact been detected on epidermal antigen presenting dendritic
cells; these include: (1) the low affinity IgE-receptor CD23/FceRII [283]; (2) the high
affinity IgE-receptor FceRI [284, 285]; and (3) the IgE-binding protein Galectin 3/eBP
[286], The expression of such IgE-binding structures on these epidermal dendritic APCs
emphasize the importance of these cells in the pathogenesis of IgE-mediated processes,
even in chronic inflammatory diseases.

Further Studies

The study by Girardi et al. (2002) showed that not only NOD.6-/- mice, but also
FVB.6-/- mice developed spontaneous inflammation of the ears as shown by highly
significant but less dramatic differences in baseline ear thickness relative to age-matched
FVB controls.

The increased ear thickness was associated with qualitatively similar,

albeit less intense, histologic differences as described tor NOD.6-/- mice. Interestingly,
such changes developed in FVB.6-/- mice in the absence of overt clinical signs of
spontaneous dermatitis, i.e. pruritus or erythema [147], It would be ot interest to measure

serum levels of IgE in mice of the FVB background, and to compare measurements
between FVB.6-/- mice housed in CNVC, FVB.6-/- housed in IVC, FVB w.t. housed in
CNVC, and FVB w.t. housed in IVC, just as was done for NOD mice of the present
study. It is curious that FVB.6-/- mice exhibit histopathologic features of AD of lesser
degree than NOD.6-/- mice but of larger degree than C57BL/6.6-/- mice, which
developed neither clinical nor histologic evidence of spontaneous dermatitis compared to
age-matched C57BL/6 controls. Perhaps serum IgE measurements would demonstrate
levels that lie in between those found for NOD.6-/- (average -300 ng/ml) and
C57BL/6.6-/- mice (average -50 ng/ml).

Such a finding would suggest that perhaps

mean baseline IgE levels are correlated with presence and/or severity of spontaneous
dermatitis, despite not seeing a correlative increase in IgE levels with the development of
SpD.
It is intriguing that among the proposed mouse models for AD, there is a
markedly wide range in total serum IgE levels found among the different strains. In the
NC/Nga mice, serum IgE levels were detectable starting at 6 weeks of age, as high as
3000 ng/ml. At 10 and 12 weeks of age, IgE levels were as high as 70 and 90 pg/ml, or
70,000 and 90,000 ng/ml.

Such levels of total IgE are almost 300 times greater than

those found for NOD mice.

Similarly, but to a lesser degree, serum IgE levels of DS-Nh

mice were also reported to be significantly higher than those found in NOD mice, with
averages of 2500, 3800, and 4500 ng/ml at 20, 25, and 30 weeks of age, respectively
[267], These levels are approximately 8 to 15 times higher than those found in NOD
mice. In a transgenic mouse line expressing epidermal IL-4, established on the CByB6
strain and mated with non-transgenic BALB/cBy strain mice, IgE levels ot atfected mice

were found to be in the average range of 4000 to 5000 ng/ml, approximately 13 to 17
times higher than those of NOD mice [287], Interestingly, in all these mouse models of
AD-like dermatitis, the clinical signs and symptoms of the spontaneous, chronic
inflammatory dermatitis were markedly more severe than those reported for the
NOD.6-/- and FVB.6-/- mice. Conventionally-housed NC/Nga mice showed severe
dermatitis with hemorrhage, edema, erosion, dryness and alopecia in the face, ears, neck
and dorsal skin [198].

DS-Nh mice showed the early clinical symptoms of erythema,

edema, excoriation, and dry skin, with increasing severity with age, associated with
habitual scratching of their cheeks, eyelids, and neck [267], In the IL-4 transgenic mice,
skin lesions initially occurred at the mice’s ears and subsequently extended to the neck,
mouth, around the eyes, tail, and legs [287], There was severe dermatitis of the head and
neck with areas of crusting, hair loss, and bacterial pyoderma as well as destruction of
external ears. Eyelid dermatitis, blepharitis, and conjunctivitis resulted in corneal and
conjunctival scarring, leading to blindness.

In contrast, the spontaneous dermatitis

exhibited in NOD.b-/- mice housed in CNVC was very mild in comparison, consisting
simply of pruritus, erythema, and edema, with visible lesions restricted to the ears.
Indeed, the total IgE levels of -300 ng/ml of these NOD mice are comparatively
miniscule to those of the previously described mice. The comparisons described here
support the idea that serum IgE levels are correlated with clinical severity of dermatitis,
not only within a specific strain, but perhaps also across mouse strains. It is possible that
genetic constraints exist which determine the potential ot IgE production, even in
response to appropriate environmental triggers. In turn, low levels ot IgE production, i.e.
a genetic “inability” or suppressive factor in producing high IgE responses to triggers,

would prevent the development of atopic dermatitis-like disease in the mice of such
genetically-designed strains. Genetic studies are currently underway to elucidate such
factors, as will be discussed in the next section.
Although the data of the present study do not appear to support a primary role of
IgE in the pathogenesis of SpD in NOD.5-/- mice, the requirement for immunoglobulins
and/or B cells can be definitively determined by analyzing mice that are “double
knockout” NOD.6-/- Ig p-null mice [288],

If indeed such NOD.6-/- Ig p-null mice

which were exposed to the appropriate environmental triggers, i.e. CNVC housing, failed
to exhibit signs of SpD, the necessity of immunoglobulins and/or B cells for the
development of SpD would be revealed. On the other hand, if such mice continued to
exhibit signs of spontaneous dermatitis, the conclusion could be made that
immunoglobulins and/or B cells are not absolutely necessary for the initiation of this
chronic cutaneous inflammatory process, and that other non-Ig-mediated processes are
primarily responsible for the pathogenesis of this phenotype.

Total IgE Levels Higher in Females versus Males

In the present study, comparison of total serum IgE levels in female mice with
those of male mice revealed an interesting observation. Among BC.6-/- mice exhibiting
obvious SpD, female mice compared to males showed a higher baseline ear thickness.
Intriguingly, total serum IgE level in the females were also found to be higher than that of
the males. When comparison of total serum IgE levels between females and males was
done in all groups, significantly higher IgE levels were, in fact, found in three other
groups of mice, all of which were 6.-/- mice housed in CNVC. Two of these groups

were B6.6-/- mice and (B6 X NOD) Fi.6—/— mice, which did not even exhibit signs of
SpD. The explanation for this finding is unclear, but readily suggests a possible femalespecific factor that is contributing to increased IgE responsiveness to the environmental
trigger(s) causing SpD. A review of literature did not reveal previous reports of higher
total IgE levels in female AD patients compared to males, or in female mice compared to
males in other mouse models of AD.

Elowever, there are several reports of slightly

increased prevalence of AD in females, with a male to female ratio of 1:1.5 [219, 289].
Additionally, several studies have reported maternal atopy to cause a greater risk of
atopic disorders in the offspring than paternal atopy [219, 288, 290-296], Though the
reasons for this phenomenon is still unclear, genetic studies have shown specifically
maternal patterns of transmission at certain loci associated with AD.

For example,

Cookson et al. (1992) found significant sharing of maternal alleles of chromosome
11 q 13, on which a gene for atopy has been assigned [297], in sibling-pairs with atopic
IgE responsiveness (defined by higher than normal total serum IgE levels) [175]. The
excess sharing of maternal alleles occurred whether or not the mother was herself overtly
atopic, which points to the possibility of genomic imprinting. It was noted that human
11 q 13 is syntemc to mouse chromosome 7Fl-ter, in one of only seven areas recognized
to show genomic imprinting [298], Such linkage of atopic IgE response to chromosome
11 q 13 maternally derived alleles was found in a separate study of Japanese families,
providing support for a maternal inheritance pattern [299], A specific examination of
gene polymorphisms for the (3 chain of the high affinity receptor for IgE (FceRI-[3),
which is a candidate accounting for the chromosome 11 q 13 effect on atopy, found that all
13 children in the study who had inherited the polymorphisms Leu 181/Leu 183
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maternally were atopic. Leul81/Leul83 had previously been found to be associated with
atopy [299]. By contrast, the eight children who had derived the variant paternally had
negative skin prick and radioallergosorbent test results and did not have increased
bronchial

responsiveness.

Thus, the authors concluded that these polymorphisms of

FceRI-|3 identified a genetic risk factor for atopy and bronchial hyperresponsiveness
when inherited maternally [300], More recently, two more polymorphisms within the
FcsRI-(3 gene, namely allele 2 of Rsa\ intro 2 and allele 1 of Rsa\ exon 7, were found to
be strongly associated with AD [301]. Furthermore, transmission of these alleles was
significantly associated with AD when maternally-inherited. Though these studies do not
directly parallel the observation of higher total serum IgE levels in females over males in
the present study, they do lend support to a female bias in both atopy prevalence and
atopic IgE responsiveness. Further studies are warranted both to confirm these findings
among the B6.6-/- and NOD.6-/- mice and to elucidate the mechanism by which this is
occurring. Perhaps, for example, the females in these mouse strains possess a gene that
codes for increased expression of the high-affinity IgE receptor, FceRI, which would lead
to increased IgE responsiveness to environmental allergens.

Examination of genes

associated with atopy or AD may in fact reveal differences in polymorphisms between
females and males.

Role of DETC in Atopic Dermatitis

From the observation that NOD.6-/- mice developed spontaneous signs of SpD.
while NOD.6+/+ mice housed in the same CNVC conditions did not, it is apparent that
the deficiency of yb T cells, presumably DETC, contributed to the pathogenesis of SpD.

In tact, Girardi et al. (2002) showed through reconstitution of 6-/— mice specifically with
Vy5+ fetal thymocytes (DETC precursors) that Vy5+, but not Vy5-, cells had the ability
to down-regulate both spontaneous and irritant dermatitis in the 6-/- mice. These results
provide a novel demonstration that a local functional impairment at an epithelial interface
can be attributed to the specific absence of the local y6 cell subset constitutively resident
within that tissue, and that DETC provide local, nonredundant regulation of cutaneous
inflammation [147], In considering the NOD.6-/- mice as a possible mouse model for
AD, the question is raised of the role of DETC specifically in allergic disease. In a study
of Brown Norway rats, tolerized to OVA by repeated aerosol exposure [302], y6 T cells
were found to produce high levels of IFN-y in response to ovalbumin (OVA) stimulation
in vitro, suggesting a mechanism for the inhibition of Tn2-type antigen responses, and

therefore for the selective suppression of IgE antibody production.

y6 T cells also

exhibited the unique potential of selective IgE antibody suppression in response to
mucosal antigen exposure; thus, it was further proposed that y6 T cells may play an
important role in protection against primary allergic sensitization in vivo [302], The same
experiment was carried out in C57BL/6 mice [302], which showed small numbers of y6 T
cells from OVA-tolerized mice selectively suppressing TH2-dependent IgE antibody
production, without affecting parallel IgG responses. Challenge of these cells in vitro
also resulted in high levels of IFN-y production. The mechanism of the tolerogenic effect
seemed to be either through the inhibition of the expansion of pre-existing OVA-specific
Th2 cells or of the development of OVA-specific Th2 cells [21]. Based on these studies,
it is possible that DETC may help in either preventing atopic dermatitis or suppressing
the propagation of AD-like lesions in the skin through the production of IFN-y and
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consequently the suppression of IgE production.

The fact that the NOD.6-/- mice

housed in CNVC of the present study showed the same levels, as opposed to higher
levels, of IgE compared to those of the NOD.5+/+ mice housed in CNVC does not
support the notion that y8 T cells contribute to the prevention of AD-like disease through
any significant suppression of IgE production.
Though the pathogenesis of AD is not completely known, almost every kind of
cell has been implicated as playing a role, including T cells, keratinocytes, mast cells, and
Langerhans cells. The roles of mast cells and Langerhans cells, in particular, have been
increasingly implicated and elucidated as part of the pathomechanism in AD. Mast cells
are known to be effector cells in IgE-mediated immediate hypersensitivity reactions
[303]. Moreover, mast cells have been reported to play an important role in eosinophil
infiltration into the lung after allergen challenge [304], In addition, it has been recently
documented that histamine, through stimulation of H2 receptors, suppresses IL-12
production and stimulates the generation of IL-10 [305, 306]. Such an alteration of local
cytokine levels could shift the Th1/Tii2 balance toward Th2 dominance, thus augmenting
eosinophil recruitment and allergic inflammation. More recently, in a study on OVAinduced skin inflammation in mast cell-deficient (W/W) mice, IFN-y mRNA expression
was found to be significantly increased in sensitized skin of W/W' mice but not in that of
wild-type controls. Additionally, total serum IgE levels were significantly increased after
OVA epicutaneous sensitization in W/W mice compared to controls [307], The results
suggested that mast cells regulate IFN-y expression in the skin and IgE levels in the
circulation. In light of these findings, it can be postulated that damage to or deficiency of
mast cells could lead to increased activity of DETC, such as in overexpressing IFN-y. As
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IFN-y can damage keratinocytes [307], it is possible that DETC may contribute not only
in down-regulation of cutaneous inflammation, but also in damage to local epithelia in
some cases.
Among professional antigen-presenting cells (APC), dendritic cells (DC) show
the unique capacity to initiate primary immune responses [308],

Immature DC are

characterized by their high capacity for antigen uptake and play primary roles in the
immune system in peripheral tissues. The prototype of immature DC are Langerhans
cells. Human Langerhans cells variably express a trimeric form of the FceRI receptor,
containing one a- and two y-chains, but lacking the (3-chain characteristic for tetrameric
FceRI on mast cells and basophils [284, 285, 309],

In contrast to the latter, ample

evidence exists that implicates the role of FceRI+ APC in IgE-mediated delayed-type
hypersensitivity reactions in atopic diseases. First, patients with AD exhibit enhanced
surface expression of FceRI on Langerhans cells [310]. Second, FceRI has been shown
to allow Langerhans cells/DC and monocytes to take up, process, and present antigens to
T cells more efficiently [282, 311]. Recently, the engagement of the FceRI was shown to
stimulate the production of IL-16 in Langerhans cell-like dendritic cells [312].

The

functional role of IL-16 in inflammatory processes is only beginning to emerge, but
evidence has shown that IL-16 could be involved in autoimmune disorders [313-315], as
well as in the pathogenic aspects of allergic asthma, including production of allergenspecific IgE, recruitment of inflammatory cells to the bronchial mucosa, and development
of airway hyper-responsiveness [316-318], Thus, IL-16 released from Langerhans cells
after allergen-mediated activation through FceRI may link IgE-driven and cellular
inflammatory responses in diseases such as AD [312].

Kraft et al. (2002) have also

recently shown that NF-kB, known to regulate genes essential for inflammatory
responses and DC differentiation and function, is activated upon FceRI ligation in
primary human monocytes and DC [319], Their study also showed that NF-kB activation
in Langerhans cells isolated from the epidermis was restricted to donors expressing high
FceRI amounts. Additionally, FceRI ligation on monocytes and DC led to synthesis and
release of TNF-a and monocyte chemoattractant protein-1 (MCP-1), which is decreased
by two distinct inhibitors of NF-kB activation. Thus NF-kB activation represents a novel
mechanism by which FceRI on monocytes and DC potentially controls inflammatory
reactions [319], As DETC have been shown to secrete several cytokines, including IFNy, IL-2, IL-3, and IL-4, as well as the potential to express mRNA for IL-la, IL-2, IL-3,
IL-4, IL-6, IL-7, IFN-y, TNF-a, TNF-[3, GM-CSF, and MIP-la [119], it is obvious that
the interplay between DETC, mast cells, and Langerhans cells, as well as other cells of
the immune system, must be quite intricate and complex. With the local, non-redundant
regulatory role in cutaneous inflammation recently implicated for DETC, it would be
interesting to investigate the condition, i.e. number, morphology, cytokine secretion, of
DETC in the different mouse models proposed for human AD. Perhaps one would find
varying degrees or ways in which DETC are damaged. Ultimately, defining the role of
DETC in AD-like disease in mice may lead to understanding the possible defect that lies
in the as-yet undefined, functionally equivalent epidermal y8 T cells found in human AD
patients.
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B. SPONTANEOUS DERMATITIS AND GENETICS
Research into AD over the last 40 years has been dominated by exploration of the
cellular and molecular mechanisms.

Much of this work has indeed produced

breakthroughs in the understanding of this enigmatic disease, such as the discovery of the
role of different T-lymphocyte cell subsets, mast cells, Langerhans cells, eosinophils,
immunoglobulins, and cytokines. However, much is still unknown particularly regarding
the genetic basis for AD, though family aggregation and twin studies provide evidence of
a considerable genetic component of this disease [151, 166],
Genetic analyses sought to elucidate the genetic control of the spontaneous
dermatitis observed in NOD.6-/- mice of the present study. The spontaneous dermatitis
that occurs in 6.-/- mice housed in conventional, non-ventilated cages is strikingly
strain-dependent, strongly pointing to a component of heritability in this phenotype [147],
Clinical and histopathologic signs of dermatitis, as well as increased baseline ear
thickness, were found in 6.-/- mice of the NOD background, while C57BL/6.8-/- and
wild-type mice showed no clinical or histologic evidence of the phenotype. When Fi, F2,
and (Fi X NOD) BC.6-/- offspring of NOD.6-/- and B6.5-/- mice were analyzed, the
incidence rates of SpD appeared to be consistent with a single autosomal recessive gene
inheritance [147], Interestingly, a genetic analysis for dermatitis performed on NC/Nga
and BALB/cA (BALB) strains demonstrated similar results [320]. As mentioned earlier,
Matsuda et al. (1997) discovered that NC/Nga mice reared under non-sterile,
conventional conditions developed spontaneous signs and symptoms of dermatitis, while
BALB mice under the same housing conditions did not. NC/Nga mice were paired with
BALB mice to produce Fi, F2, and (Fi X NC/Nga) backcross progeny.

In the Fi
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generation, no animals expressed dermatitis, with no difference shown between
reciprocal matings (NC female X BALB male vs. NC male X BALB female). The F2
generation revealed 89 mice to have dermatitis, while 232 mice did not, showing -25%
dermatitis affected rate.

Lastly, in the BC generation, 92 mice displayed dermatitis,

while 105 animals did not, showing -50% affected rate.

The authors concluded that

these incidence rates were consistent with an autosomal recessive gene [320]. Though
original analysis of the genetic data for the NOD.6-/- and B6.8-/- mice was consistent
with a single locus as the major determinant for susceptibility, microsatellite mapping
studies based on NOD and B6 SSLPs have since revealed a more complex picture. Three
candidate Nod recessive chromosomal intervals have recently been identified and are
presently under investigation [231].
Genome-wide linkage analyses for susceptibility loci for atopic dermatitis have
already been performed in two mouse models. As a logical starting point in the genetic
analysis of NOD.8-/- and B6.8-/- mice, the intervals of susceptibility identified from
these previous genome-wide studies were used to assess possible linkage to susceptibility
in the NOD.8-/- mice as well.

In the NC/Nga model [152], the locus of the major

determinant was tightly linked to six markers in a locus region (termed derml) on
chromosome 9. When genomic DNA from NOD.8-/- and B6.8-/- mice were analyzed
for linkage of SpD susceptibility to the D9Mitl05 locus, which had a position close to the
loci described for NC/Nga mice, no linkage was found. In fact, yj value was essentially
equal to 0.

Analysis in the NOA model [153] found significant association between

ulcerative skin lesions and two markers on chromosome 14. Locus D14Mit262, whose
position is approximately in the center of the interval of the two markers, was chosen to

122

be analyzed in the NOD.6-/- and B6.6-/- mice. Again, no linkage to SpD susceptibility
was found, with another % value * 0. These results clearly indicate that the loci linked to
SpD susceptibility are distinct from those found in the previous two mouse models. The
findings of the current investigation mentioned above on the three candidate Nod
recessive chromosomal intervals will indeed contribute significantly to our understanding
of this disease, and potentially to that of human AD. It will be interesting to determine
which functional candidate genes are located near the susceptibility regions identified.
For example, in the NC/Nga mice, seven candidate genes were found to be near the
derml locus, including thymus cell antigen 1 0 (Thy l), CD3 antigen 6, e, and y

polypeptide (Cd36,£,y), IL-10 Ra {IIIOra), IL-18 {1118), and C-terminal Src kinase {Csk),
all of which are involved in T-cell functions [152], In the NOA mouse model, no specific
candidate gene was located near the identified regions on chromosome 14 [153].
However, in a subsequent analysis, the authors identified two candidate loci that could
modify the gene responsible for the NOA phenotype, one in the middle of chromosome 7,
and the other in the telomeric region on chromosome 13 [154],

The gene for IL-16,

which plays a crucial role in recruiting CD4+ cells to sites of inflammation during the
acute phase of AD [195], is located near the identified locus on chromosome 7. In the
vicinity of the identified locus on chromosome 13, there is a murine gene encoding
PIK3R1 (phosphoinositide-3-kinase regulatory subunit, polypeptide 1 [p85a]). PIK3R1
regulates the signaling events that lie downstream of the FceRI-mediated activation of
tyrosine kinases [321], implicating its role in the degranulation of mast cells and
basophils, which initiate the allergic response.

Additionally, each of the candidate

modifier loci identified in the NOA mouse is syntenic to human chromosomal regions
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11 q 13 and 5ql3 [322, 323], These regions are known as consensus areas of linkage to
asthma, atopy, or related phenotypes such as serum IgE level [178, 301, 324, 325].
Indeed, the identification of genes underlying shared human and mouse linkages may
provide important insights into the etiology of atopic dermatitis.

Particularly in the

analysis of NOD mice, it will be of interest to investigate any relation of loci identified
for SpD susceptibility to those identified for the pathogenesis of the autoimmune diabetic
phenotype found in these mice, such as Idd3, IddlO, Iddl7, and Iddl8 on mouse
chromosome 3 [326],
Apart from the observation of susceptibility of the NOD background to the SpD
phenotype, the results from the present study show a distinctly higher level in baseline
total serum IgE concentration in NOD mice, regardless of genotype, compared to B6
mice. Curiously, Fi progeny showed levels similar to those of B6 mice, while (Fi X
NOD) BC animals had IgE levels similar to those of NOD mice. Such results suggest a
possible genetic component to the IgE levels seen in these strains, such as an autosomal
recessive gene in the NOD background that leads to higher IgE production.

Genetic

studies, in fact, indicate that different genes regulate the presence of increased levels of
serum total IgE and specific IgE. The genetic variance of serum IgE has been reported to
constitute about 50% of the phenotypic variance [151, 327], To date, several research
groups have been involved in attempting to isolate the genes responsible for total serum
IgE. In 1994, Marsh et al. were the first to report linkage between serum total IgE levels
and chromosome 5q in an American Amish population [173]. A study of Dutch families
that same year replicated this finding of linkage to chromosome 5q [174], Since then,
additional studies have replicated linkages to chromosome 5, while others could not
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[328], Recently, Liu et al. (2000) found a significant association between a novel IL-13
coding region variant and both high total serum IgE level and presence of atopic
dermatitis [329], Overall, linkages to chromosomes 1, 2, 4, 5, 6, 7, 9, 11, 12, 13, 14, 15,
and 16 have all been reported, with replication of significant linkage to chromosomes 5,
11 and 12 [327], In sum, studies suggest that higher than normal total IgE and specific
IgE levels in some atopic individuals are genetically controlled. With the finding that
NOD mice, regardless of phenotype, have higher total serum IgE levels, compared to B6
mice, it would be of interest to identify possible genes that may be controlling total IgE
levels in NOD mice. Though total IgE does not appear to correlate directly with clinical
dermatitis in these mice, the genes controlling their circulating levels may in fact be
tightly linked to those conferring susceptibility to SpD.
Notably, results of genetic studies have also suggested genetic linkage of atopic
IgE responsiveness (increase in IgE levels) to environmental factors.

For example,

genetic linkage of atopic IgE response to chromosome 11 q 13 [330] has been replicated
by several groups [297, 299, 331], The gene for the [3 chain of the high affinity receptor
for IgE (Fee RI - (3) is a candidate for the chromosome 11 q 13 effect [177], FCeRI-f3
polymorphisms called Leul81/Leul83 have been found to be significantly associated
with atopy as well as bronchial hyperrresponsiveness [300], Such genetic influences on
IgE responsiveness to environmental triggers, and not just on total serum IgE levels at
baseline, may be responsible for the marked differences seen in IgE levels among the
different mouse models discussed in the previous section. For example, NOD.6-/- mice
may be reacting to appropriate environmental allergens as manifested by spontaneous
dermatitis, but are not mounting a robust IgE response due to a genetic constraint
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compared to NC/Nga mice or DS-Hd mice. Thus, their total IgE levels and associated
clinical manifestation of allergic cutaneous inflammation remain of lower severity
compared to the other mice.

The study of genetics offers a structured means of investigating complex diseases
with a genetic component.

A number of advancements can be made through the

elucidation of the genetic factors [248].

First, improvements can be made in the

definition of disease. For example, various genetic polymorphisms may correlate with
specific disease characteristics and may be used to define subgroups of the disease, such
as particular responses to particular treatments. Genetic studies will also provide results
that will help to define targets of therapeutic intervention and offer a rational means of
choosing targets in the pathogenetic pathway of allergic inflammation. Finally, genetic
studies can help to define people at risk, leading to rational strategies for the prevention
of disease in genetically susceptible children. The understanding of the etiology and
heritability of human atopic dermatitis will indeed be accelerated with the use of
appropriate mouse models, through which the identification of genes is much more
feasible and will help to dissect this incredibly complicated disease.

C. y5 TCR LIGAND
The overall goal of this project was to develop a Rat Basophil Leukemia (RBL)
bioassay in order to test activation through the Vy5/V51, DETC-specific TCR.
Constructs comprised of TCR Vy5 and V61 chains ligated into pCDL-SRa296 vector
using Xho I and Bgl II sites were developed. The extracellular domain of Vy5 and V81
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were directly fused to the thrombin linker region and CD3^, which provides the
transmembrane domain for both chains. The constructs were successfully transfected
into the RBL-2H3 line, which should not express NKG2D, CD8, or other receptors
expressed by y6 T cells, and theoretically avoids the problem of cell activation through a
receptor apart from the isolated transfected y6 TCR.

Stably transfected cells were

demonstrated by positive staining with either GL3 antibody, detecting the C6 portion of
the V61 chain, or 17D1 MoAb, which recognizes the Vy5 and V61 chains expressed
together. One clone which showed a relatively high percentage of GL3-positive cells
(28%) upon initial analysis was subsequently sorted into GL3-positive-only cells and
“enriched” into a population eventually showing cells that were 81% GL3-positive and
65% 17D1-positive. These percentages showed a ratio of 17D1 to GL3 positive cells
equal to 0.8:1, i.e. 80% of cells staining positively for GL3 were also detected by 17D1.
Staining of the RBL tranfectants revealed no interference in the binding of one MoAb by
the other.

In other words, clone #45 cells exhibited 84% of cells to be GL3-positive

when stained only with PE-GL3, and 80% of cells to be GL3-positive when cells were
stained with PE-GL3, followed immediately by 17D1 and FITC-conjugated anti-rat IgG
+ IgM, demonstrating only a negligible difference in percentages of positively-stained
cells. Likewise, clone #45 cells before they were “enriched” were analyzed by staining
with MoAbs and FACS, also showing no interference in the binding of the MoAbs to the
cells. In this case, cells showed 29% to be GL3-positive when stained with PE-GL3
alone, 21% to be 17D1-positive when stained with the 17D1 MoAb alone, and 29% and
23% positive cells for GL3 and 17D1, respectively, when stained with PE-GL3 first,
followed immediately by 17D1 and FITC-conjugated anti-rat IgG + IgM. Notably, the
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same percentages of positive cells were found when the cells were stained in different
order, i.e. 17D1 first, followed by PE-GL3, and then anti-rat IgG + IgM.

This

observation indicates that there is no preferential binding of one particular antibody over
the other to the TCR, which would prevent one from accurately detecting the presence of
its target, namely the C5 or Vy5/V61 TCR. These findings are consistent with previous
results of DETC cell analyses using these MoAbs together, where the same percentages
of GL3-positive and 17D1-positive cells are found regardless of staining cells separately
or concurrently with the Abs (Tigelaar and Lewis, personal communication).
Importantly, analysis of clone #45 cells before they were “enriched” revealed the exact
same 17D1 to GL3 positive cell ratio as that found in clone #45 sorted and “enriched”
cells, i.e. 23% 17Dl-positive of 29% GL3-positive is equal to a 0.79:1 ratio, which is
essentially the same as a ratio of 0.8:1.
The percentage of GL3-positive cells was consistently higher than that of 17D1positive cells. The small discrepancy between these percentages can be explained in two
different ways. One is that the V61 chain, as detected by the staining of C5 by GL3, is
indeed expressed alone in 20% of the RBL transfectants of clone #45, without the
necessity of being associated with another chain, namely the Vy5 chain. It is unclear if
the same finding of GL3-positive cell predominance would be revealed in other clones as
well. Such a trend would indicate that the V51 chain is either more efficiently transfected
into the RBL cells compared to the Vy5 chain, or that the V61 chain is more stably
expressed on the RBL cell surface. The reason for such findings would be unclear. An
adjunctive study would include staining the clonal population with F536 MoAb
(PharMingen), which is an antibody specific for the Vy5 protein, in order to determine if

the Vy5 chain alone could be expressed. It would make a useful comparison to assess the
percentage of F536-positive cells that are also 17D1-positive.
Alternatively, the reason for a higher percentage of GL3-positive cells compared
to 17D1-positive cells could be that only 80% of all RBL Vy5/V81 transfectants, indeed
expressing both chains of the TCR, are folded in the proper 3-dimensional conformation
to be recognized by the 17D1 MoAb.

The two chains of a T-cell receptor fold in an

intricate way, in much the same way as those of a Fab fragment of an immunoglobulin
with some distinct differences in the way the domains are formed and interact [76, 332],
It is conceivable that the y and 6 chains, after transfection into RBL cells, are in fact
expressed at the cell surface, but do not always fold together into the proper formation to
be recognized by the 17D1 MoAb. The antigen receptor conformation of this TCR is
underlined by the finding that epidermal y8 cells, similar to most B cells and a(3 T cells,
may be associated more with an antigen receptor conformation than with simple linear
epitopes specifically encoded by the Vy and V6 gene segments normally used by DETC
[73]. The 17D1 MoAb, thought to react only with cells expressing both V81 and Vy5,
has been found to recognize Vyl/V81 TCRs in the absence of Vy5+ cells. Therefore, just
as the 17D1 MoAb appears to recognize TCRs of a particular conformation regardless of
particular gene segments used, it would also fail to recognize TCRs that do not express
the proper conformation despite having the Vy5 and V81 genes.

Indeed, it would be

advantageous to clarify if the 20% of GL3-positive, 17D1-negative cells are indeed F536positive, which would imply that both the y and 8 chains are being expressed but in a
conformation unrecognizable by 17D1. A salient question is whether such a TCR not in
the same conformation as that which the majority of DETC share, as detected by 17D1, is
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still functional in recognizing the DETC-specific ligand(s), becoming activated, and
successfully transmitting signals to the cell in order to carry out DETC-specific activities.
Further experiments will indeed be needed to elucidate the requirements for function of
the DETC TCR, such as the specific y and 8 gene segments used or the folding of the y
and 8 chains to produce a certain TCR conformation.
Clone #45 “enriched” (81% GL3-positive and 65% 17D1-positive) cells were
used in an experimental 3H serotonin release bioassay in an attempt to demonstrate that
the expressed TCR was able to induce signal transduction through TCRt,, and thus to
activate the transfectants. This first assay showed mixed results. First, the experimental
conditions of incubation with GL3 hybridomas and 17D1 soluble antibody failed to
induce serotonin secretion by the RBL transfectants, implying a lack of TCR activation.
Both GL3 hybridomas and 17D1 soluble antibody were designed to act as positive
controls, assuming that these antibodies would bind the Vy5/V81 TCR and induce
activation. Other studies (Steele, unpublished data) have shown the effective stimulation
and release of 3H serotonin-loaded Vy7/V85 RBL transfectants by the GL3 hybridoma in
a dose-dependent fashion. A ratio of 10:1 of GL3 hybridomas to RBL cells was found to
induce up to 20% serotonin release (Steele, unpublished data). Although a 10:1 ratio of
GL3 hybridomas to RBL cells was also used in the assay of the present study, no
serotonin release was induced.

Because GL3 MoAb detects the C8 chain, with no

constraining need for recognition of a particular conformation, it is expected that the GL3
hybridomas in sufficient concentration should stimulate the RBL y8 transfectants. Future
assays can incorporate varying ratios of GL3 hybridomas to RBL cells and to determine
if there is a dose-dependent effect. It is conceivable that the manner in which the TCR is
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expressed on the RBL transfectant causes the GL3 hybridoma to bind inefficiently to the
TCR, perhaps enough to be detected as seen in FACS analysis, but does not cross-link the
TCR strongly enough to stimulate activation and release. A higher GL3 hybridoma to
RBL cell ratio may result in functional activation through the TCR. GL3 may also have
varying binding affinities to different specific receptors, perhaps being lower for
Vy5/V61 in comparison to Vy7/V65 (a receptor characterizing murine intestinal cells)
[333], In future assays, GL3 free antibody, as well as bead-bound GL3, such as to PGS
beads, can be used to provide a direct comparison between intercellular engagement of
ligand with TCR and that of soluble antibody with the TCR. It may be found that the
assay is more suitable for detection of activation via one particular method over another.
Finally, it is possible that the physical constraints of GL3 antibody surface
expression on the hybridoma cell are preventing efficient cell-cell interaction and
antibody-TCR engagement. In theory, F(ab’)2 fragments of the GL3 antibody could be
used to assess activation through the TCR.

The F(ab’)2 fragment is produced by the

digestion action of the protease pepsin on the carboxy-terminal side of the disulfide
bonds of the immunoglobulin. The two antigen-binding arms of the antibody molecule
remain linked, retaining the same antigen-binding characteristics as the original antibody
[2]. Using such fragments of the antibody to activate cell-surface TCR would bypass the
potential physical constraints of antibodies expressed on the surface of another cell.
Clone #45 RBL transfectants also did not show stimulation by 17D1 MoAb.
Several different explanations can account for this finding. One, the concentration of
17D1 MoAb in the unpurified supernatant collected from cultures of 17D1 hybridoma
cells is unknown (Lewis, personal communication).

In this study, 50 pi of the
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supernatant was added directly to the well containing the Clone #45 cells.

It is

conceivable that the concentration of 17D1 MoAb in the supernatant is in fact rather low
such that 50 ul alone did not contain adequate amounts of antibody to activate the TCR
on the RBL transfectants.

In future assays, both higher volumes or concentrations of

17D1 MoAb in the supernatant can be used to assess activation via this antibody.
Logically, use of purified supernatant, containing a concentrated amount of 17D1 MoAb
alone, would have a much higher likelihood of demonstrating TCR activation.

An

alternative explanation for the lack of transfectant cell stimulation by 17D1 is that the
MoAb could not induce detectable activation via the TCR on the RBL cells. It is possible
that the Vy5/V61 TCR is expressed on the RBL cell surface in such a way that 17D1
MoAb does not bind accurately enough to induce activation through CD3C, i.e. does not
effectively cross-link the TCR.

Additionally, staining of the RBL transfectants with

FITC-conjugated anti-17Dl showed 65% of the “enriched” Clone #45 cells to be 17D1positive. This percentage is lower than the ideal percentage of >99% purity of 1701positive cells in a clone. Any of these factors may have contributed to the finding of
failure of activation by 17D1 MoAb, or activation at a level below detectable using this
assay system.
Though the RBL y6 transfectants failed to show activation by the GL3
hybridomas and 17D1 soluble MoAb, they did demonstrate serotonin release in response
to PDV keratinocytes. This result is intriguing. One possible interpretation is that the
Vy5/V61 TCR was in fact activated by the keratinocytes. DETC have been proposed to
recognize a unique set of molecules that may be expressed by “stressed” neighboring
cells [33], such as keratinocytes in the epidermis with which DETC are in intimate
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contact.

In fact, Havran et al. (1991) demonstrated that DETC may be stimulated to

produce lymphokines by interaction with transformed keratinocytes in vitro [105]. The
stimulation was mediated through the DETC receptor and did not appear to be subject to
MHC restriction.

This finding provides support for the hypothesis that DETC can

recognize self-antigens and may participate in immune surveillance for cellular damage
rather than for foreign antigens [105], In addition, this proposed functional role of DETC
is consistent with the extraordinary homogeneity in the TCR y and 8 gene utilization,
which implies a very limited repertoire for the antigen(s) recognized by the receptor [42],
Thus, it is possible that the TCR on the RBL transfectants successfully engaged with
ligand on the keratinocytes, induced activation through CD3^, and stimulated serotonin
release. The nature of the ligand is unclear and cannot be elucidated from this assay.
The keratinocytes used in this assay were neither heat-shocked nor infected, or otherwise
manipulated to cause purposeful damage. Yet, they had been removed from culture in a
flask by scraping just prior to incubation in the assay with the RBL transfectants.
Therefore, it is conceivable that this kind of physical “stress” and manipulation caused
expression of a molecule which was recognized by the DETC TCR.
An alternative explanation is that the RBL transfectants were stimulated to release
serotonin through a mechanism not related to TCR activation. Several different stimuli
have been found to transduce cell activation signals in DETC. Such signals include: a)
mitogenic lectins [58, 334]; 2) coculturing with a transformed keratinocyte line, Pam 212
[105], as described above; 3) epicutaneous application of irritant chemicals [110]; and 4)
epidermal injury caused by injected autoreactive cytotoxic T-cells [335], The mechanism
through which these cell activation signals act on the DETC is not clear. Activation leads
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to production of IL-2, the expression of IL-2 receptor, and vigorous proliferation [58], It
is hypothesized that the same signals also lead to the “maturation” of DETC that then
exhibit “killer leukocyte” activity towards tumors or otherwise transformed cells. IL-7
produced locally by keratinocytes has been found to promote the growth of DETC in
vitro [112, 336], Thus, IL-7 from keratinocytes may also contribute to this maturational
process of DETC into “killer cells” [109],

It is possible that the RBL y6 TCR

transfectants are receiving as-yet unidentified cell activation signals from the
keratinocytes through a non-TCR-related mechanism and are likewise transformed into a
cell of “increased” activity. Such activity could lead to serotonin release.
It is also conceivable that the RBL y5 transfectants were activated through an
alternative receptor molecule aside from the Vy5/V81 TCR. For example, NKG2D is a
receptor for the distant MHC class I homologue called MICA [98]. NKG2D has recently
been detected on most y8 T cells, as well as on CD8+ a [3 T cells and NK cells.
Engagement of NKG2D can activate cytolytic responses by y6 T cells and NK cells
against epithelial tumor cells and transfectants expressing MICA [98], Interestingly, the
NKG2D ligands of the MHC class I-like molecules called Rae-1 and H60 have been
found on skin cells exposed to carcinogens [100], It is not definitively known whether
RBL cells possess the NKG2D receptor. It is possible that Rae-1 and H60-like molecules
are being expressed on the keratinocytes, which are recognized by NKG2D or other asyet unidentified receptor on the RBL cell, thus causing activation and release of serotonin
through a non-TCR-dependent mechanism. Recently, a monoclonal antibody specific for
murine NKG2D has been generated [337], This anti-NKG2D MoAb could be used to
stain and analyze the RBL cells for detection of this receptor. One could also use the
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MoAb as a testing condition in the RBL bioassay, in which serotonin release may
indicate the presence of this receptor on the RBL surface.

Additionally, RBL y6

transfectants pre-blocked with NKG2D MoAb could be incubated with the keratinocytes
to assess any difference in serotonin release. Failure of RBL cells to release serotonin in
this condition would highly suggest the presence of NKG2D receptor.

Several steps can be taken to optimize the RBL bioassay. One of the first steps
would be to further “enrich” the Clone #45 cell line into an ideally pure, >99% 17D1positive clone. Though it is not certain whether GL3-positive cells do in fact possess
both the y and 8 chains and are not being detected by 17D1 due to conformational
differences, such cells would ideally not be included in the purified clone until such
clarification is made. Testing conditions with GL3 hybridomas and 17D1 soluble MoAb
can be adjusted as discussed above to optimize the sensitivity of the bioassay. A suitable
target to effector cell ratio of possible ligand-bearing cells and transfectants would need
to be determined.

An alternative method is to use homogenates of potential ligand¬

bearing cells, in which the proteins in the homogenates could be used to attempt
activation of RBL cells in the bioassay. Finally, in order to definitively demonstrate that
activation is indeed occurring through engagement of a particular ligand with the TCR,
production of soluble Vy5/V61 TCR (sTCR) will play a key role [338]. Once a particular
type of cell is shown to activate the RBL Vy5/V81 transfectant, sTCR can be used to
attempt blocking of activation.

If such blocking is achieved, characterization of the

activating molecule on the ligand-bearing cell can begin. Ultimately, this RBL bioassay
with TCR transfectants has the exciting potential to help identify the ligand(s) for the
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strikingly homogeneous Vy5/V61 TCR-bearing dendritic epidermal T cell. Surely, the
elucidation of such ligand(s) will radically increase the understanding of the physiologic
and functional roles of this intriguing subset of epidermis-restricted T cells.
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